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Thrombotic thrombocytopenic purpura (TTP) is a rare, life-threatening disease 
with a reported incidence of 6 cases per million per year in the UK. It is 
characterised by episodes of microangiopathic haemolytic anaemia and 
thrombocytopenia, with the widespread presence of platelet-rich thrombi in the 
microcirculation, leading to end-organ damage. TTP is a clinically 
heterogeneous disorder caused by autoantibody inhibition or clearance or by 
a deficiency in activity or secretion of the von Willebrand factor cleaving 
protease (ADAMTS13). Over 100 mutations have been identified in 
ADAMTS13 yet, in some cases, these mutations in congenital TTP alone do 
not explain the disease phenotype, particularly in late-onset congenital TTP. 
One aim of this study was to analyse the effect of single nucleotide 
polymorphisms (SNPs), in conjunction with ADAMTS13 mutations, which have 
been identified in a cohort of TTP patients with varied clinical phenotype. 
Twenty mutant expression plasmids containing an ADAMTS13 mutation and/ 
or SNP have been constructed by site-directed mutagenesis (SDM). Fourteen 
plasmids contained a new non-synonymous mutation (C3484T) which has 
been rectified by further SDM. After full sequencing of the plasmid ADAMTS13 
insert, 24 clones were identified as viable and the resultant protein was 
expressed in HEK293T cells and analysed by Western blot and ADAMTS13 
antigen ELISA. Blots were scanned by densitometry and the intensity of the 
protein species corresponding to ADAMTS13 determined using ImageJ. The 
predicted effects of mutations and/or SNPs were annotated by the in silico 
computational tools SIFT, PolyPhen2, I-Mutant 2.0 and SNPEffect 4.0.  
Results from this genotype study were compared to clinical phenotype by 
correlating data held within the TTP Registry at University College London. 
The resultant analysis showed the mutations located in the N-terminal end of 
ADAMTS13 protein induced more secretory defects and SNPs had less of an 
effect on phenotype. The p.R7W and p.A1033T SNPs showed more of an 
effect on secretion of ADAMTS13 when the mutation was located in the C-
terminal end (p.R1060W) which is associated with late-onset phenotype. 
However, other environmental factors such as changes in the ADAMTS13-
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VWF axis during pregnancy and infection make a correlation between 
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ADAMTS13 A disintegrin-like and metalloprotease with thrombospondin-type type 
13 motifs 
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Thrombotic thrombocytopenic purpura (TTP) is a rare, life-threatening 
haematological disease with a reported incidence of six cases per million per 
year in the UK (Scully et al., 2008). The disorder is characterised by episodes 
of microangiopathic haemolytic anaemia (MAHA), thrombocytopenia and the 
widespread presence of platelet-rich thrombi in the microcirculation. This leads 
to end-organ ischaemic damage, primarily affecting the heart, kidneys and 
nervous system. The diagnosis of TTP has traditionally been based on clinical 
history, examination and routine blood parameters. If left untreated, the 
disease carries a mortality rate of 90% (Scully et al., 2012). Current first-line 
treatment is plasma exchange with fresh frozen plasma (FFP), often in 
conjunction with the anti-CD20 monoclonal antibody rituximab. 
 
1.0 Historical context 
TTP was first documented in the literature by the physician Dr Eli Moschcowitz 
in the USA (Moschcowitz, 1924). A 16-year-old female student had been 
admitted to the Beth Israel Hospital in New York with a recent history of upper 
extremity weakness and fever, which progressed over four days after hospital 
admission. She lapsed into a coma and subsequently died and the histological 
evidence on post-mortem showed that ‘Death…resulted from some powerful 
poison which had both agglutinative and haemolytic properties’. Baehr et al. in 
1936 added to this report that hyaline microthrombi observed on post mortem 
were rich in platelets (Baehr et al., 1936). 
Following this, there were few sporadic documented cases until Singer et al. 
reviewed the 11 documented cases to date and were the first to use the term 
TTP in 1947. Thrombocytopenic purpura was a relatively common occurrence 
but, in combination with multiple platelet thrombi, the disorder was rare. The 
patient identified by Singer in 1947 was an 11-year-old girl who presented with 
ecchymosis and petechiae, together with neurological symptoms including 
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headache, paraesthesia and confusion. On the sixth day after admission she 
died and post-mortem histological analysis showed identical features with the 
previous 11 cases in the literature. All cases reported the presence of many 
platelet-rich microthrombi in capillaries, arterioles and the smaller arteries of 
almost all organs. Singer concluded that the disease should be recognised 
ante-mortem, rather than on post-mortem histological evidence, and 
suggested thrombotic should be added to the term thrombocytopenic purpura. 
The disease TTP was thus recognised (Singer et al., 1947). 
Schulman in 1960 reported that an eight-year-old patient, who had a history of 
severe epistaxis and petechiae from birth and no family history of similar 
problems, also suffered haemolytic anaemia and thrombocytopenia. The 
epistaxis cleared after treatment with whole blood and the patient underwent 
a splenectomy. Following this, the patient was transfused several times and 
the platelet count recovered for eight days whereupon the count fell to pre-
transfusion levels. Schulman concluded that the thrombocytopenia was due to 
‘…a deficiency of a factor, present in normal plasma, which is required for 
megakaryocyte maturation which is neutralised by a factor in normal plasma’ 
(Schulman et al., 1960). The pathophysiology of the disease still proved 
elusive. 
Amorosi and Ultmann in 1966 furthered research in the field by reporting 16 
cases and reviewing the literature to date (Amorosi & Ultmann, 1966). By this 
time, there were a total of 271 cases of reported TTP. Previously, TTP was 
considered clinically to be a triad of signs and symptoms, namely bleeding or 
purpura, haemolytic anaemia and neurologic presentations. As fever was 
observed to be almost always present, as well as renal disease, the authors 
argued that TTP should be considered to be a pentad of signs and symptoms. 
The cases they described and reviewed were between the ages of 10-39 
years, with more females than males. There was also a greater incidence of 
pregnancy in the case histories, which the authors argued could be by chance, 
or there may be an aetiological relationship. With respect to the mechanism of 
the disease, the authors suggested allergy, or possibly a toxin capable of 
causing haemolysis and platelet agglutination. It was also suggested that the 
cause could be auto-immune but it was observed that transfusion of plasma 
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from a patient with TTP to a healthy volunteer caused no untoward effects 
(which would possibly not pass ethics today). The authors concluded that TTP 
is a very variable disease, both in clinical presentation and in outcome, with 
72% of patients dying within 90 days. Hereinafter, they recommended the 
disorder should be considered to be a pentad of signs and symptoms to aid 
clinical diagnosis. 
TTP research continued apace and in 1996, Furlan et al. identified unusually 
large forms of von Willebrand factor (VWF) in patients with TTP. These large 
multimers disappeared after treatment with fresh frozen plasma. The authors 
drew the conclusion that ’…a proteolytic enzyme is responsible for VWF 
degradation in normal plasma not yet identified’. It was known that plasmin 
cleaves several bonds in VWF, leaving a high molecular weight core which 
retained 70% of its platelet-binding ability. The authors purified the ‘factor’ 
which degraded VWF and identified that the ‘proteolytic enzyme’ cleaved VWF 
at the Tyr1605-Met1606 bond and that there was a consistent proportion of 
VWF fragments produced with molecular weights of 189, 176 and 140kDa.  
They concluded that this VWF cleaving protease was not a serine protease, 
cathepsin, matrix metalloprotease nor a calpain but the true nature of the 
VWF-cleaving enzyme had yet to be elucidated (Furlan et al., 1996). 
Tsai et al. in 1996 concurrently worked on the identification of this VWF-
cleaving protease. They performed some elegant experiments placing VWF 
under shear stress, concluding that VWF in its native form existed as an 
enclosed structure that was relatively resistant to cleavage by the novel 
metalloprotease. However, when VWF was placed in conditions of shear 
stress as found in smaller arteries, arterioles and capillaries in the circulation, 
this enclosed structure unfurled and the active site was exposed to the 
protease. They identified that this process required calcium ions and that the 
unfurled multimeric structure of VWF facilitated the greatest platelet binding. 
They concluded that, after entering the circulation, proteolysis may only occur 
when VWF is exposed to shear stress. At this point, it was concluded that TTP 
induces an excessive release of ultra-large von Willebrand factor (ULVWF)  




Further work by Furlan et al. in 1997 analysed patient pedigree data in four 
families of patients with chronic relapsing TTP and concluded that TTP was 
caused by a deficiency of the protease and that this was inherited in an 
autosomal recessive pattern (Furlan et al., 1997). In 1998 this group analysed 
samples from 53 patients diagnosed with TTP or haemolytic uremic syndrome 
(HUS) which is a microvascular disorder with signs and symptoms very similar 
to TTP. In this cohort, 13 patients had been diagnosed with HUS, 24 with non-
familial TTP and 16 with familial TTP. They developed and utilised a WVF-
cleaving protease assay and looked for the presence of an inhibitor by 
measuring protease activity in samples from healthy patients after incubation 
with patient samples. From this, they recommended that these tests be 
implemented to aid differential diagnosis and to guide treatment of TTP with 
differing aetiology. They argued that patients with familial forms may relapse 
and those with the presence of an inhibitor may require greater volumes of 
FFP (Furlan et al., 1998). 
The identification and classification of the VWF-cleaving protease was finally 
elucidated in 2001 by two separate groups. Fujikawa purified the protease 
from commercial factor VIII/VWF and the N-terminal sequence was identified 
and compared to the human genome sequence published in the same year by 
the International Human Genome Consortium (Fujikawa, 2001). At the same 
time, Levy et al. studied the molecular pathogenesis of TTP using a genetic 
approach. They studied four pedigrees of patients with familial TTP. The level 
of the VWF-cleaving protease in plasma was 2-7% of normal in affected 
individuals. On analysing the levels of protease in the parents of affected 
individuals, it was found they corresponded to those consistent with a 
heterozygous carrier status. It was concluded that the plasma level of the 
protease could be used as a phenotypic trait for linkage analysis in order to 
map the locus of the protease. Through techniques such as cDNA cloning, 
polymerase chain reaction (PCR) with reverse transcription, rapid 
amplification of cDNA ends and genomic sequence analysis, the full length of 
the protease cDNA and genomic structure was deduced. The protease was 
identified as being the thirteenth member of the ADAMTS family (a disintegrin 
and metalloproteinase with thrombospondin type 1 repeats).  
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The ADAMTS13 gene was discovered to be located on chromosome 9q34, 
spanned 29 exons and encoded a protein of 1,427 amino acids. The gene was 
found to be highly conserved when compared to the mouse genome 
sequence. On analysis by northern blot, it was found ADAMTS13 was almost 
exclusively produced in the liver. Levy et al. also identified 12 mutations and a 
total of 25 single nucleotide polymorphisms (SNPs), seven of which resulted 
in non-synonymous changes which altered the amino acid sequence in the 
protein (Levy et al., 2001). 
Since the identification and classification of ADAMTS13 in 2001, the direct link 
between ADAMTS13 deficiency and TTP pathogenesis has been firmly 
established and a significant body of research has been produced in this field 
(Sadler, 2017). The development of diagnostic assays has also greatly 
contributed to the advancement of knowledge, in addition to aiding patient 
diagnosis of TTP. 
 
1.1 von Willebrand factor 
The hallmarks of TTP are caused by platelet-rich microthrombi consisting of 
multimeric ULVWF. VWF is a large, multi-domain, heterogeneous glycoprotein 
which plays a vital role in primary haemostasis. It consists of 2,050 amino 
acids in its monomeric form. The gene for VWF is located at the tip of the short 
arm of chromosome 12 (Ginsburg et al., 1985),  is ~178kb in length and 
contains 52 exons (Mancuso et al., 1989). The messenger RNA encodes a 
precursor of 2,813 amino acids in length and consists of a signal peptide (22 
amino acids), a propeptide (741 amino acids) and the mature peptide subunit 
(2,050 amino acids); (Sadler, 1998). 
 
VWF is classified as an acute phase protein and is produced constitutively in 
endothelial cells (Wagner et al., 1982) and megakaryocytes (Nachman et al., 
1977) and is secreted into the plasma, where it exists in a globular form. The 
primary functions of VWF are threefold: to bind to sub-endothelial collagen 
which has been exposed to vessel injury; to bind to receptor glycoprotein Ib 
(GPIb) complex on the surface of non-activated platelets and to bind to the 
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receptor GPIIbIIIa complex on the surface of activated platelets. A further 
function of VWF is to bind to factor VIII to protect it from proteolytic cleavage 
(Weiss et al., 1977). 
 
1.1.1 VWF synthesis 
VWF is synthesized in the endoplasmic reticulum (ER) of endothelial cells  as 
monomers consisting of unprocessed precursors termed pre-pro-VWF 
monomers (Wagner et al., 1982). These monomers are linked via C-terminal 
disulphide bonds to form dimers (pro-VWF molecules). Further post-
translational modification occurs in the Golgi apparatus and the resultant 
glycosylation  leads to the presence of  the ABO (H) group antigens (Matsui et 
al., 1992). As a consequence, populations with blood group O result in lower 
mean levels of VWF in the plasma (Gill et al., 1987). Further processing 
facilitates multimerization through N-terminal glycosylation, resulting in the 
formation of multimers varying in size.  The larger size multimers, termed ultra-
large VWF (ULVWF) are more functionally active due to increased numbers 
of platelet-binding receptors. The enzyme ADAMTS13 regulates the size of 




Figure 1.1 Regulation of ULWF in the A2 domain by ADAMTS13 (from Chapman et al., 2012). 
Reproduced with permission © Georg Thieme Verlag AG.  
 
The enzyme furin processes pro-VWF into the mature VWF multimers by 
cleavage of the pro-polypeptide von Willebrand propeptide (VW pp) from the 
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pro-VWF dimers. VWpp chaperones VWF into storage granules (Weibel-
Palade bodies in endothelial cells and α-granules in platelets) ready for 
release into the plasma (Wagner et al., 1982). Each monomer is ~250 kDa in 
size but through multimerization is stored as ULVWF; (Sadler, 2002). VWF 
can exist in the plasma as a series of oligomers whose subunits range from  
2-40 to 100-200 multimers or more, with a molecular weight exceeding 20,000 
kDa (Sadler, 1998; Zhou 2011). These high molecular-weight multimers 
(ULVWF) bind platelets and collagen more efficiently and are vital for platelet 
aggregation at the site of tissue injury (Arya et al., 2002). 
 
Platelets do not release VWF until activated whereas endothelial cells release 
VWF constitutively, particularly in response to exercise and adrenergic 
stimulation (Giblin et al., 2008). Once released from the Weibel-Palade bodies 
into the plasma, VWF exists in a globular form with the collagen-binding A3 
domain exposed to enable surveillance of the vasculature and to enable it to 
bind when the sub-endothelial matrix is exposed at sites of vessel damage. 
However, the GPIbα binding site in the A1 domain is partly concealed, 
ensuring no unwanted platelet binding occurs. The ADAMTS13 binding and 
cleavage sites (the A2 domain) are also buried, ensuring no unwanted 
proteolysis of VWF (Zhang et al., 2009). 
 
1.1.2 Platelet binding to VWF 
With vessel injury, the resultant disruption of the vessel wall exposes the pro-
coagulant sub-endothelium. In intermediate- to high-shear conditions in 
arteries, arterioles, capillaries and in stenosed vessels, platelet adherence to 
the exposed collagen is indirect, via the interaction between the A1 domain of 
VWF (Fujimura et al., 1986) and the platelet GPIb-IX-V complex. In this way, 
VWF acts as a bridge between the platelet surface and exposed collagen. In 
non-activated platelets this interaction occurs with low affinity, or not at all, as 
the GPIb-IX-V complex is masked and is therefore haemostatically inactive. If 
VWF is immobilized by binding to collagen-rich matrices via the A3 domain 
that have been exposed through damage, the VWF multimers unravel under 
the forces of shear stress on the tethered molecule by the flowing blood 
8 
 
(Siedlecki et al., 1996).  This leads to exposure of the high-affinity platelet-
binding complex and the subsequent capture of platelets that are circulating 
at the periphery of the vessel. The exposure of the linear array of VWF A1 
domains facilitates binding to multiple GP1bα receptors on the platelet surface 
(Sadler, 1998). Once tethered, platelets roll over the exposed VWF receptor 
complexes in the direction of blood flow and the process of platelet tethering 
is initiated. As this interaction is unstable due to a fast dissociation rate, further 
platelet-collagen interactions leading to platelet activation occur. The larger 
ULVWF are more haemostatically competent, due not only to the large 
numbers of collagen and platelet-binding sites, but also because they unravel 
more readily under rheological shear (Zhang et al., 2009). Under normal 
conditions the VWF polymers, when stretched, can reach up to a length of 
100μm and represent a dimer containing 5,100 amino acids and this is needed 
to stop bleeding (Schneider et al., 2007). 
 
The control of multimer length through proteolytic cleavage by ADAMTS13 is 
a delicate balance between reducing their size to ensure they remain 
sufficiently functional to stop bleeding and ensuring adequate cleavage to 
avoid unwanted thromboses.  
 
1.1.3 von Willebrand’s disease (VWD) 
von Willebrand’s disease is an autosomal bleeding disorder of variable clinical 
severity resulting from a variety of subtypes of VWF deficiency and is the most 
common inherited haemostatic disorder in the UK. This disorder has led to 
much analysis of the VWF gene (VWF gene reference sequence ID:7450). 
Mutations and polymorphisms within VWF have been studied widely and are 
compiled and maintained for the International Society of Thrombosis and 
Haemostasis at the University of Sheffield (ISTH-SSC VWF online database). 
Specific mutations within VWF are known to affect exosite binding of 
ADAMTS13 (de Groot et al., 2009; Pos et al., 2010) and ADAMTS13 activity 
(de Groot et al., 2010).  In patients with severe VWD, Factor VIII levels have 




1.2 ADAMTS13  
1.2.1 Overview of ADAMTS proteases 
ADAMTS13 belongs to the ADAMTS family of multi-domain extracellular 
proteases which all contain a reprolysin-like metalloprotease. There are 19 
members of this family and they can be sub-grouped on the basis of their 
known substrates such as the proteoglycans, the procollagen N-peptidases, 
the cartilage oligomeric matrix proteins and the VWF-cleaving protease 
ADAMTS13 (Kelwick et al., 2015). Generally they are considered to be 
remodelling enzymes of the extracellular matrix and as a family, they have 
important roles in connective tissue organization, coagulation, inflammation, 
angiogenesis and cell migration (Apte, 2004; Porter, 2005).The proteases are 
highly conserved structures containing the metalloprotease catalytic domain, 
a carboxy-terminal ancillary domain and at least one thrombospondin type 1 
repeat. 
 
1.2.2 ADAMTS13 structure 
ADAMTS13 is a ~180 kDa metalloprotease consisting of 1,427 amino acids. 
The protease contains a signal peptide, a propeptide, a metalloprotease 
domain, a disintegrin-like domain, a thrombospondin type 1 motif (TSP-1), a 
cysteine-rich domain, a spacer domain, seven TSP-1 repeats and 2 
complement C1r/C1s, sea urchin epidermal growth factor and bone 
morphogenetic protein 1 (CUB) domains (Zheng et al., 2001); see Figure 1.2. 
The ADAMTS13 gene is located on chromosome 9q34, and is approximately 
45kb in humans. The gene consists of 24 exons (Levy et al., 2001).  
 
1.2.2.1 The propeptide domain 
The ADAMTS13 propeptide is short and poorly conserved compared to those 
of other proteases in the ADAM or ADAMTS family and is not required for its 
secretion or activation. This region in other ADAMTS proteases functions as a 
molecular chaperone to direct protein folding, or the domain provides 
enzymatic latency and is cleaved during biosynthesis. This role is not apparent 
in ADAMTS13  (Majerus et al., 2003). The signal and propeptide domains 
encompass amino acid residues 1→79. 
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1.2.2.2 The metalloprotease domain 
The metalloprotease domain contains the active site and encompasses amino 
acid residues 79→286. Several metal ions bind in this site and these 
interactions are considered functionally necessary (see Table 1.1). The active 
site of all the reprolysin or adamlysin family of metalloproteases contain three 
histidine residues that co-ordinate the essential Zn2+ in the sequence 
HEXXHXXGXXHD. Three Ca2+ binding sites have also been postulated (see 
Table 1.1). The first is between amino acid residues Glu83, Asp173, Cys281 
and Asp284, which is in common with other metalloproteases. The second 
binding site is projected to be between residues Glu164, Asp166 and Asn162, 
Asp165 and Asp 168. This appears to be a low-affinity Ca2+ binding site and 
is functionally not important: mutational studies to assess the low affinity site 
have found that the apparent dissociation constant (KD app) between the 
mutants and wild type is similar (51μM, 65μM and 70μM respectively); 
(Gardner et al., 2014). The third site is between the residues Asp187, Glu212 
and Asp182 or Glu184. Through mutational analyses, any alterations in these 
residues dramatically alter function therefore this latter site is postulated to be 
a high-affinity Ca2+ binding site (Gardner et al., 2014) and aids in the 
conformation of the active site cleft. 
Table 1.1 Amino acid positions of cations binding in functional domains 
Description Amino acid position Cation 
Metal binding Glu 83 Calcium 
Metal binding Asp 173 Calcium 
Metal binding Asp 182 Calcium; high affinity 
Metal binding Glu 184 Calcium; high affinity 
Metal binding Asp 187 Calcium; high affinity 
Metal binding Glu 212 Calcium; high affinity 
Metal binding His 224 Zinc; catalytic 
Active site Glu 225  
Metal binding His 228 Zinc; catalytic 
Metal binding His 234 Zinc; catalytic 
Metal binding Cys 281 Calcium 
Metal binding Asp 284 Calcium 
 
There are also other points of recognition found to be important for the 
interaction of VWF and ADAMTS13. These are residues Leu198, Leu232 and 
Leu274 that collectively interact with Leu1603 in VWF (Xiang et al., 2011). 
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Experimental evidence has shown that the metalloprotease domain alone has 
little or no proteolytic activity towards VWF. However, as more domains are 
sequentially added, the activity towards its substrate increases. indicating that 
exosite interactions govern enzymatic activity and substrate specificity, as is 
seen in other clotting factors (Gao et al., 2008; Soejima et al., 2010; X. Zheng 
et al., 2003). Other researchers have found  that the metalloprotease and the 
disintegrin-like domain are an inseparable functional unit (Ai et al., 2005; de 
Groot et al., 2009; Gao et al., 2008); and that the dependence on calcium for 
proteolytic activity is mediated by the high affinity site (Anderson et al., 2006; 
Gardner et al., 2014). 
 
Figure 1.2 Crystal structure of ADAMTS13 (right) with corresponding domains (modified from  
Zheng et al,, 2013); PDB 3GHM. MP: metalloprotease, TSP1-1: thrombospondin type 1, Cys-
rich: cysteine-rich domain. The TSP repeats and CUB domains are not within the crystal 
structure. 
 
1.2.2.3 The disintegrin domain 
Mutational studies have shown that the disintegrin domain is important in 
substrate recognition and assists in positioning the Tyr1605-Met1606 bond of 
VWF into the active-site cleft (Xiang et al., 2011). This domain harbours an 
exosite involving residues Arg349 and Leu350 that interact with residue 
Asp1614 in the VWF A2 domain. Akiyama et al. determined two crystal 











domains and revealed folding similarities between the disintegrin-like domain 
and the N-terminal portion of the cysteine-rich domain  (termed the CA 
domain); see Figure 1.3; (Akiyama et al., 2009a). The CA domain has been 
found to have multiple interaction sites with the spacer domain. 
 
exosite structure of ADAMTS13 
Legend 
 Spacer domain, amino acids 556-680 
 Cysteine-rich domain, amino acids 440-531 
 Thrombospondin type 1 domain, amino acids 384-439 
 Disintegrin domain, amino acids 306-383 
Figure 1.3 Protein data bank crystal structure of the exosite-containing fragment of human 
ADAMTS13 (form 2) showing the spacer, the cysteine rich, thrombospondin type 1 and 
disintegrin domains; amino acid residues 286→680. Image from PDB 3GHN. (Akiyama et al., 
2009a). 
 
1.2.2.4 The thrombospondin (TSP1-1) domain 
The TSP1-1 domain (amino acids 384→439) contains six cysteine amino acid 
residues and has a stiff, rod-like structure containing stacked layers of 
tryptophan, arginine and hydrophobic residues which contribute to its rigidity 
(termed the CWR layered core); (Akiyama et al., 2009a). The role of this 




1.2.2.5 The cysteine-rich domain 
The cysteine-rich domain (amino acid residues 439→555) contains 10 
conserved cysteine residues and has a similar tertiary structure to the 
disintegrin-like domain, despite only sharing 17% homology in their amino acid 
sequence. The C-terminal is highly conserved in amino acid sequence with 
other members of the ADAMTS family which highlights its functional 
importance. It has been found that the exosites DCTS (disintegrin, cysteine-
rich, TSP1-and spacer domain) are critical for the interaction between 
ADAMTS13 and the VWF A2 domain for the proteolysis of VWF and for 
substrate specificity (De Maeyer et al., 2010; Gao et al., 2008; de Groot et al., 
2015). The presence of a VWF-binding exosite (exosite 2) consisting of 
residues His476, Ser477, Gln478, Arg448, Phe494 and Met496 has been 
postulated to exist (Akiyama et al., 2009a). ADAMTS13 variants that lack the 
cysteine-rich and/or spacer domains lack activity to the peptidyl substrate or 
cell-bound UL-VWF. If each of these non-catalytic domains is added to the 
metalloprotease domain, the cleavage of VWF substrate increases in a 
stepwise fashion. However, if the TSP1 2-8 and CUB domains are added, 
there is no increase in proteolytic activity. These domains collectively are 
thought to ensure that the scissile bond is brought into position over the active 
centre of the metalloprotease domain (Xiang et al., 2011). 
 
1.2.2.6 The spacer domain 
The spacer domain comprises amino acid residues 555→680 of the mature 
protein. This domain contains a globular functional unit with a 10-stranded β-
sandwich fold (Akiyama et al., 2009a); see Figure 1.2. Several exosites in the 
spacer domain have been found to be highly conserved among other species, 
which indicate they may have an important functional or structural role. One of 
these areas, exosite 3, which is lacking in a murine model, may be important 
in proteolytic cleavage as the mouse model shows dramatically reduced 
antithrombotic activity (Xiao et al., 2011). Deletion of certain residues within 
exosite 3 leads to the reduced cleavage of VWF substrate. The amino acid 
residues Arg659, Arg660 and Tyr661 and Tyr665 have been shown to be 
critical for cleavage and are responsible for much of the tight binding between 
ADAMTS13 and unravelled VWF(Jin et al., 2012; Pos et al., 2010) . 
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A summary of the properties of ADAMTS13 exosite domains can be seen in 
Table 1.2 
 
1.2.2.7 The thrombospondin (TSP1) repeats 
The TSP1 repeats (2-8) after the spacer domain are variable in number and 
are not well conserved amongst ADAMTS proteases but this domain 
participates in substrate recognition and cell surface binding in all ADAMTS 
proteases to some degree. In ADAMTS13, the TSP1 repeats 2-8 (amino acid 
residues 685→1131) bind VWF through the D4 domain (see Figure 1.5) and 
all repeats contain the sequence WXXW, which is often modified by the 
attachment of an α-mannosyl group (Hofsteenge et al., 2001). Seven of the 
eight repeats are also modified by the addition of the disaccharide Glc-Fuc-O-
Ser/Thr but it is not clear what the role these post-translational modifications 
have in vivo (Hofsteenge et al., 2001). 
 
1.2.2.8 The CUB domains 
The CUB domains (amino acid residues 1131→1427) are unique to 
ADAMTS13 and are not found in other ADAMTS and ADAM proteases (Apte, 
2009). Their role is not yet fully understood. Human and murine ADAMTS13 
variants which lack the TSP1 5-8 repeats and the CUB domains still cleave 
cell-bound UL-VWF under flow conditions (De Maeyer et al., 2010; Jin et al., 
2009). The C-terminal domains (TSP1 2-8 and CUB domains) appear to be 
important with respect to binding to globular VWF (Feys et al., 2009; Zanardelli 
et al., 2009). This is estimated to be approximately 3% of total ADAMTS13 
(Feys et al., 2009). The binding of ADAMTS13 to globular VWF through the 
ADAMTS13 C-terminal domains and the VWF C4-CK domains has led to the 
discovery that a small proportion of ADAMTS13 circulates in the plasma in 
combination with VWF. The secondary structures of the ADAMTS13 domains 







Table 1.2 Summary of exosite properties 
Domain Amino acid Role 
Disintegrin-like 306-383 Interaction of Arg 349 in ADAMTS13 and 
Asp1614 in VWF assists in positioning the 
scissile bond within the active site of 
ADAMTS13 enabling substrate recognition 
and proteolysis 
Thrombospondin type 1 
repeat 
384-439 The stiff, rod like structure of this domain 
contributes to the stability of ADAMTS13 and 
aids in correct positioning of the scissile bond. 
Cysteine rich 440-531 The disulphide bond reducing activity in this 
domain prevents lateral association and 
increased platelet adherence of VWF 
mutimers induced by high fluid stress (Zhou et 
al., 2010) 
Spacer 556-680 This domain interacts with the C-terminal part 
of VWF A2 domain which mediates much of 




260        270        280        290        300 
SDGAAPRAGL AWSPCSRRQL LSLLSAGRAR CVWDPPRPQP GSAGHPPDAQ  
       310        320        330        340        350 
PGLYYSANEQ CRVAFGPKAV ACTFAREHLD MCQALSCHTD PLDQSSCSRL  
       360        370        380        390        400 
LVPLLDGTEC GVEKWCSKGR CRSLVELTPI AAVHGRWSSW GPRSPCSRSC  
       410        420        430        440        450 
GGGVVTRRRQ CNNPRPAFGG RACVGADLQA EMCNTQACEK TQLEFMSQQC  
       460        470        480        490        500 
ARTDGQPLRS SPGGASFYHW GAAVPHSQGD ALCRHMCRAI GESFIMKRGD  
       510        520        530        540        550 
SFLDGTRCMP SGPREDGTLS LCVSGSCRTF GCDGRMDSQQ VWDRCQVCGG  
       560        570        580        590        600 
DNSTCSPRKG SFTAGRAREY VTFLTVTPNL TSVYIANHRP LFTHLAVRIG  
       610        620        630        640        650 
GRYVVAGKMS ISPNTTYPSL LEDGRVEYRV ALTEDRLPRL EEIRIWGPLQ  
       660        670        680        690        700 
EDADIQVYRR YGEEYGNLTR PDITFTYFQP KPRQAWVWAA VRGPCSVSCG  
       710        720        730        740        750 





1.2.3 Post-translational modifications 
Plasma ADAMTS13 is highly glycosylated, with putative N-linked glycosylation 
and O-fucosylation sites identified. O-fucosylation is thought to mediate the 
efficient secretion of ADAMTS13 (Ricketts et al., 2007). It occurs on serine or 
Figure 1.4 Secondary structures of ADAMTS13 domains mapped to the amino acid sequence 
domain: amino acids 286→382; TSP1-1 383→439, Cysteine-rich 439→555, spacer 555→680. 






threonine residues within the consensus sequence C1-X(2)-S/T-C2-G which 
occurs in the TSP1-1 repeat domains (where C1 and C2 are the first and 
second cysteine residue of the repeat). ADAMTS13 has seven predicted 
fucosylation sites; one in each TSP1 domain with the exception of TSP1-4 
(Zheng et al., 2001). The N-glycosylation of residues may also facilitate 
secretion (Akiyama et al., 2009b; Jia et al., 2009; Liu et al., 2005;  Zheng et 
al., 2001). Ten potential N-glycosylation sites have been identified; two in the 
metalloprotease domain, one in the cysteine-rich, three in the spacer, one in 
the TSP1-2 and two in the CUB domains (Zheng et al., 2001). Several potential 
C-mannosylation sites have also been identified (Sorvillo et al., 2014) although 
the role of this glycosylation has not been elucidated. 
 
1.2.4 ADAMTS13 biosynthesis and secretion 
ADAMTS13 is primarily synthesized in the liver and is localized to the hepatic 
stellate cells (Uemura et al., 2005). The full-length ADAMTS13 mRNA is 
approximately 4.3kb (Zheng et al., 2001) and protein expression in rat hepatic 
stellate cells is up-regulated upon mechanical pressure and inflammatory 
cytokines such as transforming growth factor β (TGF-β). It has been suggested 
therefore that ADAMTS13 may have a role in tissue remodelling after injury 
(Niiya et al., 2006). ADAMTS13 mRNA and protein have also been detected 
in vascular endothelial cells in vitro and in vivo (Shang et al., 2006; Zheng, 
2015). The function of ADAMTS13 secreted from endothelial cells is not known 
but the large surface coverage of endothelium in the body could potentially 
contribute a substantial quantity of the protease. ADAMTS13 released from 
endothelial cells could arguably cleave newly formed ULVWF strings on the 
cell surface. 
 
1.3 ADAMTS13 – VWF interactions 
ADAMTS13 regulates VWF proteolysis by the cleavage of a single Tyr-1605-
Met-1606 scissile bond within the A2 domain of VWF and hence reduces 
thrombus formation.  As a specific inhibitor of ADAMTS13 has not been 
identified, this process is in a sense unregulated. However, its activity is largely 
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controlled by the substrate, i.e. by the conformational change of VWF under 
shear stress which unveils the scissile bond, multiple platelet binding sites and 
other specific exosites for binding (Sadler, 1998). When the globular form of 
VWF unravels it reveals its A1 platelet-binding sites and at the same time the 
cryptic ADAMTS13 binding sites, allowing cleavage at the scissile bond 
(Zhang et al., 2009); see Figure 1.5. 
. 
 
Figure 1.5 ADAMTS13-VWF interactions. ADAMTS13 contains a signal peptide(SIG), a 
propeptide (P), a metalloprotease domain (MP), a disintegrin-like domain (D), a TSP motif 
(TSP 1), a cysteine-rich domain (CYS), a spacer domain (S), seven TSP repeats (TSP 2-8) 
and 2 CUB domains. ADAMTS13 cleaves vWF at a scissile bond in the A2 domain of vWF. 
The A1 domain binds GP1bα receptors on the platelet surface and the A3 collagen binding 
site adheres to the subendothelial matrix, 
 
A model of the interactions between VWF and ADAMTS13 has been proposed 
by Crawley and co-workers (2011) and defines a 7-step process of precise 
exosite binding between ADAMTS13 and VWF, which can be visualised like a 
‘molecular zipper’. This allows the accurate delivery of the active site of 
ADAMTS13 to the scissile bond within the A2 domain of VWF (Crawley et al., 







Figure 1.6 Seven-step model of ADAMTS13-VWF exosite binding as proposed by Crawley & 
Lane (from Crawley et al., 2011) Reproduced with permission © American Society 
Hematology.) 
 
From Figure 1.6 (A) it can be seen that VWF exists in the circulation in globular 
form, some of which is reversibly bound to ADAMTS13 through the 
ADAMTS13 TSP1 5-8 and the VWF D4-CK domains (step 1). On binding to 
collagen through the A3 domain, VWF unfurls under shear stress in the 
microvasculature revealing cryptic exosite binding sites and cleavage sites in 
the VWF A2 domain (step 2). Through the extraction of the vicinal cysteine 
plug from the hydrophobic core of the VWF A2 domain, the ADAMT13 spacer 
domain recognises the residues Glu1660-Arg1668 of the A2 VWF domain. 
Interaction between these sites lead to tight binding (step 3). The interaction 
19 
 
between the ADAMTS13 exosite residues Arg349/Leu350 in the disintegrin-
like domain then forms a low-affinity interaction with Asp1614 in VWF (step 4) 
allowing the essential binding between Leu1603 and the complementary S3 
subsite in the ADAMTS13 metalloprotease domain (residues Leu198, Leu232 
and Leu 274); (step 5). Collectively, these interactions position the Tyr1605-
Met1606 scissile bond over the ADAMTS13 active site (step 6) allowing further 
interactions between subsites in this area, leading to the proteolysis of VWF 
(step 7) (Crawley et al., 2011).  Cleavage of the scissile bond reduces the 
affinity between ADAMTS13 and VWF, allowing recycling of ADAMTS13. 
 
1.3.1 Sites of VWF proteolysis by ADAMTS13 
It has been suggested that there are three sites where VWF proteolysis 
occurs: at the site of vessel damage, in free circulation and at the endothelial 
surface (Crawley & Scully, 2013). 
 
1.3.1.1 Site of vessel damage 
At the site of vessel damage the unravelling of VWF not only exposes the 
platelet-binding sites, which enable it to perform its critical role in primary 
haemostasis, but also exposes the ADAMTS13 cleavage site, which allows 
proteolysis. Hence there is a balance between pro- and anti-platelet-binding 
functions. The binding of platelet GPIbα to VWF occurs rapidly at a rate that 
exceeds VWF proteolysis (Kim et al., 2010). At the site of vessel damage, 
collagen and thrombin are activators of activated platelets that promote more 
adhesion and aggregation, leading to formation of the haemostatic plug. At 
this point the platelets become resistant to the consequences of VWF 
proteolysis but as the plug extends further, exposure to collagen and thrombin 
is lessened and ADAMTS13 is able to cleave VWF and limit platelet plug 
formation to the site of vessel damage (Shida et al., 2008). 
 
1.3.1.2 Free circulation 
The microvasculature is a high shear environment, as are vessels that are 
stenosed. Typical shear rates in small arteries are in the range of 1,000s-1 
(Schneider et al., 2007). Some ULVWF is released into the circulation but 
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exists in globular form with platelet-binding sites hidden. In high shear 
environments these multimers uncoil, which could lead to unwanted platelet 
binding but unravelling also exposes the ADAMTS13 proteolytic site. Larger 
VWF multimers are thus processed into sizes that are less susceptible to 
uncoiling by shear force unless bound to collagen. 
 
1.3.1.3 Endothelial surface 
VWF released from the endothelia can be in the hyper-reactive ULVWF form 
which must be processed. If unprocessed, this could lead to the development 
of microthrombi. It has been found that the Weibel-Palade bodies containing 
VWF fuse with the plasma membrane of the endothelial cell to release the 
multimeric VWF. The VWF unravels as it is released through this aperture in 
the plasma membrane and is transiently tethered to the endothelial surface. 
The shear forces in the circulation unravel the VWF and allow it to conform to 
a string-like conformation, allowing processing of the multimers by 
ADAMTS13. The multimers that are released then adopt a globular form in the 
free circulation (Crawley & Scully, 2013). Another level of control exhibited by 
ADAMTS13 may be due to its apparent localization at the endothelial surface, 
thereby enabling the cleavage of ULVWF multimers at the site of release from 
the Weibel-Palade bodies (Vomund & Majerus, 2009). It has been found that 
there is an increased proteolysis of VWF by endothelial-bound ADAMTS13 
compared to ADAMTS13 in solution and the thrombospondin (TSP1) repeats 
are necessary for this endothelial localization. It has been postulated that the 
glycoprotein CD36 is responsible for this binding (Davis et al., 2009). Due to 
this localization, which would more likely occur during an acute phase as VWF 
is an acute phase protein, the apparent concentration of ADAMTS13 in the 
circulation would drop. This has been seen clinically (Rossi et al., 2001). 
Decreased levels of plasma ADAMTS13 have been seen in patients post-
surgery, in those with acute inflammatory illnesses and in pregnant patients in 
the second and third trimesters. Interestingly, in patients with congenital TTP, 
infusions of fresh frozen plasma are given every 2-3 weeks, allowing 




1.4 Pathologies of the ADAMTS13-VWF axis 
Several pathologies have been associated with the imbalance of VWF size 
caused by the dysfunction of ADAMTS13-mediated regulation. The hallmark 
of Type 2A von Willebrand’s disease is the absence of high molecular weight 
VWF multimers which is brought about by two broad mechanisms. Firstly, 
mutations in the A2 domain of VWF lead to destabilisation and unfolding of the 
protein in the circulation, leading to excessive proteolysis by ADAMTS13 (i.e. 
extracellular processing by ADAMTS13); (see section 1.1.3). This reduces 
platelet binding and as a result leads to excessive bleeding (Xu & Springer, 
2013). The second mechanism is due to intracellular processing of VWF, 
leading to qualitative abnormalities in VWF. 
 
Reduced levels of ADAMTS13 or reduced function may be due to the 
presence of autoantibodies to ADAMTS13, leading to unwanted platelet 
tethering, excessive platelet aggregation and disseminated microvascular 
VWF with platelet-rich thrombus formation. This results in thrombotic 
thrombocytopenic purpura. 
 
1.4.1 Thrombotic thrombocytopenic purpura (TTP) 
1.4.1.1 Incidence 
TTP is rare, with a reported incidence of ~6 cases per million per year (Scully 
et al., 2008). Two main subgroups of TTP have been identified: acute 
idiopathic or acquired TTP and congenital TTP (cTTP or Upshaw-Schulman 
syndrome). The latter occurs more rarely, with approximately 100 patients 
described worldwide (Scully et al., 2012). TTP may present at any age, from 
neonate to adult, but the mean age of acute presentation is 20-30 years of 
age. Approximately 7% present as neonates/in childhood (<18 years old); 
(Moatti-Cohen et al., 2012). The disease affects more women with a ratio of 
1:2 male to female, which also applies to autoimmune disorders in general. 
 
1.4.1.2 Pathophysiology of TTP 
As described previously, where control breaks down in ADAMTS13 deficiency, 
the decreased VWF proteolysis results in platelet-rich thrombus formation, 
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which breaks off as microthrombi into the microcirculation (Levy et al., 2001). 
These result in the fragmentation of erythrocytes, leading to microangiopathic 
haemolytic anaemia (MAHA), and often embolise to distal sites causing end-
organ damage. The consumption of platelets also leads to thrombocytopenia. 
These processes define the characteristics of TTP. 
 
1.4.1.3 Signs and symptoms of TTP 
Although TTP was originally defined as a pentad of symptoms, patients do not 
frequently present with all five. Approximately 65% present with neurological 
symptoms such as confusion, headache, dysarthria or visual problems and 
42% presented with cardiac involvement such as chest pain, heart failure and 
hypotension (Scully et al., 2008). However, all patients present with 
thrombocytopenia (platelet count 10-30 X 109/L);(Scully et al., 2012). This is 
due to the sequestration of platelets in microvascular thrombi. Low 
haemoglobin levels (80-100g/L), the presence of schistocytes on blood film 
and elevated lactate dehydrogenase are evidence of MAHA, which is 
pathognomonic. A raised reticulocyte count and low haptoglobin levels as a 
result of MAHA is also seen. The direct Coombs test is negative (Scully et al., 
2012). 
 
1.4.1.3 Acquired TTP 
Deficiency in idiopathic or acquired TTP is usually due to the presence of 
autoantibodies (usually IgG and, less frequently, IgA or IgM) directed against 
ADAMTS13, which reduce its activity/availability (Furlan et al., 1997; 
Scheiflinger et al., 2003). This is the more common form of TTP, affecting 95% 
of cases and has not been associated with any particular precipitant (Scully et 
al., 2008).  Several studies have found that the autoantibodies are directed 
towards epitopes in  the cysteine-rich/spacer domains, particularly the 
residues Pro660, Tyr661 and Tyr665 (Klaus et al., 2004; Pos et al., 2010). 
These domains are important in mediating tight binding between ADAMTS13 
and VWF.  Autoantibodies to the C-terminal domain of ADAMTS13 (TSP2-8 
and CUB domains) have also been identified but are thought not to have 
inhibitory effects by comparison (Zheng, 2010). Antibodies may inhibit 
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ADAMTS13 itself (Peyvandi et al., 2004; Tsai & Lian, 1998) or promote 
enhanced clearance of the protein (Scheiflinger et al., 2003). Approximately 
15% of cases have been associated with certain drugs such as quinine, 
simvastatin, trimethoprim and PEGylated interferon (Scully et al., 2012). 
Acquired TTP may also develop secondary to other diseases such as HIV, 
infection or transplantation. 
 
1.4.1.4 Inherited (congenital) TTP 
The main pathophysiological mechanisms of congenital TTP are defects in 
ADAMTS13 secretion and/or catalytic activity due to one or more mutations in 
the ADAMTS13 gene. It is inherited as an autosomal recessive disease (Levy 
et al., 2001) and is also known as Upshaw-Schülman syndrome (USS); (OMIM 
accession number 274150). Diagnosis of the subtypes is now characterised 
by ADAMTS13 activity being less than 5% of normal and the presence of 
autoantibodies and/or inhibitors (Scully et al., 2011). 
 
To date, there have been over 100 mutations reported throughout the 
ADAMTS13 gene (Lotta et al., 2010) including missense, insertions, deletions 
and splice site mutations. Approximately 60% are missense mutations and 
localize primarily in the 5’ half of the gene, towards the N-terminal end of the 
protein. Variations in ADAMTS13 activity or secretion have been documented 
and reviewed (Lotta et al., 2010). This diversity goes some way to explaining 
the clinical variability seen in congenital TTP. Some patients present in the 
neonatal period; others present in childhood or as adults whereas others may 
present only after a physiologically challenging event such as pregnancy or 
sepsis, despite having persistently low levels of ADAMTS13. After diagnosis 
of TTP some patients require frequent treatment whereas others may require 
treatment only after an infection (Camilleri et al., 2012; Donadelli et al., 2006). 
The clinical severity of disease episodes is also variable, with some patients 
presenting with asymptomatic thrombocytopenia and anaemia, through to 
multi-organ failure. Adult-onset disease may prove fatal or patients may 




A recent study has linked the genotype to the amount of residual ADAMTS13 
activity and the clinical features of the disease, but individual exceptions have 
been found with relatively high residual activity having early disease episodes 
or frequent recurrences (Lotta et al., 2012). Most patients with TTP are 
compound heterozygotes  although homozygotes have been reported, 
particularly in consanguineous families (Palla et al., 2009).  Usually, to cause 
severe ADAMTS13 deficiency (<5% activity) both alleles must be affected. 
Heterozygous carriers of an ADAMTS13 mutation are usually asymptomatic 
and free of TTP–like symptoms. The majority of mutations that have been 
analysed cause a severe deficiency due to aberrant folding of the protease, 
leading to intracellular retention. However, less severe phenotypes have also 
been associated with only one heterozygous mutation (Camilleri et al., 2008; 
Donadelli et al., 2006) which could be explained by the presence of a 
combination of single nucleotide polymorphisms (SNPs) contributing to the 
phenotype (Camilleri et al., 2012; Lotta et al., 2010; Plaimauer et al., 2006). 
SNPs may be defined and differentiated from mutations by being genetic 
variants with an allele frequency of greater than 1% in the population and are 
present in the germline (Tseng & Kimchi-Safarty, 2011). These SNPs, in the 
presence or absence of mutations, could contribute to gain-of-function or loss-
of-function phenotypes (Camilleri et al., 2012; Plaimauer et al., 2006). 
 
1.4.1.5 Treatment of TTP 
TTP is an acute, life-threatening illness that requires prompt and effective 
treatment. The standard treatment is daily plasma exchange therapy which 
has led to a reduction in mortality from ~ 90% to between 10 and 20% (Scully 
et al., 2008). This removes circulating anti-ADAMTS13 antibodies in the 
acquired form of TTP and replaces ADAMTS13 in the inherited form. The 
number of exchanges required is patient-specific but is generally more 
frequent in antibody-mediated TTP due to the continual synthesis of auto-
antibodies. Treatment is continued until two days after normalization of platelet 
count. As low levels of ADAMTS13 are needed to normalize ULVWF size in 
the plasma, treatment for the inherited form is typically every 3-4 weeks (Scully 
et al., 2008).  
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1.5 Single nucleotide polymorphisms 
Variation in the human genome can be brought about by single nucleotide 
polymorphisms and copy number variation. SNPs are associated with obvious 
phenotype variations such as blood group and eye colour and with less 
obvious factors such as responses to drugs and susceptibility to disease. With 
the full sequencing and mapping of the human genome, linking the effects of 
these SNPs to functional outcomes has become a major focus in structural 
bioinformatics. 
 
There are an estimated 150,482,730 common non synonymous SNPs in the 
human population (NCBI dbSNP Human Build 146), with each person 
expected to be heterozygous for 24,000-40,000 of these variants (Ng & 
Henikoff, 2006). SNPs in the human population are observed less frequently 
than expected from the overall mutation rate. It could be argued that this is 
evidence that they are under selection pressures. If a random mutation occurs 
in a coding region it should lead to an amino acid change approximately 2/3 of 
the time (in consideration of the degeneracy of the genetic code) but non 
synonymous SNPs lead to only half of the observed coding SNPs in the human 
genome. Also, non-conservative amino acid substitutions (i.e. substitution of 
amino acid with one of different physio-chemical properties) occur at 
approximately half the rate of conservative amino acid substitutions (one of 
similar properties), indicating they are under selection pressures. Non-
synonymous SNPs therefore may play a role in human health by altering 
protein expression and function (Ng & Henikoff, 2006). Thirty five non-
synonymous SNPs have been identified in the coding region of the 
ADAMTS13 gene (from 
SNPedia<http://www.snpedia.com/indexphp/ADAMTS13> [accessed 







Table 1.3 SNP reference numbers (from SNPedia)  





































The effect of SNPs has been further analysed (Kokame et al., 2002). Two 
Japanese families with USS (with neonatal onset and frequent relapse) were 
analysed and the resultant mutations/SNPs expressed in vitro using HeLa 
cells. The mutations R268P (G803C), Q449stop, C508Y and the SNP P475S 
were expressed and it was found the two former mutations caused non-
secretion whereas the other mutation and SNP showed normal secretion but 
minimal activity. On analysing the ADAMTS13 gene of 304 normal, healthy 
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controls, approximately 10% carried the p.P475S SNP. Activity in the control 
group showed wide variation, with ranges between 60-150% that of pooled 
normal plasma. It was postulated that the mutation leading to decreased 
secretion would affect protein folding or stability. Other synonymous changes 
were found whereupon the same amino acid would be found in the protein, 
which were T420C, C546T, G1716A, C2280T and C4421A. These 
synonymous changes would not alter amino acid sequence but could possibly 
affect expression level though gene transcription or RNA processing (Edwards 
et al., 2012). 
 
1.6 TTP Animal models 
1.6.1 Murine models 
The use of animal models has been used to further understand the 
pathophysiology of congenital TTP. Two groups have generated Adamts13-
knockout mice. Motto et al. disrupted the ADAMTS13 gene by replacing exons 
1-6. This resulted in a complete loss of activity but none of the Adamts13-/- 
knockout mice showed evidence of TTP such as  thrombocytopenia, 
schistocytosis or evidence of VWF-rich thrombi (Motto et al., 2005). Banno et 
al. also created ADAMTS13-deficient mice by eliminating exons 3-6 in the 
ADAMTS13 gene (Banno et al., 2006). There were no differences between the 
knockout mice and Adamts13+/+ in response; both strains produced viable 
offspring exhibiting normal development and survival. Motto et al. then 
backcrossed this pedigree with Adamts13-/- mice. This resulted in 
ADAMTS13-deficient mice that exhibited lower average platelet counts and 
decreased survival rates and showed a clear thrombotic phenotype such as 
increased longevity of VWF strings and an increase in VWF-mediated platelet-
endothelial interactions. These mice also exhibited a proinflammatory state (as 
observed by increased leukocyte rolling and adhesion in stimulated venules 
and enhanced extravasation of neutrophils). This suggests ADAMTS13 has 
antithrombotic and anti-inflammatory effects. 
 
Considering that lack of ADAMTS13 does not induce TTP in knockout mice, it 
has been suggested that a second hit is necessary. Two ‘second hits’ have 
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been shown to successfully induce TTP-like symptoms in murine models. The 
first is a shiga toxin (this is mainly produced by Shigella dysenteriale and 
certain strains of Eschericia coli). It has been shown that the pentameric B 
subunits of the shiga toxin are sufficient to induce UL-VWF secretion from 
endothelial cells via the GbIII receptor present in lipid rafts. The administration 
of shiga toxin in Adamts13-/- mice gave rise to symptoms closely resembling 
human TTP. CASA/Rk mice (deficient in both VWF and ADAMTS13) were not 
susceptible to shiga toxin. There was no correlation found between elevated 
VWF plasma levels and mortality or thrombocytopenia. Other genetic and/or 
environmental factors may be involved which determine the response of these 
mice to shiga toxin, protecting them from the more severe phenotype. 
 
1.6.2 Baboon model 
Feys et al. used the baboon (Papio ursinus) to model congenital TTP. A series 
of monoclonal antibodies (mAb) was generated and one was identified in vitro 
which fully inhibited human ADAMTS13. This inhibitory mAb was administered 
to healthy baboons and it was found that the activity of ADAMTS13 fell below 
the detectable limit of <5%. This effect was not observed in knockout mice. 
The inhibition of ADAMTS13 immediately provoked TTP symptoms in all test 
animals resulting in severe thrombocytopenia and haemolytic anaemia, 
reflecting early-stage TTP. It was observed that endothelial activation with 
concomitant VWF release were major contributions to TTP. However, early-
stage symptoms only were observed, suggesting an additional trigger would 
be necessary to provoke the end-stage symptoms seen in humans (Feys et 
al., 2010). 
 
1.7 Additional factors and triggers of TTP 
1.7.1 Inhibition 
ADAMTS13 has been found to be susceptible to proteolytic degradation by 
plasmin and thrombin (Crawley et al., 2005) . It is also susceptible to inhibition 
by free haemoglobin (Klaus et al., 2004) and interleukin-6 (Bernardo et al., 




Pregnancy has been found to be a trigger for congenital TTP and has been 
reported to represent 5-10% of all adult TTP cases (George et al., 2008; 




Acute infection has been associated with a TTP trigger in patients with low 
residual ADAMTS activity due to the presence of autoantibodies. In a French 
cohort of patients, 41% of acute episodes of TTP were associated with 
infection, particularly in patients with polymorphisms in the toll-like receptor 9 
(TLR 9), which may be associated with acquired TTP (Morgand et al., 2014). 
It has been suggested that infectious diseases may trigger episodes of TTP 
through the release of polymorphonuclear components such as circulating 
DNA and histone fragments (Fuchs et al., 2013). This may also explain the 
development of TTP in mice after endothelial activation with shiga toxin (Motto 
et al., 2005). 
 
1.7.4 The role of complement in endothelial activation 
There may also be a significant role of complement, which is part of the innate 
immune response, in the development of microvascular thromboses seen in 
TTP. In a recent review it was argued that complement activation is a common 
effector leading to endothelial injury and microvascular thrombosis in TTP, 
atypical HUS (aHUS) and Stx-producing Eschericia coli- associated HUS 
(Noris et al., 2012). In a recent study (Ruiz-Torres, 2005), two out of four 
patients with congenital TTP showed lower serum levels of C3 in the acute 
phase of the disease compared with healthy controls, indicating complement 
consumption.  
Noris et al. researched a case series whereby 15 patients with familial 
microangiopathy were assessed for serum levels of C3. It was found that 11 
patients had reduced levels, irrespective of a diagnosis of  TTP or HUS,  
indicating C3 consumption through the activation of complement  (Noris et al., 
1999). In a separate ex vivo study, sera from patients with acute TTP induced 
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more C3 and C5b-9 deposits on microvascular endothelial cells compared with 
sera from healthy controls. There was no observed difference in C4 deposits, 
indicating that the alternative pathway was activated. Pre-incubation with sera 
from patients with TTP showed upregulation of the expression of P selectin on 
human microvascular cells, resulting in a prothrombotic effect. 
In another study by Ruiz-Torres et al. it was found that sera from patients with 
TTP also had a marked effect on neutrophils by increasing the oxidative burst 
and degranulation, increasing the cytotoxic effects towards endothelial cells. 
Furthermore, the effects of TTP sera on the endothelium and neutrophils were 
abrogated by a blockade in complement. The researchers concluded there is 
a role of complement in microvascular thrombosis of TTP. (Ruiz-Torres et al., 
2005). 
Further research groups have measured complement activation in 13 patients 
with acute acquired TTP (Reti et al., 2012). It was found that levels of C3a and 
C5b-9 correlated with disease activity and these markers decreased with 
plasma exchange and normalised in remission. A decrease in complement C3 
levels indicative of consumption was seen in 15% of patients. There was no 
significant difference in the classical or lectin pathway activation markers, 
further indicating activation of the alternative pathway (Reti et al., 2012). 
Endothelial deposition of C3d, C4d and C5b-9 has also been observed on skin 
biopsy in a patient with severe acquired TTP, indicating complement activation 
(Tsai et al., 2013). 
With respect to the mechanism of complement activation in TTP, Polley et al. 
have postulated that endothelial damage and platelet thrombi initiate the 
coagulation and fibrinolytic pathways which may amplify complement 
activation through the direct cleavage of C3 and C5 by thrombin or other 
activated proteases (Polley & Nachman, 1978). Interestingly, it has been 
documented that a patient with acquired TTP did not respond to the usual 
established treatment but did respond to the anti-C5 humanized monoclonal 
antibody eculizumab which is further evidence of complement activity in TTP 




1.8 The role of ADAMTS13 in stroke and myocardial infarction 
An association between low ADAMTS13 plasma levels and the risk of 
myocardial infarction (MI) has been found (Crawley et al., 2008). Low levels of 
ADAMTS13 have also been observed in severe sepsis, disseminated 
intravascular coagulation (DIC) and complicated malarial infection 
(Schwameis et al., 2015). De Vries et al. recently carried out a large 
population-based cohort study (the Rotterdam Study) which looked at the 
contribution of genetic variation to ADAMTS13 with a hypothesis-free genome 
wide association study (GWA); (De Vries et al., 2015). This study was 
undertaken to investigate the association between ADAMTS13 levels and MI. 
ADAMTS13 activity was measured in more than 6,000 individuals and SNPs 
for common and rare genetic variants genotyped. After analysis, the SNP p. 
A732V was the strongest determinant of ADAMTS13 activity and was 
associated with a decrease of more than 20%. An independent association 
was found with a common variant in the SUPT3H gene outside the 
ADAMTS13 locus and five other genetic variants including p.R1060W. The 
gene SUPT3H codes for the transcription initiation protein SPT3. The 
p.R1060W mutation was found with a frequency of 0.06% in this population 
and was associated with a decrease of 47.6% in plasma activity. The more 
common insertion mutation 4143insA, found predominantly in north and 
central Europe, was not found in this population. This may be due to rare 
genetic variants showing greater geographic clustering than common variants 
(Miyata, 2015). The allele frequency of the p.R1060W variant was established 
as 0.06%, indicating a significant number of individuals carry this variant and 
may have a greater risk for TTP or an increased risk of MI or stroke. This 











To analyse the effect of SNPs within the ADAMTS13 gene, singly and in 
combination with mutations, on the expression of ADAMTS13 in vitro and 
relate these findings to clinical phenotype 
 
Objectives 
The objectives of this study were: 
o to create expression vectors containing ADAMTS13 mutations and/or 
SNPs that have been found clinically and to express the resultant 
ADAMTS13 on western blot and semi-quantify the level of ADAMTS13 
secretion by densitometry.  
o To compare the level of expression of ADAMTS13 in vitro with previous 








Materials and methods 
2.1 Construction of ADAMTS13 single nucleotide polymorphisms 
(SNPs), missense and deletion mutations 
The sequence for human ADAMTS13 cDNA was obtained from EMBL-EBI 
(www.ebi.ac.uk, gene ENSG 00000160323, CCDS 6970.1, accessed 
21.11.13). The genotypes of 17 congenital TTP patients referred to  the UK 
TTP Registry at UCL have been previously elucidated (Camilleri et al., 2012). 
In order to locate mutagenic primer sites, the nucleotide substitutions and one 
deletion identified in the genotype of patients (see Table 2.1) were mapped 
onto the ADAMTS13 cDNA sequence. Some patients carried more than one 
mutation (see Table 2.1). 
 
Table 2.1 Mutations and single nucleotide polymorphisms inserted into ADAMTS13 cDNA 
vector plasmid pcDNA3.1(+) (Invitrogen) with WT ADAMTS13 cDNA insert (from Camilleri et 
al., 2012) 



























2.1.1 Mutagenesis primer design  
Mutagenic oligonucleotide primers were designed individually according to the 
desired mutation/SNP. The required nucleotide change(s) were located in the 
centre of the primer and the number of nucleotides on both sides of the 
mutation/SNP in both forward and reverse primers was between 10-15 bases. 
The minimum GC content was 40% and the primers terminated in one or more 
C or G bases. The following formula was used to calculate the melting 
temperature (Tm) of the primers for substitution (missense) mutations (see 
Table 2.2): 
Tm = 81.5 + 0.41(%GC) – (675/N) – % mismatch 
For deletion mutations, the following formula was used to calculate the Tm (see 
Table 2.2): 
Tm = 81.5 + 0.41(%GC) - (675/N) 
where N = the primer length in bases and values for % GC and % mismatch (between the 
forward and reverse primers) were whole numbers. 
The designed primers were checked and validated against the QuikChange 
Tm calculator at www.genomics.agilent.com.  
Table 2.2 Parameters used to calculate Tm of mutagenic oligonucleotide primers 
Mutation 
Number of  
nucleotides 
% GC % mismatch Calculated Tm Tm (Agilent) 
G305A 33 55 3 80.6 80.4 
C587T 24 75 4 80.1 80.0 
C649C 27 63 4 76.3 78.6 
719_724del 20 95 n/a 81.7 81.7 
G794C+A796T 26 85 7 83.3 80.9 
G803C 23 74 4 78.5 78.1 
C1192T 31 65 3 83.3 78.6 
C1225T 31 61 3 81.7 78.8 
G1308C 31 58 3 80.5 78.6 
G1368T 25 76 4 81.6 80.0 
C1787T 31 55 3 79.2 79.0 
G2068A 27 74 3 83.8 78.1 





C2728T 25 68 4 78.3 78.4 
G2930T 29 59 3 79.2 78.1 
C3178T 23 83 4 78.4 81.6 
C19T 25 68 4 78.3 78.3 
SNP 
C1342G 29 59 3 79.2 78.8 
C1423T 30 60 3 80.6 80.3 
C1852G 29 62 3 80.6 78.9 
C2195T 25 68 4 78.3 78.8 
C2699T 25 68 4 78.3 78.3 
G3097A 29 62 3 70.6 80.2 
 
Primers were designed between 20 and 33 bases long with a Tm of >77 °C 
(see Table 2.3). The primers were manufactured and HPLC purified by 
Eurofins Genomics, Germany. Each primer was diluted as a stock solution 
with molecular grade water to a concentration of 625 ng/μl and stored at -80°C. 
The final working solution was diluted to 125 ng/μl and stored at -20 °C. 
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Table 2.3 Mutagenic oligonucleotide primers used to generate specific ADAMTS13 mutations/SNPs 
 
Mutation/SNP Forward primer 5'-3' Reverse primer 5'-3' 
G305A CAG GAG GAC ACA GAG CAC TAT GTG CTC ACC AAC  GTT GGT GAG CAC ATA GTG CTC TGT GTC CTC CTG  
C587T GGT GCG GGG CGT CAT CCA GCT GGG  CCC AGC TGG ATG ACG CCC CGC ACC  
G649C GGA CAC TGG CTT CCA CCT GGG AGT CAC  GTG ACT CCC AGG TGG AAG CCA GTG TCC  
G794C+A796T TCG CCT GGT CCC CCT CCT GCC GCC GG CCG GCG GCA GGA GGG GGA CCA GGC GA 
G803C CTG CAG CCG CCC GCA GCT GCT GA  TCA GCA GCT GCG GGC GGC TGC  AG  
C1192T CGA AGT CCT TGC TCC TGC TCC TGC GGA GGA G  CTC CTC CGC AGG AGC AGG AGC AAG GAC TTC G  
C1225T GTG GTC ACC AGG AGG TGG CAG TGC AAC AAC C  GGT TGT TGC ACT GCC ACC TCC TGG TGA CCA C  
G1308C GAT GTG CAA CAC TCA CGC CTG CGA GAA GAC C  GGT CTT CTC GCA GGC GTG AGT GTT GCA CAT C  
G1368T GAC CGA CGG CCA TCC GCT GCG CTC C  GGA GCG CAG CGG ATG GCC GTC GGT C  
C1787T TCT TCA CAC ACT TGG TGG TGA GGA TCG GAG G  CCT CCG ATC CTC ACC ACC AAG TGT GTG AAG A  
G2068A CTG GGT GTG GGC CAC TGT GCG TGG GCC  GGC CCA CGC ACA GTG GCC CAC ACC CAG  
C2195T AGC AGC CAC CAG TGT GGC CAG AGG C  GCC TCT GGC CAC ACT GGT GGC TGC  T  
T2260C GGA GAC TTC GGC CCA CGC AGC GCC TCC TGT G  CAC AGG AGG CGC TGC GTG GGC CGA AGT CTC C  
C2728T CTC CTG CGG GCG TGG TCT GAT GGA G  CTC CAT CAG ACC ACG CCC GCA GGA G  
G2930T GAG GAT CCT GTA TTT TGC CCG GGC CCA TG  CAT GGG CCC GGG CAA AAT ACA GGA TCC TC  
C3178T CGG CGC TGG TGTGGC CCG AGG CC  GGC CTC GGG CCA CAC CAG CGC CG  
C3484T CCC TGG AGT GGT TCC AGG CCC GG  CCG GGC CTG GAA CCA CTC CAG GG  
SNP 
C19T CAG CGT CAC CCC TGG GCA AGA TGC C   GGC ATC TTG CCC AGG GGT GAC GCT G  
C1342G TGG AGT TCA TGT CGG AAC AGT GCG CCA GG  CCT GGC GCA CTG TTC CGA CAT GAA CTC CA  
C1423T CTG GGG TGC TGC TGT ATC ACA CAG CCA AGG  CCT TGG CTG TGT GAT ACA GCA GCA CCC CAG  
C1852G CTA ACA CCA CCT ACG CCT CCC TCC TGG AG  CTC CAG GAG GGA GGC GTA GGT GGT GTT AG  
C2195T AGC AGC CAC CAG TGT GGC CAG AGG C GCC TCT GGC CAC ACT GGT GGC TGC T 
C2699T TGT GGA CCC CTG TGG CAG GGT CGT G  CAC GAC CCT GCC ACA GGG GTC CAC A  
G3097A GTG GCC TTG GCA CTA CTA GAC GCT CGG TG  CAC CGA GCG TCT AGT AGT GCC AAG GCC AC  
Shaded nucleotide denotes substitution  
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The mutations/SNPs in Table 2.1 were introduced into the ADAMTS13 cDNA 
insert of the pcDNA3.1(+) vector (Invitrogen), using the QuikChange Lightning 
Site Directed Mutagenesis kit (Stratagene, Agilent Technologies, UK) 
according to the manufacturer’s instructions. 
 
2.1.2 The pcDNA3.1(+) vector 
The pcDNA3.1(+) vector (Invitrogen) containing the 5’ sequencing primer T7 
and the ampicillin resistance gene was kindly donated by Dr James Crawley 
at Imperial College, London. A myc tag (comprised of 10 amino acids: N-
EQKLISEEDL-C) had previously been ligated into the insert immediately 
before the stop codon sequence. The size of the plasmid to include the 
ADAMTS13 cDNA insert was approximately 5,500 base pairs (5458bp) and 
with ADAMTS13 insert is 9739 bp long. The vector pcDNA 3.0 (Invitrogen) 
with no insert acted as a negative control in transient transfection studies and 
was also approximately 5,500 base pairs in size (5,446bp). 
 
2.2 Single-site directed mutagenesis (SDM) 
2.2.1 Mutant strand synthesis reaction (polymerase chain reaction) 
The size of the plasmid to include the ADAMTS13 cDNA insert was 9739 base 
pairs. In consideration of this relatively large double stranded (ds) DNA vector, 
the PCR conditions using the Techne Prime™ thermal cycler were optimised 
as follows: 1 cycle at 95 °C for 2 min to denature the DNA template initially; 95 
°C for 20 s to denature the DNA template product; 60°C for 20 s to anneal the 
mutagenic primers to the template; and 68 °C for 8 min to extend the primers 
with Pfu DNA polymerase, (18 cycles) and 68 °C for 8 min (1 cycle) as a final 
extension step. To minimise the number of second site errors, a low 
concentration of ADAMTS13 DNA template (1 µL of 50 ng/µL solution, giving 
a final concentration of 1ng/uL) and low number of thermal cycles was used 
(18 cycles). An excess of oligonucleotide primers was used to increase 
mutagenesis efficiency (1 µL of 125 ng oligonucleotide primers forward and 




Table 2.4 Preparation of sample reaction, single site SDM 
PCR reaction component Volume (μL) 
10x reaction buffer 5 
50ng dsDNA template 1 
125 oligonucleotide primer 1 1 
125 oligonucleotide primer 2 1 
dNTP mix  1 
QuikSolution reagent (Agilent 
Technologies, UK) 
1.5 
Molecular grade water 39.5 
 
All other cycling parameters were as per the manufacturer’s protocol.  
 
2.2.2. Digestion of amplification products and transformation 
The treatment of PCR products with DpnI restriction enzyme (Agilent 
Technologies, UK) to digest the parental methylated and hemi-methylated 
non-mutated plasmid DNA was optimised to 1 hour at 37 °C. In brief, 2 μl DpnI 
was added and thoroughly mixed with the amplification products and 
incubated at 37 °C for 1 hour. The digested products were then transformed 
into XL10-Gold ultracompetent E.coli cells for nick repair: 45 μl cells thawed 
on wet ice were added to a pre-chilled round bottomed polypropylene Falcon® 
BD tube (Fisher Scientific, UK) and 2 μl β-mercaptoethanol was added and 
swirled to mix. After 2 min incubation on wet ice, 2 μl Dpn I treated 
amplification product was added, gently mixed and further incubated on wet 
ice for 30 min. Following this step, the Falcon tube was heat pulsed in a water 
bath for 30 s at 42 °C and further incubated on wet ice for 2 min. A volume of 
0.5 ml preheated (42 °C) NZY+ broth (see Appendix 1) was added and the 
tube incubated at 37 °C with shaking at 240 rpm for 1 hour.  
The products of the transformation reaction were spread on Luria Bertani (LB) 
agar plates (see Appendix 1) containing 0.1mg/ml ampicillin at volumes of 50, 
100, 150 and 200 μl. The plates were incubated at 37 °C for >16 hours and 
stored at 4 °C until further analysis. If no or a low number of colonies were 
found the volume of Quik solution (Agilent Technologies, UK) was increased 
to 2 μl, and/or 5 μl 5 % DMSO (Applichem, Germany) was added to the PCR 
mixture and the volume of water adjusted accordingly.  
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2.3 Multi-site directed mutagenesis (multi-SDM) 
To introduce more than one SNP together with a mutation into the dsDNA 
plasmid, the QuikChange Multi site-directed mutagenesis kit was used (Agilent 
Technologies, UK). This was performed on mutations G649C and G305A to 
introduce three SNPs together with the mutation. The dsDNA template already 
containing the required mutation was used and up to three nucleotide 
changes, reflecting the patient genotype, were inserted. Initially, thermal 
cycling was performed to denature the mutant DNA template and the 
mutagenic primers of the SNPs were annealed to the template, with all primers 
binding to the same strand. The PfuTurbo polymerase then extended the 
primers, generating dsDNA molecules, with one strand containing multiple 
mutations together with nicks, which were then sealed by the enzyme blend. 
The parental blend was then digested with Dpn I, as per the single site SDM 
method described previously.  To transform XL10-gold Ultracompetent cells 
(Agilent Technologies, UK), 45 μl cells were gently thawed on wet ice and 
added to a pre-chilled round bottomed polypropylene Falcon® BD tube (Fisher 
Scientific, UK). As per the single SDM reaction, 2 μl β-mercaptoethanol was 
added and the mixture swirled every 2 min for a total of 10 mins, after which 
1.5 μl Dpn I treated DNA from each mutagenesis reaction product was added 
to the ultracompetent cells. This was gently mixed and further incubated on 
wet ice for 30 min. Following this step, the Falcon tube was heat pulsed in a 
water bath for 30 s at 42 °C and further incubated on wet ice for 2 min. A 
volume of 0.5 ml preheated (42 °C) NZY+ broth (see Appendix 1) was added 
and the tube incubated at 37 °C with shaking at 240 rpm for 1 hour.  
 
The products of the transformation reaction were spread on Luria Bertani (LB) 
agar plates (see Appendix 1) containing 0.1mg/ml ampicillin at volumes of 1 
μl, 10 μl, and 100 μl. The plates were incubated at 37 °C for >16 hours and 
stored at 4 °C until further analysis. The mutant, closed circle ssDNA was 
converted into dsDNA in vivo. 
The primers used for single site SDM were used as per the multi-site method. 
In order to add primers in approximately equimolar amounts, the length 
between primers was established and, as there was less than 20% difference, 
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no adjustment in volume was made (see Table 2.5). The primers were diluted 
to a concentration of 100 ng/μl from the working solution of 125 ng/μl. 
Table 2.5 SDM primer length used in multi-site SDM 
Mutations incorporated within dsDNA 
template 
SNP primer Primer length 
(nucleotides) 
G305A C1342G (p.Q448E) 29 
 C1852G (p.P618A) 29 
 C2699T (p.A900V) 25 
G649C C19T (p.R7W) 25 
 G3097T (p.A1033T) 29 
 C1342G (p.Q448E) 29 
 
2.3.1 Control reaction for multi-SDM 
A control reaction was first performed to test the efficiency of simultaneous 
SDM at three independent sites. The principle of this control method was 
based on the production of β-galactosidase, encoded by the LacZ gene, 
resulting in blue colonies on media containing X-gal in the presence of the 
inducer IPTG (see Appendix 1). The template encoded the first 146 amino 
acids of β-galactosidase and contained stop codons at three positions in the 
LacZ coding sequence. These modifications prevented the production of β-
galactosidase and resulted in the appearance of white colonies on X-gal 
media. The control primers converted the individual stop codons to wild type 
in the LacZ gene. All three reversion events were required to produce blue β 
gal+ colonies. Each plate was scored for the triple mutant plasmid (blue vs 
white colonies).  
The control reaction was prepared and components added in the order shown 
in Table 2.6. 
Table 2.6 Preparation of sample reaction multi-site SDM 
Reaction component  Volume (μl) 
10X reaction buffer 2.5 
Molecular grade water 18.5 
Quik solution - 
dsDNA template (50ng) 1 
Mutagenic primers (100 ng per primer) 1 
dNTP mix 1 




The cycling parameters seen in Table 2.7 were used: 
Table 2.7 Cycling parameters for multi-site SDM PCR 
Stage Number of cycles Temperature Time (min) 





95 °C 1 
55 °C 1 
65 °C 17 
3 1 65 °C 8 
 
 
For Dpn I digestion of the amplification products, 1 μl restriction enzyme was 
added, mixed thoroughly and incubated at 37 °C for 1 hour. For the 
transformation, 45 μl slowly thawed XL10-Gold ultracompetent cells were 
aliquoted into 14 ml Falcon® round-bottomed polypropylene tubes. β-
mercaptoethanol (2 μl) was added, gently mixed and incubated on ice for 10 
min, swirling gently every 2 min. Dpn I treated DNA (1.5 μl) from the control 
reaction was then added to the cells, swirled and incubated on wet ice for 
30 min. The heat pulse and incubation steps were carried out as per the single 
site SDM protocol. A volume of 10 μl of the control transformation reaction was 
plated onto LB-ampicillin agar plates that were prepared with 80 μg/ml X-gal 
and 20 mM IPTG and incubated at 37 °C overnight  (<16h) (see Appendix 1).  
It was expected that >50% colonies from the control mutagenesis 
transformation should appear as blue colonies on X-gal agar plates. The 
expected number of colonies per plate was between 50 to 800. 
2.3.2 Mutant strand PCR for multi-SDM 
The parameters for thermal cycling of mutant strand synthesis can be seen in 







Table 2.8 PCR components for multi-site (Agilent Technologies, UK) 
 
Reaction component Volume 
10 X reaction buffer 2.5 μl 
Molecular grade water Final volume 25 μl 
Quik solution 0.5 μl 
dsDNA template (50-100ng) 1 μl (100 ng) 
Mutagenic primers (100 ng per primer) 1 μl (100 ng for each primer) 
dNTP mix 2 μl 
QuikChange Multi enzyme blend 1 μl 
 
All other parameters were followed as per the Multi site control reaction, with 
the exception of the plating out volumes on LB agar, which were 1 μl, 10 μl 
and 100 μl. 
2.4 Mini preparation of colonies 
 
Eight colonies were picked from a range of plates and incubated overnight (16 
h) in 5 mL LB media containing 0.1 mg/ml ampicillin sodium salt (Calibiochem) 
to an optical density at 600nm (OD600) of 1.2-1.6. A negative control was 
performed with each run, using 5 ml media with no inoculation. Following 
incubation, plasmid glycerol stocks were prepared by mixing 810 µL LB culture 
with 190 µL 80 % glycerol (VWR, UK) for storage at -80 °C. Plasmid DNA was 
extracted from the remaining inoculum using the QIAGEN QIAprep Spin 
Miniprep kit (QIAGEN, Manchester, UK) according to the manufacturer’s 
protocol. This method utilises the alkaline method of bacterial lysis. In brief, 
the bacteria were pelleted at 5000 rpm for 5 min and the supernatant 
discarded. Using 250 μl Buffer P1 (50mM Tris-HCl,pH 8.0, 10mM EDTA, 
100μg/ml RNAse), the cells were re-suspended and lysed under alkaline 
conditions using 250 μl Buffer P2 (200mM NaOH, 1%SDS). This was 
subsequently neutralised with 250 μl Buffer N3 (4.2M guanidinium-HCl, 0.9M 
potassium acetate), adjusting to high salt binding conditions. The genomic 
DNA and cell debris were pelleted by centrifugation at 13,000 rpm for 10 min 
and the plasmid DNA in the supernatant adsorbed onto the silica membrane 
of the QIAprep spin column in high salt buffer. Subsequent washes with 500 
μl Buffer PB (5M guanidinium-HCl, 30% isopropanol) removed endonucleases 
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and salts were removed with 500 μl Buffer PE (10mM Tris-HCl, pH 7.5, 80% 
ethanol). Plasmid DNA was eluted with 50 μl Buffer EB (10mM Tris-HCl), 
ensuring a pH of 7.0-8.5 which allowed storage of the plasmid solution at 4 °C. 
The DNA concentration of the resultant plasmids was quantified using the 
Nanodrop 2000 spectrophotometer (Thermo Scientific). 
 
2.5 Sanger sequencing to verify successful nucleotide change 
The presence of the expected mutation or SNP and the absence of unwanted 
non-synonymous mutations (NSM) were verified by Sanger sequencing 
(GATC Biotech, Germany), which utilised the KB™ Basecaller (Applied 
Biosystems). Prior to sequencing, plasmid DNA samples were diluted to a 
concentration of 100 ng/µL. In order to sequence the whole plasmid insert, a 
total of 6 forward and reverse sequencing primers were designed using Primer 
3 software (www.primer3.ut.ee), ensuring an approximate overlap of 200 
nucleotides between each amplification product. The T7 promoter site on the 
pcDNA3.1+ plasmid was utilised for sequence 1. Primers were designed with 
a Tm between 57 °C and 61 °C and were between 18 and 20 nucleotides in 
length (see Table 2.9). Chromas Lite (Technylesium Pty Ltd,) software was 
used to open chromatograms for analysis 
(<http://www.technelysium.com.au/wp/chromas>). The sequence data was 
then exported in FASTA format to the multiple sequence alignment tool Clustal 
Omega (<http://www.ebi.ac.uk/Tools/msa/clustalo/>). Prior to initial SDM 
cloning, sequencing of the wild type insert was performed to ensure no 
unwanted nucleotide changes leading to non-synonymous amino acid 
changes were present in the insert. The alignments were scrutinised for any 
variation from the wild type cDNA sequence. If variations were present, these 
were compared to the reference amino acid/codon sequence alignment. The 
nucleotide sequence was aligned to the amino acid sequence by using the 
online translate tool ExPASy (expasy.org/translate) to establish whether the 




Table 2.9 Oligonucleotide primers used to sequence ADAMTS13 cDNA 
Primer name Forward primer 5'-3' 
New seq 01 CAG CCT GGC CTC TAC TAC AG 
Seq 02 CAG CCT GGC CTC TAC TAC AG 
Seq 03 GTA CCA CAC AGC CAA GGG   
Seq 04 ACC TTC ACC TAC TTC CAG CC 
Seq 05 GCA CAT CAG CTG GTG GAG 
Seq 06 GAA AGT CAT GTC CCT TGG CC 
Seq 07 GAA AGT CAT GTC CCT TGG CC 
 
2.6 Plasmid copy amplification 
Prior to transfection, plasmid copy numbers were amplified and purified using 
maxi and midi prep protocols. 
 
2.6.1 QIAGEN HiSpeed®Plasmid Maxi preparation 
The maxi procedure was performed according to the manufacturer’s protocol. 
In brief, a single colony was picked from a freshly streaked plate of WT/ mutant 
E.coli containing WT/mutant ADAMTS13 cDNA and inoculated into 5ml LB 
medium containing 0.1 mg/ml ampicillin as a starter culture. This was 
incubated at 37 °C and shaken at 250 rpm for approximately 8 hours. For each 
mutation or WT, 250 ml LB medium plus 0.1 mg/ml ampicillin was inoculated 
with 5ml starter culture and grown to a cell density of approximately 3-4 x 109 
cells per ml (3 g/L biomass) by incubating at 37°C and shaking at 240 rpm for 
12-16 hours. Cultures were harvested after 12-16 hours during the transition 
from logarithmic growth to stationary growth phase.  
The cells were then harvested by centrifuging at 5000 rpm at 4 °C for 15 min 
and the supernatant discarded. The resultant pellet was thoroughly re-
suspended in 10ml Buffer P1 and the cells lysed by the addition of 10ml Buffer 
P2. This solution was neutralised by the addition of pre-chilled Buffer N3. The 
lysate was then loaded into a previously equilibrated QIAfilter cartridge and 
incubated at room temperature for 10 min, allowing separation of the genomic 
DNA, proteins and SDS from the plasmid DNA. The filtrate was then loaded 
into the HiSpeed tip allowing the filtrate to adsorb onto the resin. The resin was 
washed with 60 ml Buffer QC and plasmid DNA was eluted with 30 ml Buffer 
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QF. DNA was eluted with the addition of 10.5ml isopropanol (Fisher Scientific, 
UK) and incubated for 5 min. The isopropanol mixture was then filtered through 
the QIA precipitator and the membrane dried. DNA was precipitated with the 
addition of 1 ml Buffer TE and the resultant plasmid stored at 4°C. The DNA 
concentration of the resultant plasmids was quantified using the Nanodrop 
2000 spectrophotometer (Thermo Scientific, UK). 
 
2.6.2 Invitrogen PureLink® HiPure Plasmid DNA purification Midi preparation 
Transformed E.coli cells were grown overnight (16 h) in 250ml LB medium with 
0.1mg/ml ampicillin until the culture was confirmed to have an absorbance of 
1-1.5 at 600 nm, or approximately 1 x 109 cells. The cells were harvested by 
centrifugation at 5,000 rpm at 4 °C and the supernatant discarded. The cells 
were then thoroughly re-suspended in Buffer R3 with RNase (20 mg/ml). Lysis 
buffer (4 ml) which contained 0.2 M NaOH and 1% w/v SDS was added, mixed 
and incubated at room temperature for 5 min. Precipitation buffer (4 ml) 
containing 3.1 M potassium acetate at pH 5.5 was added and gently mixed to 
avoid the shearing of DNA and the solution and precipitate centrifuged at 
13,000 rpm for 10 min at room temperature (RT). The supernatant was then 
loaded onto a previously equilibrated HiPure filter midi column, allowing the 
clearance of bacterial lysates but binding DNA directly to the anion exchange 
resin. Wash buffer (10 ml) containing sodium acetate at pH 5.0 and 825 mM 
NaCl was added to the filter column twice, discarding the flow-through. DNA 
was eluted from the filter column by adding 5 ml elution buffer containing 
100 mM Tris-HCl at pH 8.5 and 1.25 M NaCl. This was followed by a 
precipitation and wash stage. Isopropanol (3.5 ml, Fisher Scientific) was 
added to the eluate and mixed well. The eluate and precipitated DNA was then 
centrifuged at 13,000 rpm at 4 °C for 30 min. The supernatant was discarded, 
ensuring the pellet was not dislodged. Ethanol (3 ml, 70 %) was then added to 
the pellet and centrifuged at 13,000 rpm for 5 min at 4°C. The supernatant was 
removed and the pellet air dried for 10 min. Plasmid DNA was then re-
suspended in 200μl TE buffer containing 100 nM Tris-HCl at pH 8.0. The DNA 
concentration of the resultant plasmid was quantified using the Nanodrop 2000 
spectrophotometer (Thermo Scientific) and the solution stored at -20°C. 
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2.6 Preparation of HEK293T cells 
Approximately two weeks’ prior to transfection, one aliquot (1 mL) of HEK293T 
cells stored in 10% DMSO was taken out of nitrogen storage (77 K) and 
thawed slowly on wet ice. The cells were then added to 10 mL pre-warmed 
(37 °C) Modified Eagle’s Medium (MEM) with Earle’s salts and L-glutamine 
(Invitrogen, UK), containing 10 % fetal bovine serum (Invitrogen) and 10 ml 
penicillin/streptomycin 10,000U/ml (Biochrom AG, Germany). The cells were 
centrifuged at 1,000 rpm for 5 min and re-suspended in fresh MEM before 
being transferred to T75 culture flasks and incubated in a humidified incubator 
(37 °C, 5% CO2). The cells were checked for recovery after 24 hours’ 
incubation and subsequently passaged using 5 mL Dulbecco’s phosphate 
buffered saline (D-PBS, Invitrogen, UK) and 1mL 0.05 % Trypsin-EDTA 
(Invitrogen, UK) at 37 °C when the cells reached 70-80 % confluence. 
Passaging of these cells continued until transfection. 
The number of plated cells was counted using a haemocytometer and these 
were seeded at a density of 5 x 106 live cells per 10 ml plate/ T75 flask or 8 x 
105 per 6 well plate. The use of 0.04 % trypan blue (Sigma Aldrich, UK) in a 
50/50 dilution with the re-suspended cells in media allowed the differentiation 
between live and dead cells and this was reflected in the count. 
It was important to ensure that over-passaging did not occur which may incur 
DNA damage/alteration thus changing the nature of the cells and expression 
of protein. If at any point 20 passaging events were reached, a new aliquot of 
cells was taken from nitrogen storage and passaged as described previously.  
 
2.7 Transfection of HEK293T cells 
2.7.1 Transfection agent 
Branched chain polyethylenimine (PEI) (Invitrogen, UK) was used as a 
transfection agent. A 10 mM solution was prepared by dissolving 4.5 mg PEI 
in 10 mL distilled water, adjusted to a pH of 6.6-7.5 with 1M hydrochloric acid 
and subsequently filtered through a 0.2 µm filter, aliquoted and stored at - 




Ensuring 70-80 % confluence of HEK293T cells, the complete media was 
changed 1 hour prior to transfection. For transfection studies using 10 cm 
culture dishes, a total quantity of 33 ug plasmid DNA was added to 625 µL 
150 mM sterile NaCl per culture dish. For 6 well plates, a total quantity of 6.6 
µg plasmid DNA was added to 125 µL 150 mM sterile NaCl per well. The 
volume required for this quantity of plasmid DNA was calculated from the 
results of the Maxiprep and Midiprep Nanodrop measurements. Using the 
optimum PEI (μL): DNA (μg) ratio of 2.25 for one 10 ml culture dish, 75 µL 
10 mM PEI was added to 625 µL 150 mM DNA (33 μg plasmid DNA) and 
incubated at RT for no longer than 20 min. For 6 well plates, 15μl 10mM PEI 
was then added to 125μl 150mM NaCl. Cells at 70-80% confluency were 
rinsed with 10 mL pre-warmed Opti-MEM® reduced serum medium with L-
Glutamine (Invitrogen, UK) to remove serum contents (2 ml for 6 well plates) 
and 9 mL Opti-MEM® was added (2 mL for 6 well plates). The transfection 
complex consisting of 700 µL (10 ml)/ 140 µL (6 well) PEI mixture was added 
dropwise to the culture dishes/6 well plates containing the cells and Opti-
MEM®, ensuring the transfection complex was evenly distributed. The cells 
were incubated at 37 °C in 5 % humidified CO2 for 2-3 days. The conditioned 
media was then collected from each culture dish and placed on wet ice, 
subsequently centrifuged at 3000 rpm at 4 °C for 5 min to pellet any cell debris 
and the supernatant collected in a clean tube and stored at -80°C before 
analysis. The adherent HEK293T cells were bathed in 1.5 mL (10ml) / 0.8ml 
(6 well) D-PBS (without calcium or magnesium) and harvested from the 
surface of the culture dish/6 well plate using a cell scraper or sterile pipette tip 
and collected in a 15 mL Falcon® tube kept on wet ice. The cells were 
centrifuged at 3000 rpm at 4 °C before the supernatant was discarded. The 
pelleted cells were then stored at -80°C prior to analysis. 
 
2.8 Measure of transfection efficiency 
To measure the efficiency of transfection, a reporter plasmid containing the 
Lac Z gene (kindly donated by Dr Edward Wright, University of Westminster) 
was co-transfected with the WT or mutated ADAMTS13 plasmid. The size of 
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the reporter vector was 8.9kb in total. This allowed the localization of β-
galactosidase activity in fixed cells to be visualized by light microscopy and the 
percentage transfection efficiency to be calculated. With this protocol it was 
necessary to make the assumption that the reporter plasmid was transfected 
at the same rate as the ADAMTS13 plasmid therefore the quantity of plasmid 
containing the Lac Z reporter and the plasmid containing the ADAMTS13 insert 
were transfected in a 1:1 ratio. 
 
For 10 cm culture dishes the media was discarded and 2 ml 0.5% v/v 
glutaraldehyde solution diluted in PBS (Sigma-Aldrich, UK) was added and 
incubated at 4 °C for 10 min. This was discarded, 2 ml PBS added and 
incubated at 4 °C for 5 min. The PBS was discarded and 2 ml X-gal solution 
(final concentration 1mg/ml) added. This was incubated for 1 hour at 37°C and 
protected from light. Following incubation, the cells were examined under the 
microscope. Cells successfully transfected appeared blue. The X-gal and 
buffer were tipped off and cells washed once in PBS. A total of 5 fields were 
visualised microscopically (X100) and imaged for cell counts. For 6 well plates, 
5 μl X-gal and 400 μl buffer and PBS were used.  
 
2.9 Cell lysate preparation 
Lysates previously stored at -80°C were gently thawed and re-suspended in 
0.1% Triton X cell lysis buffer (2ml for 10cm dishes; 800μl for 6 well plates) in 
15ml tubes. This solution was kept on wet ice and the cell suspension 
sonicated using the Bandelin SONOPULS homogeniser probe (MS 72 micro 
tip; Sigma Aldrich, UK) at 35 % power for 5 x 10 s, with 50 s cooling between 
each iteration. The protein content of the sonicated suspension was quantified 







2.10 Concentration of conditioned media 
A total volume of 10 ml per plate and 2 ml per well of conditioned media was 
harvested from 10 cm culture dishes and 6 well plates respectively. The media 
was concentrated using Macrosep™ and Microsep™ Advance Centrifugal 
devices (PALL Life Sciences, UK); see Table 2.10. 
Table 2.10 The concentration of conditioned media 
Culture plate Device Centrifugal conditions 
10 ml  MWCO 30K Omega, Macrosep™ 3,000g, 4°C, 6 min 
6 well  MWCO 30K Omega, Microsep™ 3,000g, 4°C, 2 min 
MWCO =molecular weight cut-off. For maximum retention, a device was selected with a 
MWCO 3 to 6 times less than the molecular weight of the protein to be retained. 
 
The harvested conditioned media was pipetted into the sample reservoir and 
the cap replaced to prevent evaporation. The device was centrifuged for the 
required length of time at 4 °C. It was necessary for the membrane paddle of 
the device to be oriented with the end pointing towards the centre of the rotor 
to ensure adequate microfiltration. After centrifugation the concentrated 
conditioned media was retained in the sample reservoir and transferred to a 
1.5 ml Eppendorf tube kept on wet ice. The protein content of the conditioned 
media was quantified by BCA assay and stored at -80°C prior to analysis. 
 
2.11 Protein quantification 
Total protein quantification of the cell lysates and conditioned media was 
carried out using the Pierce™ BCA Protein Assay kit (Thermo Scientific, UK), 
based on the biuret method. To produce a standard curve the reference 
standard (bovine serum albumin (BSA), 2mg/ml) was diluted to the 
concentrations seen in Table 2.11. The blank used was DMEM media. 
Table 2.11 BCA protein standard concentrations 









The protocol was followed according to manufacturer’s instructions. In brief, 
the working reagent (WR) was diluted 50 parts reagent A with 1 part reagent 
B. A volume of 25 μl of each standard or unknown was pipetted into each 
microwell, with each test performed in triplicate. Working reagent (200 μl) was 
added to each well and mixed thoroughly, the plate covered and incubated at 
37 °C for 30 min then cooled to RT. The absorbance was read at 562nm using 
the BMG Labtech SPECTROSTAR Nano® microplate reader.  
 
2.11.1 Analysis of protein quantification results 
The mean of three absorbance values of standards and unknowns was 
determined and the average blank standard replicate value subtracted. A 
standard curve was plotted of BSA concentration (μg/ml) vs average blank 
corrected absorbance (562nm) for each standard. The concentrations of 
unknown samples were interpolated from the standard curve. 
 
2.12 Western blot 
2.12.1 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS 
PAGE) 
To prepare conditioned media and cell lysis samples, 150 μl sample was 
added to 50 μl 4x Laemmli buffer (pH 6.8; see Appendix 1) and boiled at 
100 °C for 5 min in a 1.5 ml Eppendorf tube. The samples were cooled and 
stored at -20 °C. To prepare the resolving and stacking buffers, Tris base was 
dissolved in 15 ml deionized water and the pH adjusted to pH 8.8 (resolving 
buffer) and pH 6.8 (stacking buffer) using 1M HCl. The final volume was then 
adjusted to 20 ml (see Appendix 1). Buffers were stored at 4 °C for up to 1 
month. To pour the gels, the Bio-Rad Mini-Protean®Tetra casting plates were 
securely placed in the casting stands, ensuring a tight seal was formed. The 
10% acrylamide resolving gel was made up with the APS and TEMED added 
last (see Appendix 1). The gel was added to the casting plates ensuring no 
bubbles formed in the solution. A thin layer of butanol (Fisher Chemical, UK) 
was laid over the top of the gel surface and allowed to set for 30 mins. Once 
set, the butanol was removed and washed off with deionized water. The 4% 
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acrylamide stacking gel was prepared, with APS and TEMED added last (see 
Appendix 1), and laid on the top surface of the resolving gel, again ensuring 
no bubbles were introduced. The gel comb was placed in the stacking gel and 
was allowed to set for 20 mins. 
 
2.12.2 Running SDS PAGE 
Ensuring the BioRad Mini-Protean® gel tank was assembled correctly, the gel 
combs were removed and the tank half filled with running buffer. The wells 
were washed with running buffer before sample loading. Lane 1 was loaded 
with 3 μl Precision Plus Protein™ Dual Colour Standard (Bio-Rad, UK) and 
subsequent lanes loaded with a positive control (WT), cell lysates or 
conditioned media. Protein loading volumes were normalised according to 
concentrations established by the BCA assay. The gels were run for 80 min at 
a voltage of 110V or until the dye front was within 1 cm of the bottom of the 
gel. 
  
2.12.3 Transfer and western blot 
Fifteen min prior to blotting, the nitrocellulose membrane (Hybond™-ECL™, 
Amersham Biosciences, UK) was activated in 100% HPLC grade methanol 
(Fisher Scientific). The gels were removed from the casings and placed in 
chilled transfer buffer for 5 min. Ensuring the correct orientation of the 
cassette, a fibre pad was submerged in buffer onto the cassette and filter 
paper placed over the pad. The gel was then placed on the sandwich and the 
activated membrane placed on top. A second filter paper and fibre pad 
completed the sandwich and any trapped air bubbles removed. The cassette 
was submerged in the transfer buffer. The tank was assembled with a 
magnetic stirrer and ice block in place and filled with chilled transfer buffer. 
The blot was run for 2 hours at 100 V on a magnetic plate to allow for adequate 
heat dissipation. On completion, the blot was disassembled and the 
membrane orientated protein side up. To assess even protein transfer with 
0.1% Ponceau S solution, the membrane was allowed to stand in solution for 
1 min. Distilled water (20 ml) was used to rinse the membrane until the 
molecular weight marker and bands became visible. Once the bands were 
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checked for even transfer, the membrane was rinsed in TBS until the bands 
were no longer visible. The membrane was then incubated in 3 % w/v blocking 
buffer in TBS for 1 hour at RT.  
 
Following blocking, the membrane was washed 3 x 5 min in TBST. Primary 
anti-myc tag antibody (5 μl, 1 mg/ml mouse monoclonal IgG1, clone A46, 
Merck-Millipore, UK) was added and incubated at RT for 1 hour. The 
membrane was washed 3 x 5 min with TBST and in the case of cell lysis 
samples, further incubated with 10ml of 1μl/ml primary anti-mouse monoclonal 
β-actin antibody (clone 8226, Abcam, UK) and incubated at RT for 1 hour. For 
conditioned media samples and following β-actin antibody incubation for cell 
lysate samples, the membrane was washed 3 x 5 min with TBST and the 
secondary HRP antibody added (10 ml 0.2 μl/ml goat anti-mouse IgG, clone 
A4416, Sigma-Aldrich, UK) and incubated for 1 hour at RT. The membrane 
was then washed 6 x 5 min in TBST and stored in TBS at 4 °C until visualised. 
 
2.12.4 Visualisation using enhanced chemiluminescence (ECL) reagent 
The ECL working solution was prepared by mixing 500 μl each of the peroxide 
solution and luminol/enhancer SuperSignal® West Femto Maximum Sensitivity 
Substrate (Thermo Scientific, UK) per blot. The solution was uniformly pipetted 
onto the blot and incubated for 5 mins. The working solution was drained and 
the blot visualised with the UVP BioSpectrum®515 Imaging System™ fitted 
with camera GDS (12.5-75mm, f1.2, motorized Sigma zoom lens). 
 
2.12.5 Determination of the appropriate sample load for Western blot 
Prior to running conditioned media or cell lysate samples, the appropriate 
sample load was determined. A blot was loaded with 1, 4, 8, 12 and 15 μg WT 
ADAMTS13 protein in 2 sets of lanes separated by a known concentration of 
BSA protein standard to assess protein target load for ADAMTS13 anti-myc 
tag and the housekeeping protein β actin. After transfer, the membrane was 
cut before the second protein standard lane, producing 2 blots. The anti-myc 
primary antibody was applied to one blot and the anti-β actin antibody applied 
to the other blot. The secondary antibody was then added and after incubation 
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the 2 blots were visualised using the UVP BioSpectrum®515 Imaging 
System™ fitted with camera GDS (12.5-75mm, f1.2, motorized Sigma zoom 
lens). Using ImageJ software the target (anti-myc) and housekeeping protein 
signal intensity was read. The intensity was then plotted against the protein 
load and the linear dynamic range was determined. The protein load that gave 
the quantitative reading in the linear dynamic range was selected. 
 
2.12.6 Densitometry analysis 
Images of the developed blots were analysed using ImageJ software 
(<http://www.imageJ.net>). 
 
2.13 Commercial ADAMTS13 antigen quantification: IMUBIND® 
ADAMTS13 ELISA 
 
The assay was performed according to manufacturer’s instructions. 
 
2.13.1 Preparation of ADAMTS13 standards  
Using the supplied 96 well plate, five standards were prepared by serial 
dilution using the manufacturer’s proprietary ADAMTS13 standard supplied. A 
volume of 200 μl of prepared standard was added to microwell A1/A2. To each 
microwell from B1/2 to G1/2, 100 μl assay buffer (IMUBIND®) was added and 
100 μl of standard serially diluted from microwells A1/2 to F1/2, discarding 
100 μl from wells F1/2. Wells G1/2 served as a negative control (blank). The 
concentration of the standards from A1/2 to G1/2 was: 100, 50, 25, 12.5, 6.25, 
3.12 and 0 ng/ml respectively. 
 
2.13.2 ADAMTS13 assay 
Each sample was diluted 1:20 with assay buffer. To each ADAMTS13 
monoclonal antibody (mAb) coated microwell, 100 μl positive control or sample 
was added, covered and incubated at 37 °C for 1 hour, allowing any 
ADAMTS13 present in the sample to bind to the mAb in the microwell. The 
microwells were then emptied and washed 4 times with wash buffer. 100 μl of 
the detection antibody (biotinylated rabbit anti-ADAMTS13 polyclonal 
54 
 
antibody) was added to each microwell, binding to any ADAMTS13 captured 
on the plate, covered and incubated at RT (18-25 °C) for 30 min on an orbital 
microwell plate shaker (250 rpm).  The microwells were then emptied and 
washed 4 times with wash buffer. The enzyme conjugate (100 μl streptavidin-
horseradish peroxidase conjugate (SA-HRP)) was added to each microwell 
plate and incubated at room temperature (18-25 °C) on a microwell shaker 
(250 rpm) for 30 min, forming the antibody-enzyme detection complex. The 
microwells were then emptied and washed 4 times with wash buffer. 100 μl 
perborate-3, 3’-5,5’-tetramethylbenzidine (TMB substrate) was added 
immediately to each microwell and incubated for 5 min at room temperature. 
The reaction of TMB and the HRP turned the substrate a blue colour. The 
reaction was stopped by adding 50 μl 0.5 M sulphuric acid, ensuring even 
distribution and effecting a colour change from blue to yellow. The absorbance 
of each well was read at 450 nm using the BMG Labtech Spectrostar Nano 
microplate reader. 
 
2.14.3 Analysis of results 
A standard curve was plotted of ADAMTS13 concentration vs Absorbance 
reading at 450 nm and values of concentration for the unknown samples 
interpolated from the standard curve. The reading from the graph was 






Chapter 3  
In silico analysis of mutations and single nucleotide 
polymorphisms 
3.1 Introduction  
In silico analysis has been used to predict the association of ADAMTS13 
mutations and clinical phenotype (Edwards et al., 2012; Hing et al., 2013; Lotta 
et al., 2012). The crystallographic structure of the ADAMTS13 protein has 
been eluciated and can viewed in the Protein Data Bank (identification codes 
3GHM and 3GHN); (Akiyama et al., 2009a). The exosite domains of the 
disintegrin, thrombospondin type 1, the cysteine rich and signal domain have 
been analysed but the catalytic metalloprotease domain has not.  
 
The X-ray crystallographic stucture has revealed  ADAMTS13 to be complex 
structural protein with numerous short-range and long-range covalent and 
non-covalent interactions which provide stability to the functional protein. 
These interactions are mainly brought about by hydrophobic, hydrogen and 
disulfide bonding. In consideration of this, mutations found ouside of the 
catalytic region can have consequences on the stability and functionality of 
ADAMTS13. 
 
As the clinical phenotye of congenital TTP (cTTP) differs amongst patients, 
and even among siblings with the same genotype, some studies have used in 
silico tools to look at a larger number of patient genotype data in order to 
assess the correlation between genotype and phenotype (Hing et al., 2013; 
Lotta et al, 2010; Moatti-Cohen et al., 2012). Hing et al. assessed several 
parameters including the N/C terminal score (the position of the mutation in 
relation to the catalytic N-terminus of ADAMTS13); the amino acid evolutionary 
conservation score; the changes in electrostatic charge of the amino acid 
substitution and phosphorylation.  The relative synonymous codon usage and 
crystal structure in silico modelling was also analysed and carried out. This 
was perfomed on data from 144 cTTP patients. They found statistically 
significant associations between homozygous patients with non-synonymous 
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missense mutations that were found in highly conserved areas and the 
requirement of increased TP prophylaxis treatment. Additionally, those 
mutations found in highly conserved areas showed an earlier age of TTP 
onset. A statistically significant correlation between rarer codon usage and 
late-onset disease in patients with homozgous missense mutations was also 
found. Codon usage has been postulated to alter the translation rate of the 
proten, thereby causing misfolding of the protein and altering function 
(Edwards et al., 2012).  
 
Interestingly, many missense mutations involve cysteine which is involved in 
disulfide bond formation. Previous studies have indicated that disulfide bond 
formation is an important factor in the correct folding of proteins thus mutations 
involving the substitution of cysteines could result in the misfolding or 
proteolysis of the protein, triggering its removal and breakdown (Salamanca 
et al., 2003). Similarly, arginine is an amino acid that is more easily mutated 
and serves an integral finction in hydrogen bonding, leading to stablisation of 
the protein. 
 
There is a limitation to in silico tools as they can only be applied to the 
homozygous genotype. In the study performed by Hing et al, this only 
represented 38.9% of cTTP pateints whereas 61.1% of patients were 
compound heterozygotes. In silico tools are also predictive and rely on the 
parameters written into the alogorithm or, if using a machine learning tool, may 
reflect the biases of the training set. In consideration of siblings with the same 
genotype presenting a different phenotype, other genes not yet recognized or 
epigenetic factors could be other areas to consider. 
 
3.2 Methods 
In this study, the following in silico tools were applied:  
 MUSCLE (multiple sequence comparison by log expectation) alignment 
(<www.ebi.ac.uk/Tools/msa/muscle/> [Accessed 16/6/16]); 
 FOLD X (<http://www.foldx.embl.de/> [Accessed 2/7/16]);  
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 SNP Effect 4.0 (<http://www.snpeffect.switchlab.org/>[Accessed 
20/7/17]); 
 I-Mutant2.0 (<http:www.folding.biofold.org/i-mutant/i-mutant2.0.html> 
[Accessed 15/5/17]); 
  SIFT (sorting tolerant from intolerant) (<http://www.sift.jcvi.org> 
[Accessed 23/5/17]), 
  PolyPhen2.0 (Polymorphism phenotyping 2) 
(<http://www.genetics.bwh.harvard.edu/pph2/> [Accessed 23/5/17]); 
and  
 Predict SNP (https://loschmidt.chemi.muni.cz/predictsnp [Accessed 
28/7/17].  
The global prevalence of SNPs investigated in this study has also been 
elucidated from the dbSNP database 
(<http://www.ncbi.nlm.nih.gov/snp>[Accessed 30/7/17]). 
 
3.2.1 MUSCLE alignment  
Conservation of amino acids has been postulated to be the second most 
predictive factor of the impact of a mutation (Lee et al., 2009). To assess the 
conservation in regions of TTP mutations and SNPs, alignment of orthologs 
was performed on the following species: Mus musculus (the house mouse), 
Rattus norvegicus (the brown rat), Papio Anubis (the olive baboon), Homo 
sapiens (the human), Gorilla gorilla (the gorilla), Pan troglodytes (the common 
chimpanzee), Ovis aries (the sheep) and Bos Taurus (the cow); see Figure 
3.1. 
 
3.2.2 FOLD X 
The FOLDX algorithm is used to calculate the change in free energy the 
mutation has on the protein. If the mutation destabilizes the structure, the 
change in Gibbs free energy (ΔΔG) is increased whereas if the mutation 
stabilizes the structure, ΔΔG is decreased. A homology model is built from 
PDB 3GHM (Schymkowitz et al., 2005). The FOLD X scores for mutations and 




3.2.3 I-Mutant2.0  
The I-Mutant ΔΔG in silico tool (Capriotti et al., 2006) can evaluate the stability 
change on single missense mutations based on the protein structure found in 
the PDB or on the amino acid sequence of the protein. This alogorithm has 
been found to predict whether the mutation stabilises or destabilises the 
protein in 80% of cases when the three dimensional structure is known and 
76% of cases when only the amino acid sequence is known; see   
 
3.2.4 Sorting intolerant from tolerant (SIFT) 
Previous published studies have used PolyPhen and SIFT as predictors of 
phenotype based on genotype (Lotta et al., 2012; Moatti-Cohen et al., 2012). 
Since its release in 2001, the SIFT algorithm has become one of the standard 
tools for characterizing missense mutations (Sim et al., 2012). The SIFT 
prediction is based on the degree of conservation of residues in sequence 
alignments from closely related sequences which have been collected through 
PSI-BLAST (Position-specific iterative basic local alignment search tool); 
(Kumar et al., 2009). To assess the effect of an amino acid residue 
substitution, the programme uses the premise that important positions in the 
amino acid sequence have been conserved throughout evolution and 
substitutions in these conserved areas will have a significant effect on protein 
function. The programme predicts the effects of all possible substitutions at 
each amino acid position and predicts if the missense mutation will be 
damaging or tolerated. 
 
3.2.5 PolyPhen2.0  
The PolyPhen2 programme uses physical and comparative evolutionary 
considerations, and utilses functional annotations of SNPs from the 
UniProtKB/SwissProt databases, maps coding SNPs to gene transcripts, 
extracts protein sequence annotation and maps to known 3D structures. The 
programme then estimates the probability of a missense mutation being 
damaging, based on a combination of these parameters (Adzhubei et al., 
2013). The prediction of benign, possibly damaging or probably damaging is 
then made. Estimates of false positives (the chance that the mutation is 
classified as damaging when it is in fact non-damaging) and the true positive 
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(the chance that the mutation is classified as damaging when it is indeed 
damaging) is scored. 
3.2.6 PredictSNP 
The PredictSNP is a meta-analysis tool and consensus classifier combining 
six best performing prediction methods to provide more accurate and robust 
alternative to the predictions delivered by individual integrated tools (Bendl et 
al., 2014). The predictions from the computational tools are supplemented by 
experimental annotations from two databases Uniprot (Q76LX8) and PMD 
A010243. 
3.3 Results 
3.3.1 MUSCLE alignments 
The results of the alignments can be seen in Table 3.1. The amino acid 
position of the SNP mutation or is shaded. 
Table 3.1 Conservation of amino acid residues among orthologs: SNPs and mutations 
Key: 
 * (asterisk): positions having single, fully conserved residues 
: (colon): conservation between groups of strongly similar properties 
. (period): conservation between groups of weakly similar properties 
- (dash): no corresponding amino acid at this position 
 
Mus musculus             MSQLCLWLTCQP-CYAVSVRGILTGAIFILGCWGLSDFQKSLLQDLEPKDVSSYFGHHAA 
Rattus norvegicus        MSQLCLWLPCQP-FLAASIRGILTGAIFILGCWGLSDFQKSFLQDLEPKDLSSSFSRHTA 
Papio anubis           MRQRHPQARCPS----LCVAGILACG-FLLGCWGPSHFQQSFLQALEPQAVSSYLS-SGA 
Homo sapiens            MHQRHPRARCPP----LCVAGILACG-FLLGCWGPSHFQQSCLQALEPQAVSSYLS-PGA 
Gorilla  gorilla        MHQRHPRARCPP----LCVAGFLACG-FLLGCWGPSHFQQSCLQALEPQAVSSYLS-PGA 
Pan  troglodytes        MHQRHPRARCPP----LCVAGILACG-FLLGCWGPSHFQQSCLQALEPQAVSSYLS-PGA 
Ovis aries              ---MIAGSMAPS-TLGRCMQGTLTSALFLLSCWALPDPRQQFLQALEPGDVTSYFG-PDA 
Bos  taurus             ESRVSLGFISPCVTTGRX--GTLTSALFFLSCWALPDPRQQFLQVLEPADVTSYFG-PDA 
                                 .          * *: . *:*.**. .  .:. ** ***  ::* :.   * 
SNP p.R7W 
 
Mus musculus             CVGEDLQAKMCNT-QACEKTQLEFMSEQCAQTDRQPLQLSQGTA-SFYHWDAAVQYSQGD 
Rattus norvegicus        CVGEDLQAKMCNT-QACEKTQLEFMSEQCAQTDRHPLQLSQGSA-SFYHWDAAVQYSQGD 
Papio anubis             CVGADLQAEMCNTQQACEKTQLEFMSEQCARTDGQPLHSSPGGA-SFYHWGAAVPHSQGD 
Homo sapiens             CVGADLQAEMCNT-QACEKTQLEFMSQQCARTDGQPLRSSPGGA-SFYHWGAAVPHSQGD 
Gorilla  gorilla         CVGADLQAEMCNT-QACEKTQLEFMSEQCARTDGQPLRSSPGGA-SFYHWGAAVPHSQGD 
Pan  troglodytes         CVGADLQAEMCNT-QACEKTQLEFMSEQCARTDGQPLRSSPGGA-SFYHWGAAVPHSQGD 
Ovis aries               CVGSDLQAEMCNT-QACETTQLEFMSEQCAQTDGEPLHLSPGGSTSFYRWGTATLLSPGN 
Bos  taurus              CVGSDLQAEMCNT-QACEKTQLEFMSEQCAQTDSEPLRLSPGGSTAFYRWGTAEQYSEGN 
                       *** ****:**** ****.*******:***.**  **. * * : :**.*.:*   * *: 
SNP p.Q448E 
 
Mus musculus             CVGEDLQAKMCNT-QACEKTQLEFMSEQCAQTDRQPLQLSQGTA-SFYHWDAAVQYSQGD 
Rattus norvegicus        CVGEDLQAKMCNT-QACEKTQLEFMSEQCAQTDRHPLQLSQGSA-SFYHWDAAVQYSQGD 
Papio anubis             CVGADLQAEMCNTQQACEKTQLEFMSEQCARTDGQPLHSSPGGA-SFYHWGAAVPHSQGD 
Homo sapiens             CVGADLQAEMCNT-QACEKTQLEFMSQQCARTDGQPLRSSPGGA-SFYHWGAAVPHSQGD 
Gorilla  gorilla         CVGADLQAEMCNT-QACEKTQLEFMSEQCARTDGQPLRSSPGGA-SFYHWGAAVPHSQGD 
Pan  troglodytes         CVGADLQAEMCNT-QACEKTQLEFMSEQCARTDGQPLRSSPGGA-SFYHWGAAVPHSQGD 
Ovis aries               CVGSDLQAEMCNT-QACETTQLEFMSEQCAQTDGEPLHLSPGGSTSFYRWGTATLLSPGN 
Bos  taurus              CVGSDLQAEMCNT-QACEKTQLEFMSEQCAQTDSEPLRLSPGGSTAFYRWGTAEQYSEGN 






Mus musculus             ------GEMPEDPSL----YLATDFLVFEMPPPLTPGAWWEKPNSPDPLRAATLTAKLIP 
Rattus norvegicus        ------GEMTEDPS-----------LHLHVLVFEMPSLWWE-PNSPDLMRAATLTPKLIP 
Papio anubis           GRYVVAGKTSISSNTTYPSLLEDGRVEYRVALTEDRLPRLEEIRIWGPLQEDA------E 
Homo sapiens           GRYVVAGKMSISPNTTYPSLLEDGRVEYRVALTEDRLPRLEEIRIWGPLQEDA------D 
Gorilla  gorilla       GRYVVAGKMSISPNTTYPSLLEDGRVEYRVALTEDRLPRLEEIRIWGPLQEDA------D 
Pan  troglodytes       GRYVVAGKMSISPNTTYPSLLEDGRVEYRVALTEDRLPHLEEIRIWGPLQEDA------D 
Ovis aries             THAAAGGLGSHSEPTGAPGVL---RAAQRESPAEGPGASREGALQLRPRRARQ------R 
Bos  taurus            GRYVVAGNGSASASTSYPSLLEDNRVEYRVTLSEDRLPRREEIRIRGPTRDDM------E 
                             *  . .                            *        .    
SNPp.P618A 
 
Mus musculus             QDKWVKNAQCQGSPQPPAWQEPCVSAPCSPYWVAGDFSPCSVSCGGGLRERSLRCVETQD 
Rattus norvegicus        QNKWVRNAQCQGSPQPPAWQEPCVSAPCPPHWVADDFGPCSVSCGGGLRERSLRCVEAHN 
Papio anubis             RKELVETARCQGSQQPPAWPEACVLEPCPPYWAVGDFGPCSVSCGGGLRERPVRCVEAQG 
Homo sapiens             RKELVETVQCQGSQQPPAWPEACVLEPCPPYWAVGDFGPCSASCGGGLRERPVRCVEAQG 
Gorilla  gorilla         RKELVETVQCQGSQQPPAWPEACVLEPCPPYWAVGDFGPCSASCGGGLRERPVRCVEAQG 
Pan  troglodytes         RKELVETVQCQGSQQPPAWPEACVLEPCPPYWAVGDFGPCSASCGGGLRERPVHCVEAQG 
Ovis aries             RSEWVEAAGCAGSRPPEAWSGACTLEPCPPQ----------------------------- 
Bos  taurus              RSEWVEAAHCAGSQPPVAWSETCTPGPCPPHWEAGDFGPCSASCGGGLREREVRCVEARG 
                                ..: *  . * **  * **  .*.  **.*                               
SNP p.A732V 
 
Mus musculus             GAQAEHVWTPLVGLCSISCGRGLKELYFLCMDSVLKMPVQEELCGLASKPPSRWEVCRAR 
Rattus norvegicus        SSQAEHVWTPLVGLCSISCGKGLKELYFLCMDSVLKMPVQEELCGLASKPPSRWEVCRAR 
Papio anubis             GAQAAHVWTPLAGPCSVSCGRGLMELRFLCMDSALRVPVQEELCGLASKPGSRWEVCQAV 
Homo sapiens             GAQAAHVWTPAAGSCSVSCGRGLMELRFLCMDSALRVPVQEELCGLASKPGSRREVCQAV 
Gorilla  gorilla         GAQAAHVWTPAAGSCSVSCGRGLMELRFLCMDSALRVPVQEELCGLASKPGSRQEVCQAV 
Pan  troglodytes         GAQAAHMWTPAAGSCSVSCGRGLMELRFLCMDSALRVPVQEELCGLASKPGSRREVCQAV 
Ovis aries               EALAKHVWTPLAGPCSASCGQGLAELHFVCMDPALRTPVREELCDLASKPGSRREACQAA 
Bos  taurus              EALAAHVWTPLAGPCSVSCGQGLVELRFVCMDTALRTPVREELCDLASKPGSRREACQAA 
                        : * *:*** .* ** ***.** ** *:***..*. **.****.***** **.*.*.*  
SNP A900V 
 
Mus musculus           PEPCPAR----------------------------------------------------- 
Rattus norvegicus      PEPCPAR----------------------------------------------------- 
Papio anubis             LEPCPPRWKVTSLGPCSASCGLGTARRSVACVQLDQGQDVEVDEAACAALVRPQASVPCL 
Homo sapiens             LEPCPPRWKVMSLGPCSASCGLGTARRSVACVQLDQGQDVEVDEAACAALVRPEASVPCL 
Gorilla  gorilla         LEPCPPRWKVMSLGPCSASCGLGTARRSVACVQLDQGQDVEVDEAACVALVRPQASVPCL 
Pan  troglodytes         LEPCPPRWKVMSLGPCSASCGLGTARRSVACVQLDQGQDVEVDEAACVALVRPQASVPCL 
Ovis aries               PGPCPPRWKVTSLGPCSASCGLGTATRSVACVRLDRGQDTEVDRAACAGLVRPQASIPCI 
Bos  taurus              LEPCPARWKVTSLGPCSASCGLGTATRSLACVRLDHGQDTEVDGAACAGLVQPQASIPCI 
                         ***.*                 
SNP p.A1033T 
 
Mus musculus             LEDILHLELLVAVGPDVSRAHQEDTERYVLTNLNIGSELLRNPSLGVQFQVHLVKLITLS 
Rattus norvegicus        SEDILHLELLVAVGPDVYQAHQEDTERYVLTNLNIGSELLRNPSLGAQLQVHLVKLIILS 
Papio anubis             VSHHLHLELLVAVGPDVFQAHQEDTERYVLTNLNIGAELLRDPSLGAQFRVHLVKMVILT 
Homo sapiens             AGGILHLELLVAVGPDVFQAHQEDTERYVLTNLNIGAELLRDPSLGAQFRVHLVKMVILT 
Gorilla  gorilla         AGGILHLELLVAVGPDVFQAHQEDTERYVLTNLNIGAELLRDPSLGAQFRVHLVKMVILT 
Pan  troglodytes         AGGILHLELLVAVGPDVFQAHQEDTERYVLTNLNIGAELLRDPSLGAQFRVHLVKMVILT 
Ovis aries               TGHILHLELLVAVGPDVQRTHGEETERYVLTNLNMGSELLRDPSLGAQFRVHLVKMVILT 
Bos  taurus              AGHVLHLELLVAVGPDVHRTHGEETERYVLTNLNMGSELLRDPSLGAQFRVHLVKMVILT 
                            ************* .:* *:**********:*:****:****.*:.*****:: 
Mutation p.R102H 
 
Mus musculus             TQLGGACSLSWSCLITEDTGFDLGVTIAHEIGH-----SFGLDHD-GAPGSGSTCKASGH 
Rattus norvegicus        TQQGGACSPSWSCLITEDTGFDLGVTIAHEIGH-----SFGLDHD-GAPGSGSTCEARGH 
Papio anubis             TQLGGACSPTWSCLITEDTGFDLGVTIAHEIGH-----SFGLEHD-GAPGSG--CGPSGH 
Homo sapiens             TQLGGACSPTWSCLITEDTGFDLGVTIAHEIGH-----SFGLEHD-GAPGSG—-CGPSGH 
Gorilla  gorilla         TQLGGACSPTWSCLITEDTGFDLGVTIAHEIGH-----SFGLEHD-GAPGSG--CGPSGH 
Pan  troglodytes       TQLGGACSPTWSCLITEDTGFDLGVTIAHEIGH--------------------------- 
Ovis aries               TQLGGACSSSWSCLITEDTGFDLGLTIAHEIGHRTVTRSLGLHGVLGAPQPPPPSVLSGE 
Bos  taurus              TQLGGACSSSWSCLITEDTGFDLGLTIAHEIGH-----SFGLEHD-GVPGSG--CGPSGH 
                       ** ***** :**************:********                            
Mutation p.T196I 
 
Mus musculus             TQLGGACSLSWSCLITEDTGFDLGVTIAHEIGH-----SFGLDHD-GAPGSGSTCKASGH 
Rattus norvegicus        TQQGGACSPSWSCLITEDTGFDLGVTIAHEIGH-----SFGLDHD-GAPGSGSTCEARGH 
Papio anubis             TQLGGACSPTWSCLITEDTGFDLGVTIAHEIGH-----SFGLEHD-GAPGSG--CGPSGH 
Homo sapiens             TQLGGACSPTWSCLITEDTGFDLGVTIAHEIGH-----SFGLEHD-GAPGSG—-CGPSGH 
Gorilla  gorilla         TQLGGACSPTWSCLITEDTGFDLGVTIAHEIGH-----SFGLEHD-GAPGSG--CGPSGH 
Pan  troglodytes       TQLGGACSPTWSCLITEDTGFDLGVTIAHEIGH--------------------------- 
Ovis aries               TQLGGACSSSWSCLITEDTGFDLGLTIAHEIGHRTVTRSLGLHGVLGAPQPPPPSVLSGE 
Bos  taurus              TQLGGACSSSWSCLITEDTGFDLGLTIAHEIGH-----SFGLEHD-GVPGSG--CGPSGH 




Mus musculus             K-WCSKARCRSLAELAPVAAVHGHWSSWGPHSPCSRSCGGGVITRRRWCNNPRPAFGGRA 
Rattus norvegicus        K-WCSKARCRSLAELAPVAVVHGHWSSWGPHSPCSRSCGGGVITRRRWCNNPRPAFGGRA 
Papio anubis             K-WCSKGRCRSLVELTPIAAVHGHWSSWSPQSPCSRSCGGGVVTRRRQCNNPRPAFGGRA 
Homo sapiens             K-WCSKGRCRSLVELTPIAAVHGRWSSWGPRSPCSRSCGGGVVTRRRQCNNPRPAFGGRA 
Gorilla  gorilla         K-WCSKGRCRSLVELTPIAAVHGRWSSWGPHSPCSRSCGGGVVTRRRQCNNPRPAFGGRA 
Pan  troglodytes         K-WCSKGRCRSLVELTPIAAVHGRWSSWGPQSPCSRSCGGGVVTRRRQCNNPRPAFGGRA 
Ovis aries               KDACSRARCGGLRTGVWVGV--GCLWVWGALGGGGWGGGGGVVTRRRRCDNPRPAFGGRA 
Bos  taurus              K-WCSKGHCRSLAELAPVGVVHGHWSGWGPASPCSRSCGGGVITRRRRCNNPRPAFGGRT 
                          *  **...* .*   . :..  *    *.. .  ... ****:****.*:*********: 
Mutation p.R409W 
 
Mus musculus             K-WCSKARCRSLAELAPVAAVHGHWSSWGPHSPCSRSCGGGVITRRRWCNNPRPAFGGRA 
Rattus norvegicus        K-WCSKARCRSLAELAPVAVVHGHWSSWGPHSPCSRSCGGGVITRRRWCNNPRPAFGGRA 
Papio anubis             K-WCSKGRCRSLVELTPIAAVHGHWSSWSPQSPCSRSCGGGVVTRRRQCNNPRPAFGGRA 
Homo sapiens             K-WCSKGRCRSLVELTPIAAVHGRWSSWGPRSPCSRSCGGGVVTRRRQCNNPRPAFGGRA 
Gorilla  gorilla         K-WCSKGRCRSLVELTPIAAVHGRWSSWGPHSPCSRSCGGGVVTRRRQCNNPRPAFGGRA 
Pan  troglodytes         K-WCSKGRCRSLVELTPIAAVHGRWSSWGPQSPCSRSCGGGVVTRRRQCNNPRPAFGGRA 
Ovis aries               KDACSRARCGGLRTGVWVGV--GCLWVWGALGGGGWGGGGGVVTRRRRCDNPRPAFGGRA 
Bos  taurus              K-WCSKGHCRSLAELAPVGVVHGHWSGWGPASPCSRSCGGGVITRRRRCNNPRPAFGGRT 
                          *  **...* .*   . :..  *    *.. .  ... ****:****.*:*********: 
Mutation p.R398C 
 
Mus musculus             CVGEDLQAKMCNT-QACEKTQLEFMSEQCAQTDRQPLQLSQGTA-SFYHWDAAVQYSQGD 
Rattus norvegicus        CVGEDLQAKMCNT-QACEKTQLEFMSEQCAQTDRHPLQLSQGSA-SFYHWDAAVQYSQGD 
Papio anubis             CVGADLQAEMCNTQQACEKTQLEFMSEQCARTDGQPLHSSPGGA-SFYHWGAAVPHSQGD 
Homo sapiens             CVGADLQAEMCNT-QACEKTQLEFMSQQCARTDGQPLRSSPGGA-SFYHWGAAVPHSQGD 
Gorilla  gorilla         CVGADLQAEMCNT-QACEKTQLEFMSEQCARTDGQPLRSSPGGA-SFYHWGAAVPHSQGD 
Pan  troglodytes         CVGADLQAEMCNT-QACEKTQLEFMSEQCARTDGQPLRSSPGGA-SFYHWGAAVPHSQGD 
Ovis aries               CVGSDLQAEMCNT-QACETTQLEFMSEQCAQTDGEPLHLSPGGSTSFYRWGTATLLSPGN 
Bos  taurus              CVGSDLQAEMCNT-QACEKTQLEFMSEQCAQTDSEPLRLSPGGSTAFYRWGTAEQYSEGN 
                       *** ****:**** ****.*******:***.**  **. * * : :**.*.:*   * *: 
Mutation p.Q436H 
 
Mus musculus           VWDACQVCGGDNSTCSSRNGSFTAGRAREYVTFLIVTPNMTNAHIVNRRPLFTHL----- 
Rattus norvegicus      VWDACQVCGGDNSTCTSQNGSFTAGRAREYVTFLIVTPNMTSAHVINHRPLFTHL----- 
Papio anubis             VRDMCQVCGGDNSTCSPRNGSFTAGRAREYVTFLTVTPNLTSVYIANHRPLFTHLAVRIG 
Homo sapiens             VWDRCQVCGGDNSTCSPRKGSFTAGRAREYVTFLTVTPNLTSVYIANHRPLFTHLAVRIG 
Gorilla  gorilla         VWDRCQVCGGDNSTCSPRKGSFTAGRAREYVTFLTVTPNLTSVYIANHRPLFTHLAVRIG 
Pan  troglodytes         VWDRCQVCGGDNSTCSPRKGSFTAGRAREYVTFLTVTPNLTSVYIANHRPLFTHLAVRIG 
Ovis aries               VRDVCQVCGGDSSTCRPQNGSFTAGRAREYVTFLTVTPNLTSISVINRRPLFTHLASRAA 
Bos  taurus              VRDVCQVCGGDNSTCQPQSGSFTAGRAREYVTFLTVTPNLTSIYIINRRPLFTHLAVRVR 
                       *.* *******.*** ...*************** ****:*.  : *.*******      
Mutation p.A596V 
 
Mus musculus             GKVYRRYGGEYGDLTHPDITFSYFQLKQQAAWVWTAKRGPCSVSCGAGLRWVTYSCQDQA 
Rattus norvegicus        GKVYRRYGGEYGGLTHPDITFTYFQRKQQAAWVWAAKRGPCSVSCGAGLRWVTYSCQDQA 
Papio anubis             IQVYRRYGEEYGNLTCPDITFTYFQPKPRQAWVWAAVRGPCSVSCGAGLRWVNYSCLDQA 
Homo sapiens             IQVYRRYGEEYGNLTRPDITFTYFQPKPRQAWVWAAVRGPCSVSCGAGLRWVNYSCLDQA 
Gorilla  gorilla         IQVYRRYGEEYGNLTRPDITFTYFQPKPRQAWVWAAVRGPCSVSCGAGLRWVNYSCLDQA 
Pan  troglodytes         IQVYRRYGEEYGNLTRPDITFTYFQPKPRQAWVWAAVRGPCSVSCGAGLRWVNYSCLDQA 
Ovis aries               GRPCRRPGLEAXSPARPDITFTYFQPEQRRAWAWAPLRGPCSVSCGAGLRQVTYSCWDQS 
Bos  taurus              IQVYRRYSEEYGSPARPDITFIYFQPEQRRAWAWVPVQGPCSVSCGAGLRQVTYRCRDQS 
                            ** . *  . : ***** *** : . **.*.. .************.*.* * **: 
Mutation p.A609T 
 
Mus musculus             PCPARWETQVLAPCPVTCGGGRVPLSVRCVQL--DRGHPISVPHSKCSPVPKPGSFEDCS 
Rattus norvegicus        PCPARWETRVLAPCPVTCGGGRVPLAIHCVQL--DHGRPVSVPHSKCWPAPRPGSFEDCS 
Papio anubis             PCPARWQYK-LAACSVSCGEGVMRRILYCARAHGEDDEEEILLDTQCQGLPRPEPQEVCS 
Homo sapiens             PCPARWQYK-LAACSVSCGRGVVRRILYCARAHGEDDGEEILLDTQCQGLPRPEPQEACS 
Gorilla  gorilla         PCPARWRYK-LAACSVSCGGGVVRRILYCARAHGEDDGEEILLDTQCQGLPRPEPQEACS 
Pan  troglodytes         PCPARWRYK-LAACSVSCGGGVVRRILYCARAHGEDDGEEILLDTQCQGLPRPEAQEACS 
Ovis aries               PCPARWRYK-LAACSLSCGGGVAQRILYCARAHGEDTDEEILPDTQCQGLPRPEQQEACS 
Bos  taurus              PCPARWETRALAPCPVTCGGGQVPLAVRCVRM--DQGRLVSLPHSKCWPMPRPRTLEDCS 
                       ******  . **.*.::** *     : *..   :      :  ::*   *.*   * ** 
Mutation p.C977F 
 
Mus musculus           PEPCPAR----------------------------------------------------- 
Rattus norvegicus      PEPCPAR----------------------------------------------------- 
Papio anubis             LEPCPPRWKVTSLGPCSASCGLGTARRSVACVQLDQGQDVEVDEAACAALVRPQASVPCL 
Homo sapiens             LEPCPPRWKVMSLGPCSASCGLGTARRSVACVQLDQGQDVEVDEAACAALVRPEASVPCL 
Gorilla  gorilla         LEPCPPRWKVMSLGPCSASCGLGTARRSVACVQLDQGQDVEVDEAACVALVRPQASVPCL 
Pan  troglodytes         LEPCPPRWKVMSLGPCSASCGLGTARRSVACVQLDQGQDVEVDEAACVALVRPQASVPCL 
Ovis aries               PGPCPPRWKVTSLGPCSASCGLGTATRSVACVRLDRGQDTEVDRAACAGLVRPQASIPCI 
Bos  taurus              LEPCPARWKVTSLGPCSASCGLGTATRSLACVRLDHGQDTEVDGAACAGLVQPQASIPCI 




3.3.2 FOLD X 
The FOLD X scores for mutations and SNPs can be seen in Table 3.2. 
 
Table 3.2 FOLD X ΔΔG scores for mutations and SNPs 
Mutation ΔΔG value prediction (kcal/mol) Effect on stability of 
mutation 
p.R102H (G305A) No reliable structural information  
p.T196I (C587T) No reliable structural information  
p.D217H (G649C) No reliable structural information  
p.Q436H (G1308C) 0.29 No effect on protein stability 
p.R398C (C1192T) No reliable structural information  
p.R409W (C1225T) 7.95 
Severely reduces protein 
stability 
p.Q436H (G1308C) 0.29 No effect on protein stability 
p.A596V (C1787T) 1.92 Reduces protein stability 
p.A690T (G2068A) No reliable structural information  
p.C977R (G2930T) No reliable structural information  
p.R1060W (C3178T) No reliable structural information  
SNP   
p.R7W (C19T) No reliable structural information  
p.Q448E (C1342G) No reliable structural information  
p.P475S (C1423T) 1.70 Reduces protein stability 
p.P618A (C1852G) 3.95 Reduces protein stability 
p.A732V (C2195T) No reliable structural information  
p.A900V (C2699T) No reliable structural information  
p.A1033T (G3097A) No reliable structural information  
 
As summarised in Table 3.2, the following mutations and SNPs were found to 
reduce protein stability (see Figures 3.1-3.4): 
 
 
Figure 3.1 Mutation p.R409W from FOLD X analysis: molecular visualisation of the wild type 
(left) and the variant p.R409W (right) mutation. The residue coloured in red represents the 





Figure 3.2 Mutation p.A596V from FOLD X analysis: molecular visualisation of the wild type 
(left) and the variant p.A596V (right) mutation. The residue coloured in red represents the wild 




Figure 3.3 SNP p.P475S from FOLD X analysis: molecular visualisation of the WT (left) and 
the variant p.P475S (right) SNP. The residue coloured in red represents the wild type (proline) 




Figure 3.4 SNP p.P618A from FOLD X analysis molecular visualisation of the wild type (left) 
and the variant P618A (right) SNP. The residue coloured in red represents the wild type 
(proline) and variant residue (alanine) respectively. 
 
Table 3.3 Summary of SNP Effect 4.0: FOLD X findings 
Mutation Effect 
C1787T p.A596V Amno acid substitution reduces protein stability 
C1308C p.Q436H Amno acid substitution has no effect on protein stability 
C1225T p.R409W Amno acid substitution i severly reduces protein stability 
C1423T p.P475S Amno acid substitution reduces protein stability 
C1852G p.P618A Amno acid substitution reduces protein stability 




The results from the I-Mutant 2.0 analysis of mutations and SNPs can be seen 
in Table 3.4. 
Table 3.4 Results from I-Mutant algorithm for mutations and SNPs . ΔG = Dg (new protein) – 
ΔG (wild type). The mutation is said to destabilize the protein if ΔΔG < -0.5kcal/mol or largely 
stabilize if ΔΔG > +0.5 kcal/mol. Neutral stability is between ΔΔG -0.5 and 0.5 kcal/mol 
Mutation ΔΔG value prediction 
(kcal/mol) 
Effect on stability of 
mutation 
p.R102H (G305A) -1.24 Large decrease 
p.T196I (C587T) -0.29 Neutral 
p.D217H (G649C) 0.24 Neutral 
p.Q436H (G1308C) -0.49 Neutral  
p.R398C (C1192T) -0.99 Decrease 
p.R409W (C1225T) -0.44 Neutral/decrease 
p.A596V (C1787T) -0.07 Neutral 
p.A690T (G2068A) -0.38 Neutral 
p.C977R (G2930T) -0.04 Neutral 
p.R1060W (C3178T) -0.19 Neutral 
SNP   
p.R7W (C19T) -0.1 Neutral 
p.Q448E (C1342G) 0.14 Neutral 
p.P475S (C1423T) -1.5 Large decrease 
p.P618A (C1852G) -1.8 Large decrease 
p.A732V (C2195T) 0.02 Neutral 
p.A900V (C2699T) -0.03 Neutral 
p.A1033T (G3097A) -0.59 Decrease 
 
3.3.4 Sorting intolerant from tolerant (SIFT) analysis  
The results of the SIFT analysis predicts whether the amino acid substitution 
will be damaging or not. The scores range from 0 - 1 and is the scaled 
probability of the substitution being tolerated. Those falling below 0.05 are 
predicted to alter the protein function (Kumar et al., 2009). The median info 
content is the conservation value for a position ranging from 0, when all amino 
acids are observed at a position in the alignment to log2 20 (=4.32) when only 
one amino acid is observed at that position. The SIFT scores for mutations 
and SNPs can be seen in Table 3.5. 
 
Table 3.5 SIFT scores for mutations and SNPs 
Mutation Prediction SIFT score Median info content 
p.R102H (G305A) Tolerated 0.28 2.12 
p.T196I (C587T) Damaging 0 2.09 
p.D217H (G649C) Tolerated 0.08 2.09 
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p.Q436H (G1308C) Tolerated 0.18 2.09 
p.R398C (C1192T) Damaging 0 2.11 
p.R409W (C1225T) Damaging 0 2.08 
p.A596V (C1787T) Tolerated 0.28 2.09 
p.A690T (G2068A) Tolerated 0.62 2.09 
p.C977R (G2930T) Damaging 0 2.15 
p.R1060W (C3178T) Damaging 0 2.17 
SNP    
p.R7W (C19T) Tolerated 0.09 4.32 
p.Q448E (C1342G) Tolerated 2.09 2.09 
p.P475S (C1423T) Tolerated 0.6 2.10 
p.P618A (C1852G) Tolerated 0.14 2.17 
p.A732V (C2195T) Tolerated 0.26 2.11 
p.A900V (C2699T) Tolerated 0.29 2.17 
p.A1033T (G3097A) Tolerated 2.15 2.15 
 
3.3.5 PolyPhen2.0 
The results of the analysis of mutations and SNPs by PolyPhen2.0 can be 
seen in Table 3.6. 
 
Table 3.6 Results of PolyPhen2.0 analysis for mutations and SNPs (based on HumDiv) 
Mutation Prediction Score Sensitivity* Specificity* 
p.R102H (G305A) Probably damaging 1 0 1 
p.T196I (C587T) Probably damaging 1 0 1 
p.D217H (G649C) Probably damaging 1 0 1 
p.Q436H (G1308C) Probably damaging 1 0 1 
p.R398C (C1192T) Probably damaging 1 0 1 
p.R409W (C1225T) Possibly damaging 0.597 0.87 0.91 
p.A596V (C1787T) Probably damaging 1 0 1 
p.A690T (G2068A) Possibly damaging 0.597 0.87 0.91 
p.C977R (G2930T) Probably damaging 0.997 0.41 0.98 
p.R1060W Probably damaging 0.998 0.27 0.99 
SNP     
p.R7W (C19T) Benign  0 1 0 
p.Q448E (C1342G) Benign 0 1 0 
p.P475S (C1423T) Benign 0.024 0.95 0.81 
p.P618A (C1852G) Probably damaging 1 0 1 
p.A732V (C2195T) Possibly damaging 0.949 0.79 0.95 
p.A900V (C2699T) Benign 0 1 0 
p.A1033T Possibly damaging 0.14 0.14 0.99 
p.C977R (G2930T) Probably damaging 0.997 0.41 0.98 
p.R1060W Probably damaging 0.998 0.27 0.99 
p.A1033T Possibly damaging 0.14 0.14 0.99 
Scores between 0.0-0.15 are predicted to be benign; scores between 0.15-1.0 are predicted 
to be possibly damaging and 0.85-1.0 are more confidently predicted to be damaging 
*Sensitivity denotes the true positive rate and specificity is 1 minus the false positive rate. 




3.3.6 Frequency of SNPs in the population 
3.3.6.1 The European population 
The Exome Aggregation consortium (ExAC) is a coalition of investigators 
seeking to aggregate and harmonise exome sequencing data from a variety 
of large-scale sequencing projects. The data set spans 60,706 unrelated 
individuals sequenced as part of various disease-specific and population 
genetic studies (Lek et al., 2016).Results of the frequency of SNPs in the 
European population can be seen in Tables 3.7. 
 








p.R7W rs34024143 11387 121274 691 0.09389 
p.Q448E rs2301612 18000 35440 3655 0.5079 
p.P475S rs11575933 78 29234 1 0.00266 
p.P618A rs28647808 6559 72646 327 0.09287 
p.A732V rs41314453 1095 71486 11 0.1553 
p.A900V rs685523 10062 115078 532 0.08744 
p.A1033T rs28503257 3182 72598 61 0.0438 
 
3.3.6.2 The global population 
The frequency of SNPs in the global population can be seen in Table 3.8 
(dbSNP <http:// www.ncbi.nlm.nih.gov/snp> [accessed 10/6/2017]). 
 
Table 3.8 Frequency of SNPs in the global population (based on minor allele frequency, 
MAF) 
SNP dbSNP accession 
number 




p.R7W1 rs34024143 0.0527 Likely benign 
p.Q448E2 rs2301612 0.2716 Pathogenic 
p.P475S2 rs11575933 0.0561 Likely benign 
p.P618A1 rs28647808 0.0323 Likely benign 
p.A732V1 rs41314453 0.0056 Likely benign 
p.A900V3 rs685523 0.0765 Likely benign 
p.A1033T1 rs28503257 0.0156 Likely benign 
Validation by: 1 1000G, cluster, frequency; 2 1000G, 2hit 2allele, cluster, frequency, hapmap; 




3.3.7 Predict SNP 
The results of analysis by Predict SNP with annotations can be seen in Table 
3.9. 
Table 3.9 Summary of prediction and expected accuracy of prediction for each analytical tool 
 PolyPhen 1 PolyPhen 2 MAPP PhD-SNP SIFT SNAP 
Expected 
accuracy 
68.1% 69.2% 70.7% 71.5% 70.3% 67.6% 
 


































































































































































































Mutation PredictSNP Amino acid change 
R102H (G305A) Neutral 65% Arginine (polar basic) → histidine (polar basic) 
No annotation 
T196I (C587T) Deleterious 87% Threonine (polar neutral) → Isoleucine (hydrophobic non 
polar) 
Annotation: natural variant in TT dbSNP rs121908470 
D217H (G649C) Neutral 63% Aspartic acid (polar acidic) → histidine (polar basic) 
No annotation 
R398C (C1192T) Deleterious 76% Arginine (polar basic) → cysteine (polar neutral SH) 
No annotation 
R409W (C1225T) Deleterious 87% Arginine (polar basic) → tryptophan (non-polar aromatic) 
No annotation 
Q436H (G1308C) Neutral 65% Glutamine (polar neutral) → histidine (polar basic) 
No annotation 
A596V (C1787T) Deleterious 72% Alanine (hydrophobic non polar) → valine (hydrophobic non-
polar) 
Annotation: natural variant in TTP dbSNP, rs281875299 
C977F (G2930T) Deleterious 87% Cysteine (polar neutral S) → phenylalanine (hydrophobic 
aromatic) 
No annotation 
R1060W (C3778T) Deleterious 87% Arginine (polar basic) → tryptophan (hydrophobic aromatic) 
Annotation: in TTP affects protein secretion, the mutant 
protein has reduced activity: dbSNP rs142572218 
SNP 
R7W Neutral 75% Arginine (basic) → tryptophan (non-polar aromatic) 
Annotation: does not affect protein secretion, dbSNP 
rs34024143 
Q448E (C1342G) Neutral 83% Glutamine (neutral polar) → glutamic acid (polar acidic) 
Annotation: natural variant, does not affect protein secretion, 
normal proteolytic activity dbSNP rs2301612 
P475S (C1423T) Neutral 75% Proline (hydrophobic kinky) → Serine (polar neutral) 
Annotation: natural variant in dbSNP rs11575933 
P618A (C1852G) Neutral 63% Proline (hydrophobic kinky) → Alanine (hydrophobic) 
Annotation: natural variant rs28647808 
A732V (C2195T) Neutral 83% Alanine (hydrophobic) → valine (hydrophobic) 
Annotation: natural variant in dbSNP rs41314453 
A900V (C2699T) Neutral 83% Alanine (hydrophobic) → valine (hydrophobic) 
Annotation: natural variant in dbSNP rs685523 
A1033T (G3097A) Neutral 63% Alanine (hydrophobic) → threonine (polar neutral) 




The prediction of protein structures and the effect a variant will have on the 
expression and secretion of a protein is very challenging and cannot be 
considered proof that the predicted structures will form and produce the 
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predicted effects. However, when backed up by experimental data it can be a 
useful form of analysis and direct further research. Additionally, a single variant 
should not be compared to coupled variants within a frequently seen haplotype 
as there may be some functional synergistic effects (Plaimauer et al., 2006). 
With respect to variants seen in rare diseases such as congenital TTP, the 
information regarding the frequency of these variants in different populations 
is scarce and detailed analysis will not be undertaken until additional data is 
obtained by sequencing a significant number of patient populations. 
 
This study has analysed the predicted effects of several single mutations and 
SNPs identified in patients within the UK TTP Registry (Camilleri et al., 2012) 
where the clinical information is known. Several in silico tools have been 
employed which have looked at changes in ΔΔG estimates of the variants, 
indicating if the substitution will affect protein stability (I-Mutant and SNP 
Effect). The degree of the conservation of residues within a protein sequence 
(MUSCLE alignment of orthologs, SIFT and PolyPhen2.0) has also been 
analysed, with varying degrees of correlation. 
 
The basic premise that substitutions in highly conserved areas will have a 
significant effect on protein function has been applied by looking at the 
MUSCLE alignment between eight species (Table 3.1). Single nucleotide 
polymorphisms were originally defined as codon substitutions that occur in 
>1% of the population and are found across the entire human genome coding 
sequence (Edwards et al., 2012). As such, it may be considered that these 
polymorphisms contribute to natural variation and are not under significant 
evolutionary selection pressures. However, SNPs are now classified as 
genomic variants and it may now no longer be possible to distinguish between 
SNPs and mutations based on their frequency (Sherry et al., 2001).  
 
3.4.1 Analyses of polymorphisms  
The alignment for the SNP p.R7W can be seen in Figure 3.1. This variant 
(highlighted in yellow) lies within the signal peptide area of the ADAMTS13 
protein and, as can be seen, the region shows variance between species and 
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this area is not highly conserved. In the estimation of ΔΔG using I-Mutant 
(there is no PDB structure for this region of the protein), the substitution of 
arginine (a polar, positively charged amino acid) for tryptophan (an aromatic, 
non-polar amino acid) at this position does not result in a significant Gibbs free 
energy change and is considered neutral. Using the PredictSNP analysis, the 
variant is tolerated and considered neutral, which would be expected for a 
polymorphism occurring at a frequency of 0.0527 of the global population. 
 
The polymorphism p.Q448E, with the substitution of glutamine (a neutral 
amino acid) for glutamic acid (an acidic, charged amino acid) lies within a more 
conserved region (see Figure 3.1), which is within the cysteine-rich domain of 
the protein. As there is no PDB structure for this domain, based on I-Mutant 
analysis using the amino acid sequence only, it is predicted that there is no 
change in Gibbs free energy for this substitution. SIFT, PolyPhen2.0 and 
PredictSNP analyses predict the variant is tolerated, benign and neutral, which 
is as expected for a SNP with a frequency of 0.217 of the global population. 
 
The polymorphism p.P475S is within a more variable region with respect to 
the MUSCLE alignment (see Figure 3.1). The variant is within the ADAMTS13 
cysteine-rich domain with the substitution of proline (with a hydrophobic kink) 
for serine (polar and neutral); (see Figure 3.4). As there is structural data on 
this region, the amino acid substitution has been predicted by SNPEffect and 
I-Mutant to result in a ΔΔG of +1.7kcal/mol and +1.5kcal/mol respectively, 
destabilising the protein structure. However, SIFT, PolyPhen2.0 and 
PredictSNP have predicted the variant to be benign and neutral. The SNP 
occurs in 0.0561 of the global population, which could indicate a level of 
selection pressure. 
 
Interestingly, the polymorphism p.P618A, which substitutes proline (a cyclic, 
non-polar amino acid) for alanine (a hydrophobic amino acid) at amino acid 
618 lies within the spacer domain and is also found in a more variable area as 
seen in Figure 3.5. This SNP has been predicted to induce a ΔΔG of +3.95 
and +1.8kcal/mol by SNPEffect and I-Mutant respectively. The variant is 
predicted to be tolerated by SIFT but probably damaging, with a score of 1, by 
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PolyPhen2.0. Predict SNP predicts this variant to be likely benign clinically. 
This data suggests the substitution will reduce protein stability. The SNP 
occurs at a global frequency of 0.032 but has been reported only in the 
Japanese population. In expression studies the SNP has been associated with 
a decrease in secretion levels of ADAMTS13 (Kokame et al., 2002; Plaimauer 
et al., 2006).  
 
The polymorphism p.A732V, which substitutes alanine (a hydrophobic amino 
acid) for valine (similarly hydrophobic), is found within the TSP1-2 domain. As 
can be seen from Figure 3.1, alanine is conserved at this position among 
species but lies within a more variable area. As there is no structural data for 
this region of the protein, I-Mutant predicted the substitution to be neutral with 
no significant ΔΔG based on the amino acid sequence. The variant has been 
predicted to be tolerated by SIFT. However, it has been predicted to be 
probably damaging by PolyPhen2.0 with a score of 0.949. This score carries 
a high false positive rate, with a specificity of 0.95. PredictSNP has annotated 
this SNP as likely benign clinically. The SNP occurs with a frequency of 0.0056 
of the global population which indicates there may be some selection pressure 
on the SNP.  
 
The polymorphism p.A900V also substitutes alanine for valine and is located 
in the TSP1-6 domain of the protein. The amino acids in this area are 
moderately conserved across orthologs (see Figure 3.7) and it has been 
predicted on the amino acid sequence that there will be no significant ΔΔG 
increases. SIFT and PolyPhen2.0 analyses predict the polymorphism to be 
benign and tolerated, which is to be expected in an SNP with a frequency of 
7.6% of the global population.  
 
The final polymorphism to be analysed appearing in this group of patients is 
p.A1033T, which substitutes alanine (a hydrophobic amino acid) for threonine 
(a hydrophilic amino acid but similar in size to valine) and is located in the 
TSP1-7 domain of the protein. It is in an amino acid region that is conserved 
among primates, as seen in MUSCLE alignment (see Table 3.1). There is no 
structural data for this region of the protein but it has been predicted by I-
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Mutant to decrease the structural stability of the protein with a change in ΔΔG 
of 0.59kcal/mol. On SIFT analysis the substitution is predicted to be tolerated 
but has been predicted to be possibly damaging by PolyPhen2.0. PredictSNP 
has annotated this SNP as likely benign However, this is based on a sensitivity 
score of 0.14 (true positive) which is very low. The SNP occurs in the global 
population at a frequency of 0.0156. 
 
3.4.2 Analyses of mutations 
As missense mutations have been previously been classified as those 
substitutions causing a change in the amino acid sequence and occur in <1% 
of the population, it may be assumed that mutations are deleterious and are 
under considerable evolutionary selection pressures. It may also be assumed 
that these mutations occur in highly conserved areas of the protein and cause 
a change in the protein structure, leading to a decrease in activity or secretion 
of the protein. The mechanism by which this occurs may be due to the 
decreased structural stability of the protein, leading to enhanced degradation 
and clearance by the cellular quality control pathways.  
 
The mutation p.R102H was identified as a novel homozygous mutation in a 
pregnant patient who had three previous live births (Camilleri et al., 2012). As 
the clinical phenotype can be classified as late-onset, the mutation may not be 
considered significantly deleterious. The missense mutation is located in the 
metalloproteinase domain of the protein. This region is highly conserved, as 
can be seen in Table 3.1. There is no reliable structural data on this domain 
but from the amino acid sequence it has been predicted to have a large effect 
on ΔΔG and destabilise the protein (see Table 3.4). However, as can be seen 
in Table 3.9, it has been predicted to be deleterious only by SIFT and SNAP 
and overall neutral by PredictSNP. 
 
The mutation p.T196I was found in a three-year-old patient who needed PT 
prophylaxis treatment as required. Due to the early onset of TTP in this patient, 
the mutation would be expected to have a significant deleterious effect. The 
mutation p.T196I is found within the metalloproteinase domain and again there 
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is no structural information on this region. From Table 3.1 it can be seen that 
the mutation lies within a highly conserved area across species. On analysis 
by I-Mutant, the substitution is not predicted to produce a significant change in 
ΔΔG hence the resultant protein would not be destabilised. However, Predict 
SNP has annotated the mutation to be deleterious with all prediction tools and 
this is seen in the clinical phenotype. 
 
The mutation p.D217H was identified in an 18-month-old patient who required 
FFP prophylaxis treatment infrequently, mainly as a response to severe 
infection. The mutation is located within the metalloproteinase domain and lies 
within a highly conserved area (see Table 3.1) within the amino acid sequence. 
Based on the clinical and alignment data, this mutation would be expected to 
be deleterious. There is no reliable structural information on this area of the 
protein but based on I-Mutant analysis the substitution was not predicted to 
lead to a significant ΔΔG and destabilise the protein. The mutation has been 
predicted to be deleterious with PolyPhen and SNAP predictive tools but 
overall to be neutral. 
 
The mutation p.R409W was identified in a patient who showed a more severe 
clinical phenotype and presented as a neonate, requiring plasma therapy 
prophylaxis treatment every 1-2 weeks. From the alignment (Table 3.1) the 
mutation lies within a conserved area in the TSP1-1 domain. Structural data is 
available for this domain. On analysis by FOLDX, a predicted Gibbs free 
energy change of 7.75 kcal/mol, predicted the mutation to severely reduce 
protein stability. The ΔΔG was predicted to be less with I-Mutant (0.44 
kcal/mol) but still predicted to affect protein stability. The mutation was also 
predicted to be deleterious by all tools in Predict SNP. This is aligned to the 
clinical phenotype. 
 
The mutations p.R398C and p.Q436H were identified as a compound 
heterozygote in a neonatal patient who presented with a severe clinical 
phenotype, requiring PT prophylaxis every 1-2 weeks. Both mutations lie 
within conserved regions (see Table 3.1) which would concur with the clinical 
phenotype. The p.R398C mutation, lies within the TSP1-1 domain. The 
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p.Q436H mutation also lies within the TSP1-1 domain. There is no reliable 
structural information for the p.R398C mutation but based on structural data, 
p.Q436H is predicted not to result in a ΔΔG thus having no effect on protein 
stability. Based on the amino acid sequence alone predicted by I-Mutant, 
p.R398C decreases ΔΔG whereas p.Q436H has no effect. Both mutations are 
predicted to be deleterious by Predict SNP. 
 
The mutation p.A596V was identified in a pregnant patient, together with 
another novel mutation p.R1095Q and SNP p.P475S as a compound 
heterozygote. She had a clinical history of no live births. Another 18-month-
old patient also had the p.A596V mutation in homozygous form. The p.A596V 
mutation is found in a conserved region (see Table 3.1) so would be expected 
to be deleterious. The p.A596V is found within the spacer domain. Structural 
data is available and the mutation is predicted to induce a ΔΔG of 1.92kcal/mol 
with a resultant decrease in protein stability by SNPEffect However, it is not 
predicted to have a significant effect by I-Mutant. On analysis by SIFT, the 
mutation is predicted to be deleterious by Predict SNP. This mutation was 
identified both in a late-onset TTP patient and an 18-month-old child in 
homozygous form thus this conflicting analysis may be bourne out by the 
clinical data. 
 
The mutation p.A690T was found as a compound heterozygous genotype 
(together with the deletion mutation C241_C242del) in a pregnant patient who 
had a clinical history of one live birth and four losses. The A690T mutation is 
found in a relatively conserved area of the protein (see Table 3.1). The 
mutation is found within the TSP1-2 domain of the protein. There is no 
structural data available for this region but the substitution was predicted to 
have no significant effect on ΔΔG by I-Mutant. It is predicted to be tolerated by 
SIFT and possibly damaging by PolyPhen2.0.  This was found in a patient with 
late-onset symptoms as a compound heterozygote, together with a deletion 
mutation. These results affirm the clinical phenotype. 
 
The final mutation to be analysed, p.C977F, was found in a pregnant patient 
with a clinical history of one live birth. This indicates that this is not a clinically 
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severe mutation. The mutation, involving the substitution of the residue 
cysteine (which is polar and can form disulphide bonds with other cysteine 
residues and is involved in protein stabilization) with phenylalanine (an 
aromatic hydrophobic residue which is often located in the interior structure of 
proteins), is found within the TSP1-5 domain of the protein. The amino acid 
lies within a moderately conserved area (see Table 3.1). There is no reliable 
structural information available but I-Mutant has predicted the substitution to 
be neutral, with no significant change in ΔΔG. However, Predict SNP has 
annotated this mutation as deleterious with all predictive tools. 
 
The mutation p.R1060W is analysed and discussed in Chapter 4. 
 
3.5 Concluding remarks 
From the in silico analysis of mutations and SNPs using various predictive 
tools, it can be concluded that the effect of SNPs on the expression of 
ADAMTS13 will be minimal and have no appreciable clinical effect on the 
phenotype of TTP patients. However, the effect of the mutations p.T196I, 
p.R398C, p.R409W, p.596V, C977F and p.R1060W on the phenotype of 
patients will be clinically significant and have a deleterious effect. The 
mutations p.R102H, p.D217H and p.Q436H have been predicted to have a 
neutral effect on clinical phenotype. 
 
In silico tools can be a useful adjunct to experimental data but as they are 
predictors of structure and function, the results should be interpreted with a 
degree of caution. It is important to understand the algorithms that are used 
and the degree of sensitivity and specificity. Further discussion can be found 








Pregnancy-associated congenital TTP (Upshaw-Schulman 
syndrome) 
4.1 Introduction 
4.1.1 Thrombotic microangiopathies 
Thrombotic microangiopathies (TMA) are a group of haemolytic disorders 
characterised by thrombocytopenia and microangiopathic haemolytic anaemia 
(MAHA). Pregnancy is known to be a risk factor for the development of TMA, 
with an incidence of 1 in 25,000 – 100,000 deliveries. This represents 25% of 
TMA cases in adults (Kentouche et al., 2013). Pregnancy- associated TTP 
shares similar clinical features but different aetiologies with other TMA 
disorders such as HELLP syndrome (haemolysis, elevated liver enzymes and 
low platelet count) and HUS (haemolytic uraemic syndrome), which can make 
differential diagnosis between these conditions a challenge. 
 
4.1.1.1 Thrombotic thrombocytopenic purpura 
The overall prevalence of congenital TTP or Upshaw Schulman syndrome 
(USS) is 4 -10 cases per million per year and the global mortality rate for both 
inherited and acquired forms is 20 %, in spite of advances in treatment and 
diagnosis (Veyradier et al., 2012). The incidence of TTP occurring in 
pregnancy was found to be much higher than in the general population; in a 
recent study the occurrence was documented as 1 in 200,000 (Scully et al., 
2014). Between 10-30% of cases of TTP were diagnosed during pregnancy or 
during the post-partum period (Moatti-Cohen et al., 2012; Fujimura et al., 
2009).  
 
4.1.1.2 Pregnancy-associated TTP 
In the UK over a five-year period, 1% of all maternal deaths were found to be 
due to TTP (Hunt et al., 2013). A diagnosis of USS is confirmed by low 
ADAMTS13 activity, the absence of anti-ADAMTS13 antibodies and 
mutational analysis. The initial presentation is frequently thrombocytopenia, 
microangiopathic haemolytic anaemia (MAHA) and <13% ADAMTS13 activity 
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(Scully et al., 2014).  If left untreated, mortality remains high for mother and 
foetus. Pregnancy loss is usually seen in the second trimester caused by 
inadequate placental function, leading to severe intrauterine growth 
retardation and foetal loss (Scully et al., 2014). The organs involved in 
microangiopathic damage are the kidneys, heart, brain and placenta. In TTP 
patients with foetal loss, all had placental infarction (Kentouche et al., 2013). 
Plasma therapy (PT) remains the only treatment for USS and the risk of 
recurrence in subsequent pregnancies is 100% in the absence of PT 
prophylactic treatment. 
 
Women with the inherited TTP present more frequently in pregnancy 
compared with those with the acquired form of TTP (Scully et al., 2014). 
However, pregnancy has been found not to be a risk factor for acquired TTP 
(Tsai, 2010). Clinically, late-onset TTP appears to follow a quiescent course 
until a major physiological stress such as pregnancy brings on the first 
manifestations of the disease. In the majority of cases, no signs and symptoms 
develop before pregnancy but it has been found that 20% of patients required 
regular plasma therapy after delivery (Scully et al., 2014). This suggests that 
genotype alone cannot explain this clinical effect, indicating other 
environmental factors may be involved.  
 
In a publication of the French TMA Registry, an unexpectedly high frequency 
of pregnancy-associated TTP was found (24%, or 10 out of 42 cases), with 
eight out of ten cases being heterozygous carriers of the p.R1060W mutation 
(Moatti-Cohen et al., 2012). The stillbirth rate in the French cohort was stated 
as 40% for patients with TTP, with the majority of cases becoming 
symptomatic in the late-second or early-third trimester. A worse prognosis was 
associated with the earlier onset of TTP (Fujimura et al., 2009).  
 
In another recent systematic review (Veyradier et al., 2012), 350 cases of TTP 
or TTP/HUS appeared in the English language literature. However, many 
cases were not systematically investigated for ADAMTS13 antigen or activity 
level. Between 1976 and 2011, 32 patients were documented with pregnancy-
associated TTP (although eight patients were not assessed for ADAMTS13 
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levels). In the remaining 24 patients, the level of ADAMTS13 was <10 %, with 
no anti-ADAMTS13 antibodies present. Fifteen of these cases were 
genotyped and six cases carried the p.R1060W mutation, either in 
heterozygous or homozygous form. Interestingly, these cases were seen in 
the Western world only (Europe or North America). In the nine remaining 
cases, which were recorded in Japan, miscellaneous mutations were seen. 
The p.R1060W mutation has not been found in Japanese patients (Fujimura 
et al., 2009). 
 
4.2 Pathophysiology of pregnancy-associated TTP 
4.2.1 Genotype of pregnancy-associated TTP 
Patients diagnosed with TTP have been observed on all continents of the 
world. More than 120 different mutations have been documented, the majority 
of which are confined to single families. In a study in Norway, patients with 
homozygous mutations were encountered in areas with a high prevalence of 
consanguinity (von Krogh et al., 2016). However, two mutations observed in 
TTP patients of European ancestry were exceptions to this: the frameshift 
mutation c4143_4144 dupA, which induces a premature termination of the 
protein at amino acid 1386 and the p.R1060W mutation in exon 24. The 
p.R1060W lies within the TSP1-7 domain in the ADAMTS13 protein and is a 









The p.R1060W mutation has been genotyped in patients from Turkey, Central 
Europe, Scandinavia, Europe and in North Americans of European descent 
(von Krogh et al., 2016). It causes impaired secretion but has been associated 
with some residual activity in plasma. The mutation in relation to late-onset 
TTP was first identified in 2006 (Tao et al., 2006) in a 34-year-old male patient 
who was compound heterozygous for p.R1060W and a deletion mutation 
(C365del). The patient had been diagnosed with idiopathic thrombocytopenic 
purpura as a young adult and was diagnosed with TTP 14 years later. The 
mutation p.R1060W was subsequently identified by Camilleri et al. in a cohort 
of TTP patients and was identified in six out of 53 cases. Three patients had 
pregnancy-associated USS and three had chronic/relapsing USS. One patient 
was homozygous for the p.R1060W mutation and the other five were 
heterozygous but had ADAMTS13 activity  < 5% at presentation (Camilleri et 
al., 2008).   
 
In a recent prospective study of TTP cases from the UK TTP Registry, 17 out 
of 23 patients with USS who showed the initial presentation in pregnancy 
carried the p.R1060W mutation (Scully et al. 2014). Out of these patients, six 
were homozygous for p.R1060W and 11 were compound heterozygotes for 
p.R1060W and deletion mutations. The SNPs p.R7W and p.A1033T were also 
co-inherited and were present in 74% and 70% of cases respectively. This was 
in contrast to the incidence of these SNPs in healthy European controls of 13% 
and 2% respectively (Scully et al. 2014). These SNPs may be inherited as a 
haplotype with the p.R1060W mutation. 
 
4.2.2 Location of p.R1060W and SNPs in ADAMTS13 
The single nucleotide polymorphism (SNP) p.R7W is located in the propeptide 
domain. In comparison with other ADAMTS or ADAM proteases, the 
ADAMTS13 propeptide is only 41 residues long and is exceptionally short 
compared to the approximate 200 residues in other members of this family 
(Apte, 2009). The propeptides in members of the ADAMTS family act as 
molecular chaperones, assisting in the correct protein folding and ensuring 
latency of the protein until it has been trafficked to the correct destination. 
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However, the propeptide in ADAMTS13 does not have this function and it has 
been shown not to be required for the secretion and activation of the protein 
(Majerus et al., 2003). 
The mutation p.R1060W and SNP p.A1033T are located in the distal TSP1-7 
domain. The number of TSP repeats in members of the ADAMTS proteases 
varies, however they have been shown to play a role in substrate recognition 
and cell surface binding (Apte 2009; Turner et al. 2009). The TSP1 domains 
show post-translational modifications but it is unclear whether these have a 
function in vivo (Zheng, 2013). All contain the amino acid sequence WXXW 
whereby an α-mannosyl group is attached to the first C2 group of tryptophan 
(W). Seven of the eight TSP1 groups also contain the conserved sequence 
CSX(S/T)CG whereby the amino acid at position 4 is modified by the 
disaccharide Glc-Fuc-O-Ser/Thr (Hofsteenge et al., 2001). TSP1 repeats 5-8 
appear to bind native VWF through the D4 domain (Zanardelli et al. 2009) and 
the terminal repeats have been shown to interact with the endothelial cell 
surface receptor CD36 (Asch et al., 1991). This could lead to enhanced 
proteolytic cleavage under flow conditions (Vomund & Majerus, 2009). 
Mutations in this area could disrupt these interactions.  A further role of the 
TSP repeats could be to reduce the force of VWF-mediated platelet adhesion 
and aggregation. The TSP repeats contain free thiols that may react with free 
thiols on the surface of ULVWF or plasma VWF exposed under shear stress. 
This interaction may prevent disulphide bond formation between apposed 
VWF multimers under these conditions (Yeh et al., 2010). 
 
4.3 Previous expression studies of mutation p.R1060W and SNPs 
4.3.1 Expression studies of p.R1060W mutation 
In previous expression studies, the catalytic activity of p.R1060W was found 
to be conserved. Carriers of the p.R1060W mutation have been shown to 
display small residual amounts of secretion.  The level of secretion was found 
to be 11% of wild type (WT) in HeLa cells  (Tao et al., 2006) and < 5% in 
HEK293T cells (Camilleri et al., 2008). This may reflect inherent differences in 
protein expression between the different cell lines (HeLa cells are derived from 
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cervical cancer cells whereas HEK are not) thus no direct conclusions can be 
made. A study of 29 USS patients from four European centres (Milan, the UK, 
Bergamo and France) found  four unrelated USS patients who were 
homozygous for this mutation displaying residual ADAMTS13 activity of 5-7% 
normal plasma (Lotta et al., 2012). All were late-onset presentation with 
pregnancy being the trigger for the first occurrence of TTP. 
 
4.3.2 Expression studies of p.R7W and p.A1033T SNPs with mutation 
p.R1060W 
The SNPs p.R7W and p.A1033T, together with p.R1060W are often inherited 
as a haplotype. The presence of SNPs have previously been suggested as 
modifiers of ADAMTS13 expression (Plaimauer et al., 2006; Camilleri et al., 
2008). Levy et al. first identified the following SNPs in TTP patients: p.R7W, 
p.Q448E, p.P618A, p.R625H, p.A732V, p.A900V and p.A1033T. These were 
also identified in 92 unrelated healthy controls (Levy et al., 2001). Tao et al. 
analysed secretion and activity levels of p.A1033T, which is found in the TSP1-
7 domain together with p.R1060W and substitutes alanine for threonine. This 
SNP was found to conserve secretion and activity by 80% (Tao et al., 2006).  
Plaimauer et al. also carried out expression studies and analysed the effects 
of four SNPs: p.R7W, p.Q448E, p.P618A and p.A732V in tandem with a rare 
mutation p.R1336W. It was shown that the effect of a single amino acid 
substitution in a mutation or SNP can be interactive, altering the phenotype of 
ADAMTS13 deficiency (Plaimauer et al,. 2006). The SNP p.R7W was found 
to have no effect on ADAMTS13 secretion singly but acted as a positive 
modifier in the context of p.P618A and p.A732V, which were known to cause 
secretory defects. In the context of the mutation p.R1336W, the SNP p.R7W 
enhanced the detrimental effect of the mutation and led to undetectable 
enzyme activity. It was also observed that the SNPs p.R7W and p.Q448E 
ameliorated the defects induced by a combination of the SNPs p.P618A and 
p.A732V.  
 
Edwards et al. also carried out expression studies with SNP p.A1033T 
(Edwards et al., 2012). It was found that p.A1033T increased secretion of 
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ADAMTS13 by 35% of WT. From this experimental data, it can be concluded 
that SNPs contribute to modification of ADAMTS13 expression and could 
explain the course of milder, late onset phenotypes. However, changes in 
physiology during pregnancy also need to be considered. These include the 
effect pregnancy has on the ADAMTS13-VWF axis and also the effect of 
pregnancy hormones on ADAMTS13 itself, which will be discussed in section 
4.9. 
 
4.4 Aims of this study 
This study investigated the in vitro effect of the individual SNPs p.R7W and 
p.A1033T singly and in combination with the missense mutation p.R1060W on 
ADAMTS13 expression levels in order to relate genotype to the late-onset 
phenotype observed in patients with pregnancy-associated TTP. 
 
4.5 Methods 
4.5.1 In silico modelling of mutation p.R1060W and SNPs R7W and A1033T 
A full description of in silico modelling can be seen in Chapter 3. The 
conservation of amino acids in the ADAMTS13 protein in the region of the 
mutation p.R1060W and SNPs p.R7W and p.A1033T was investigated by 
aligning the amino acid sequence of human ADAMTS13 with the amino acid 
sequence of ADAMTS13 orthologs using the MUSCLE (Multiple Sequence 
Comparison by Log-Expectation) alignment tool. The results can be seen in 
Table 3.1.  
 
The likely effect of the amino acid substitutions of mutation p.R1060W and 
SNPs p.R7W and p.A1033T was predicted using the following computational 
based tools: I-Mutant, SIFT, PolyPhen2 and PredictSNP (see Chapter 3). A 







Table 4.1 Summary of in silico analysis 
Predictive software p.R1060W p.R7W p.1033T 
MUSCLE alignment Partially conserved Not conserved Conserved 
IMutant ΔΔG -0.19 (neutral: no 
effect on protein 
stability) 
-0.1 (neutral: no 
effect on protein 
stability) 
-0.59 (Decrease in 
protein stability) 
SIFT Damaging Tolerated Tolerated 
PolyPhen2 Probably damaging Benign Possibly damaging 
PredictSNP Deleterious Neutral except 
SNAP 




0.12% 9% 4% 
 
4.5.2 In vitro expression studies of mutation p.R1060W and SNPs p.R7W 
and p.A1033T 
Site directed mutagenesis (SDM) was used to create a combination of six 
expression vectors, each containing a mutation, a SNP or mutation and/or 
SNP in various combinations (see Table 4.2). 
 
Table 4.2 Expression vectors created by site directed mutagenesis 
Expression vector Description 
R1060W Missense mutation 
R7W SNP 
A1033T SNP 
R1060W + R7W Missense mutation + SNP 
R1060W + A1033T Missense mutation + SNP 
R1060W + R7W + A1033T Missense mutation + 2 SNPs 
 
Two complementary mutagenic oligonucleotide primers were designed and 
purified by HPLC (Eurofins, Germany) to insert nucleotide substitutions into 
the ADAMTS13 cDNA insert of the pcDNA3.1+ vector (Invitrogen, UK), (see 
Table 4.3). 
 
Table 4.3 Nucleotide substitutions for site directed mutagenesis primers 
 
Amino acid change Nucleotide change (cDNA) 
1060 R→W 3178 C→T 
7 R→W 19 C→T 




Site directed mutagenesis was performed as previously described in section 
2.2. The presence or absence of the nucleotide substitutions were verified by 
Sanger sequencing (GATC, Germany). Mutant plasmids were amplified and 
purified with MaxiPrep kits (QIAGEN, UK) prior to transfection into human 
embryonic kidney cells (HEK293T). To measure transfection efficiency, 
HEK293T cells were co-transfected with a reporter plasmid expressing E.coli 
β galactosidase in a 1:1 molar ratio. Sub-confluent HEK293T cells were grown 
in 100mm dishes in DMEM medium until 70-80% confluency. Transient 
transfections of WT and mutant expression vectors were performed with 33 μg 
total DNA and 10mM PEI in Opti-Mem with cells and incubated for 72 hours at 
37°C, 5% CO2 in a humidified incubator.  
 
Transfection efficiency of each construct was examined in three transfections. 
Transfection efficiency by β-galactosidase activity has been previously 
described (see section 2.8). Cells were collected, the cells lysed in 20mM 
Triton X (Sigma-Aldrich, UK) and sonicated prior to protein quantitation by 
BCA assay (Thermo-Scientific, UK). Conditioned media was harvested and 
concentrated prior to protein quantitation by BCA assay (Thermo-Scientific, 
UK). Western blot analyses were performed on cell lysates and conditioned 
media (see section 2.12). An equal quantity of protein was loaded per well for 
SDS-PAGE. The housekeeping protein β-actin was used as a loading control 
(cell lysates only) to normalize protein loading. Recombinant ADAMTS13 was 
visualized by western blotting using an antibody to the myc insert (Merck 
Millipore, UK). Alkaline phosphate-conjugated goat anti-mouse IgG was used 
for the secondary antibody (Abcam, UK). The western blot band intensities 
were analysed by densitometry using ImageJ software. To correct for sample-
to-sample and lane-to-lane variability in SDS-PAGE, the intensity of the 
ADAMT13 band on the western blot image for each lane was normalized to 
the internal loading control of the endogenous protein β actin. Blots were 
assessed for quality of the primary and secondary antibody interactions in 
relation to band intensities of the housekeeping protein and positive (WT) 
control and repeated if necessary To monitor the transfection efficiency and to 
obtain normalized expression values in order to compare the results of 
transfections with different constructs, the appearance of blue colonies 
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(indicating the reporter plasmid) was quantified (as described in section 2.8). 
ADAMTS13 antigen quantitation was performed on the concentrated 
conditioned media using the commercially available IMUBIND® ADAMTS13 
ELISA (Sekisuidiagnostics UK). Values (mean of replicate transfections) are 
presented as % of WT values ± SEM (WT = 100%). 
 
4.6 Results of transient expression studies of mutation p.R1060W 
mutation and SNPs  
4.6.1 Sanger sequencing of WT ADAMTS13 cDNA insert 
Initially the WT expression vector was sequenced by Sanger sequencing to 
ensure there were no non-synonymous mutations present (i.e. those that 
would result in an amino acid change). It was found that the ADAMTS13 cDNA 
contained the following synonymous changes (i.e. those that differ in 
nucleotide sequence from the reference sequence but would not result in an 
amino acid change); see Figure 4.2 and Table 4.4. 
 
 
WTADAMTS           TTGCCTGTGGCTTTCTCCTGGGCTGCTGGGGACCCTCCCATTTCCAGCAGAGTTGTCTTC 115 
WTADAMTS13-T7      TTGCCTGTGGCTTTCTCCTGGGCTGCTGGGGACCCTCCCATTTCCAGCAGAGCTGTCTTC 180 
                   **************************************************** ******* 
WTADAMTS           GTGCCCCAAATATCACAGCCAACCTCACCTCGTCCCTGCTGAGCGTCTGTGGGTGGAGCC 475 
WTADAMTS13-T7      GTGCTCCAAATATCACAGCCAACCTCACCTCGTCCCTGCTGAGCGTCTGTGGGTGGAGCC 540 
                   **** ******************************************************* 
ADAMTS13           GGCGTGGAGAAGTGGTGCTCCAAGGGTCGCTGCCGCTCCCTGGTGGAGCTGACCCCCATA 1140 
45HI86            GGCGTGGAGAAGTGGTGCTCCAAAGGTCGCTGCCGCTCCCTGGTGGAGCTGACCCCCATA 212 
                   ***********************.************************************ 
ADAMTS13           TCTTTCACAGCTGGCAGAGCGAGAGAATATGTCACATTTCTGACAGTTACCCCCAACCTG 1740 
45HI86            TCTTTCACAGCTGGCAGAGCGAGAGAATATGTCACGTTTCTGACAGTTACCCCCAACCTG 812 
                  ***********************************.************************ 
WTADAMTS                     CTTCGGCCCATGCAGCGCCTCCTGTGGGGGCGGCCTGCGGGAGCGGCCAG 2299 
WTADAMTS13-ADAMTS13seq3     CTTCGGCCCATGCAGCGCCTCCTGTGGGGGTGGCCTGCGGGAGCGGCCAG 851 
                            ****************************** ******************* 
WTADAMTS                     GCAGGGTCGTGCTCCGTCTCCTGCGGGCGAGGTCTGATGGAGCTGCGTTT 2750 
WTADAMTS13-ADAMTS13seq5     GCAGGGTCGTGCTCCGTCTCCTGCGGGCGAGGTCTGATGGAGCTCCGTTT 272 






Table 4.4 Synonymous changes in WT ADAMTS13 cDNA insert 
Nucleotide change Codon change  Amino acid 
T108C AGT → AGC  Serine → serine 
C420T GCC → GCT  Alanine → alanine 
G1104A AAG → AAA  Lysine → lysine 
A1716G ACA → ACG  Threonine → threonine 
C2280T GGC→ GGT  Glycine → glycine 
G2744C CTG → CTC  Leucine→ leucine 
Figure 4.2 Wild type full sequencing ADAMTS13 results: synonymous changes in WT cDNA 




Once confirmation by Sanger sequencing had confirmed that the 
mutation/SNP had successfully been introduced and the full insert was 
screened for unwanted non-synonymous changes (those that would result in 
an amino acid substitution), the WT and mutant expression vectors were 
amplified using the Maxiprep QIAGEN kits according to manufacturer’s 
instructions (QIAGEN). As can be seen from Table 4.5, this often yielded very 
poor DNA concentrations, even after troubleshooting the method. 
 
Table 4.5 DNA concentration of expression vectors (QIAGEN Maxiprep) 
 
Clone DNA Concentration (ng/μl) 
p.A1033T (3) + C384T (9) 880 
p.R1060W (4) + C3484T (2) 91, 93 
p.R7W (8) + C3484T (2) 133 
p.R7W (8) + p.R1060W (8) + C3484T (2) 34, 36, 567, 694 
p.R1060W (4) + p.A1033T (3)+ C3484T(2) 25, 36, 56, 124 
p.R7W (8) + p.R1060W (8) + p.A1033T (4) + 
C3484T (1) 
28, 25, 113 
X gal reporter plasmid  132 
Naked vector  1099 
WT 528, 314, 94, 63 
 
4.6.1.1 Non-synonymous mutation introduced by SDM 
After SDM and confirmation by Sanger sequencing, a non-synonymous 
mutation was found in the cDNA ADAMTS13 insert arising at nucleotide 
position 3484 in several plasmids. This substitution of cytosine for thymine 
(C>T) resulted in an amino acid change of serine (codon TCC) to proline 
(codon CCC). This occurred at the same position in several SDM expression 
vectors and was reverted by a repeat SDM experiment using the primer seen 
in Figure 4.3. 
 
CCC TGG AGT GGT TCC AGG CCC GG CCG GGC CTG GAA CCA CTC CAG GG 




Repeat Sanger sequencing was performed of the cDNA insert to verify the 
nucleotide sequence had reverted back to the WT sequence and that no other 




changes were inserted (see Figures 4.4 – 4.9). It is unclear as to why this 
nucleotide substitution occurred in all expression vectors. 
4.6.1.2 Sanger sequencing of expression vectors 
The Sanger sequencing results can be seen in Figures 4.4 - 4.9. 
G3097A (p.A1033T)  
 
WTADAMTS13                   AGTCATGTCCCTTGGCCCATGTTCGGCCAGCTGTGGCCTTGGCACTGCTA 3100 
ADAMTS13A1033T3-Seq05       AGTCATGTCCCTTGGCCCATGTTCGGCCAGCTGTGGCCTTGGCACTACTA 621 
                            **********************************************.*** 
 
C3484T insertion in G3097A 
 
ADAMTS13           TGGTCCCAGGCCCGGGGCCTGCTCTTCTCCCCGGCTCCCCAGCCTCGGCGGCTCCTGCCC 3540 
45HI45            TGGCCCCAGGCCCGGGGCCTGCTCTTCTCCCCGGCTCCCCAGCCTCGGCGGCTCCTGCCC 465 
                  *** ******************************************************** 
 
G3097A + C3484T reversion 
 
32EG49            TGGTCCCAGGCCCGGGGCCTGCTCTTCTCCCCGGCTCCCCAGCCTCGGCGGCTCCTGCCC 467 
ADAMTS13           TGGTCCCAGGCCCGGGGCCTGCTCTTCTCCCCGGCTCCCCAGCCTCGGCGGCTCCTGCCC 3540 





C3178T (p.R1060W)  
 
WT                 CAGCTCGACCAAGGCCAGGACGTGGAGGTGGACGAGGCGGCCTGTGCGGCGCTGGTGCGG 3180 
R1060W406         CAGCTCGACCAAGGCCAGGACGTGGAGGTGGACGAGGCGGCCTGTGCGGCGCTGGTGTGG 108 
                  ********************************************************* ** 
 
C3484T insertion into C3178T 
 
WT                 TGGTCCCAGGCCCGGGGCCTGCTCTTCTCCCCGGCTCCCCAGCCTCGGCGGCTCCTGCCC 3540 
R1060W406         TGGCCCCAGGCCCGGGGCCTGCTCTTCTCCCCGGCTCCCCAGCCTCGGCGGCTCCTGCCC 468 
                  *** ******************************************************** 
 
C3178T + C3484T reversion 
 
ADAMTS13cDNA               ACAGCCACCCCTGCTGGTGCCTCCCTGGAGTGGTCCCAGGCCCGGGGCCT 3500 
68R1060W4C3484T2           ACAGCCACCCCTGCTGGTGCCTCCCTGGAGTGGTCCCAGGCCCGGGGCCT 1026 
                           ************************************************** 
 
  
Figure 4.2 Sequencing results of expression vector p.A1033T SNP Sequencing results of 
expression vector p.A1033T (G3097T) SNP with non-synonymous mutation reverted to WT. 
 
Figure 4.3 Sequencing results of expression vector p.R1060W mutation with non-




C19T (p.R7W)  
 
ADAMTS13           ------ATGCACCAGCGTCACCCCCGGGCAAGATGCCCTCCCCTCTGTGTGGCCGGAATC 54 
45HI60              GCCACCATGCACCAGCGTCACCCCTGGGCAAGATGCCCTCCCCTCTGTGTGGCCGGAATC 120 
                         ****************** *********************************** 
 
C3484T insertion into C19T 
 
ADAMTS13           TGGTCCCAGGCCCGGGGCCTGCTCTTCTCCCCGGCTCCCCAGCCTCGGCGGCTCCTGCCC 3540 
45HI79            TGGCCCCAGGCCCGGGGCCTGCTCTTCTCCCCGGCTCCCCAGCCTCGGCGGCTCCTGCCC 466 
                  *** ******************************************************** 
 
C19T + C3484T reversion 
ADAMTS13           TGGTCCCAGGCCCGGGGCCTGCTCTTCTCCCCGGCTCCCCAGCCTCGGCGGCTCCTGCCC 3540 
26R7W8             TGGTCCCAGGCCCGGGGCCTGCTCTTCTCCCCGGCTCCCCAGCCTCGGCGGCTCCTGCCC 1062 
                  ************************************************************ 
 
Figure 4.6 Sequencing results of expression vector p.R7W (C19T) SNP with non-synonymous 




C19TcDNA                     ---------------------ATGCACCAGCGTCACCCCCGGGCAAGATG 29 
R7W8R1060W8C3484T2            TGGTGGAATTCGCCGGCCACCATGCACCAGCGTCACCCCTGGGCAAGATG 100 
                                                  ****************** ********** 
C3187T (p.R1060W) 
 
cDNA                         GACGAGGCGGCCTGTGCGGCGCTGGTGCGGCCCGAGGCCAGTGTCCCCTG 3200 
R7W8R1060W8C3484T2          GACGAGGCGGCCTGTGCGGCGCTGGTGTGGCCCGAGGCCAGTGTCCCCTG 731 
                            *************************** ********************** 
C3484T insertion 
 
WTADAMTS13         TGGTCCCAGGCCCGGGGCCTGCTCTTCTCCCCGGCTCCCCAGCCTCGGCGGCTCCTGCCC 3540 
67GD97            TGGCCCCAGGCCCGGGGCCTGCTCTTCTCCCCGGCTCCCCAGCCTCGGCGGCTCCTGCCC 471 




ADAMTS13                    ACAGCCACCCCTGCTGGTGCCTCCCTGGAGTGGTCCCAGGCCCGGGGCCT 3500 
87DI38R7W+R1060W+C3484T     ACAGCCACCCCTGCTGGTGCCTCCCTGGAGTGGTCCCAGGCCCGGGGCCT 429 
                            ************************************************** 
 
  
Figure 4.4 Sequencing results of expression vector p.R7W+ p.R1060W SNP + mutation with 







cDNA               CTTGGCCCATGTTCGGCCAGCTGTGGCCTTGGCACTGCTAGACGCTCGGTGGCCTGTGTG 3120 
R1060WA1033T      CTTGGCCCATGTTCGGCCAGCTGTGGCCTTGGCACTACTAGACGCTCGGTGGCCTGTGTG 651 
                  ************************************.***********************                    
C3178T (p.R1060W) 
 
cDNA               CAGCTCGACCAAGGCCAGGACGTGGAGGTGGACGAGGCGGCCTGTGCGGCGCTGGTGCGG 3180 
R1060WA1033T      CAGCTCGACCAAGGCCAGGACGTGGAGGTGGACGAGGCGGCCTGTGCGGCGCTGGTGTGG 711 
                  ********************************************************* **          
C3484T insertion 
 
ADAMTS13cDNA                 ACAGCCACCCCTGCTGGTGCCTCCCTGGAGTGGTCCCAGGCCCGGGGCCT 3500 
R1060WA1033T                ACAGCCACCCCTGCTGGTGCCTCCCTGGAGTGGCCCCAGGCCCGGGGCCT 430 
                            ********************************* **************** 
C3878T reversion 
 
cDNA                         ACAGCCACCCCTGCTGGTGCCTCCCTGGAGTGGTCCCAGGCCCGGGGCCT 3500 
R1060W+A1033T+C3484T        ACAGCCACCCCTGCTGGTGCCTCCCTGGAGTGGTCCCAGGCCCGGGGCCT 424 









cDNA                         -------------------ATGCACCAGCGTCACCCCCGGGCAAGATGCC 31 
R7WR1060WA1033TC3484T        GTGGAATTCGCCGGCCACCATGCACCAGCGTCACCCCTGGGCAAGATGCC 100 
                                                ****************** ************ 
G3097A (p.A1033T) 
 
cDNA                         AGTCATGTCCCTTGGCCCATGTTCGGCCAGCTGTGGCCTTGGCACTGCTA 3100 
R7WR1060WA1033TC3484T        AGTCATGTCCCTTGGCCCATGTTCGGCCAGCTGTGGCCTTGGCACTACTA 1050 
                             **********************************************.*** 
C3187T (p.R1060W) 
 
cDNA                         GGACGAGGCGGCCTGTGCGGCGCTGGTGCGGCCCGAGGCCAGTGTCCCCT 3199 
R7WR1060WA1033TC3484T       GGACGAGGCGGCCTGTGCGGCGCTGGTGTGGCCCGAGGCCAGTGTCCCCT 723 
                            **************************** ********************* 
C3878T reversion 
 
cDNA                         CACAGCCACCCCTGCTGGTGCCTCCCTGGAGTGGTCCCAGGCCCGGGGCC 3499 
R7WR1060WA1033TC3484T        CACAGCCACCCCTGCTGGTGCCTCCCTGGAGTGGTCCCAGGCCCGGGGCC 1023 




4.6.2 Transfection efficiencies 
A total of five fields were examined microscopically (X100) and a grid overlaid 
on each image. A differential count of the total number of cells and number of 
blue cells was performed. Blue coloured cells indicated successful co-
transfection with the reporter plasmid containing the LacZ gene, producing β- 
galactosidase. A representative plate from each transfection is shown in 
Figures 4.10 - 4.17. 
Figure 4.5 Sequencing results of expression vector p.R1060W + p.A1033T with non-
synonymous mutation reverted to WT 
Figure 4.6 Sequencing results of expression vector p.R1060W + p.R7W + p.A1033T with 
non-synonymous mutation reverted to WT 
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Figure 4.8 Co-transfection negative 
control 
Figure 4.7 Co-transfection positive 
control 
Figure 4.9 Co-transfection p.R1060W  Figure 4.10 Co-transfection p.R7W 




     
 
From the differential counts, the transfection efficiency for each expression 
vector can be seen in Table 4.6.The total number of blue stained cells were 
counted (those successfully transfected with the reporter plasmid) together 
with the total number of cells to calculate the percentage of cells 
successfullyntransfected. It was assumed that the ADAMTS13 expression 
vector was transfected at the same efficiency as the reporter vector.The 
protocol was repeated once, as can be seen in Table 4.6. 
 
Table 4.6 Estimated transfection efficiencies of expression vectors 
Clone % transfection 
efficiencies 
% transfection efficiencies 
(repeat) 
WT 18 30 
p.A1033T 25 24 
p.R1060W 28 26 
p.R7W  18 25 
p.R7W + p.R1060W  32 20 
p.R1060W + p.A1033T  20 22 
p.R7W + p.R1060W + p.A1033T  24 35 
 
Quantitation of total protein in cell lysates and conditioned media was 
performed by BCA assay (Thermo Scientific, UK); for results see Appendix 
1.0. 
 
Each expression vector was transiently transfected into HEK293T cells in 
triplicate. The resultant cell lysate and conditioned media were analysed on 
western blot. If it was found that the transient transfection was unsuccessful, 
Figure 4.13 Co-transfection p.R1060W 
+ p.A1033T  
Figure 4.17 Co-transfection p.R1060W + 
p.R7W + p.A1033T 
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only two expression vectors can be seen on western blot. The transient 
transfection was then repeated. 
 
4.6.3 Western blot analysis of cell lysates  
After transient transfection, cells were harvested and initially untreated by cell 
lysis and sonication (see Figure 4.18). The expected size of ADAMTS13 




Figure 4.14 Western blot analysis cell lysates (untreated) Western blot of cell lysate 
(untreated): WT, p.R1060W and p.R1060W + p.R7W  
(WT 1, 2 and 3 denotes the cell lysates from separate transient transfections) 
 
 
Due to the difficulty in manipulating and loading the untreated samples, cell 
lysates were lysed using 20mM Triton X (Sigma-Aldrich UK) and sonicated. 
An antibody directed against the housekeeping protein β-actin of molecular 
weight 45kDa was used as a loading control (see Figures 4.19-4.21). An equal 
amount of total protein was loaded into each well of SDS-PAGE, as 
determined by BCA assay. The optimal quantity of protein to load to ensure a 
linear relationship between sample and signal was evaluated and is described 









Figure 4.15 Western blot analysis cell lysates p.A1033T, p.A1033T + p.R1060W (β actin was 




Figure 4.16 Western blot analysis cell lysate p.R1060W, p.R1060W + p.R7W, p.R1060W + 
















4.6.4 Western blot analysis of conditioned media (concentrated) 
The conditioned media of the expression vectors analysed in Figures 4.19 - 
4.21 were harvested, concentrated and analysed on western blot as described 













Figure 4.20 Western blot analysis conditioned media p.R1060W + p.R7W + p.A1033T, 








4.6.5 Western blot analysis of cell lysates, repeat transient transfections 
A repeat transfection was carried out with the same expression vectors using 
the same protocol and experimental conditions. The cells were lysed and 
sonicated as previously described and analysed on western blot (see Figures 
4.25 - 4.26.  
 
 
Figure 4.21 Western blot analysis conditioned media p.A1033T, p.R1060W + p.A1033T + 




Figure 4.22 Western blot analysis cell lysate (rpt) p.R1060W, p.R1060W + p.A1033T 
  
4.6.6 Western blot analyses of conditioned media, repeat transient 
transfections 
The conditioned media of the expression vectors analysed in Figures 4.25 - 















Figure 4.24 Western blot of conditioned media, repeat transient transfection: WT, p.R1060W 
+ p.R7W, p.R1060W + p.R7W + p.A1033T and p.R7W 
 
4.6.7 ImageJ analysis of western blots: cell lysates 
The band intensities on western blots were scanned using ImageJ software 
and the cell lysates normalized to the β-actin housekeeping protein by 
comparing the signal intensity of the housekeeping protein to the target 
ADAMTS13 signal. This normalized ADAMTS13 signal was then compared 
with the positive control (WT) values (%) and the standard error of the mean 
for each expression vector calculated (see Table 4.7 and Figure 4.29). Each 
expression vector was transiently transfected in triplicate and analysed on 
western blot (one lane per transfection). For example, p.R7W1 is transfection 
1. Transfection was then repeated in triplicate. As it was found that not all 
vectors were transfected successfully, only the results from duplicate 







Table 4.7 Normalized protein ratio of expressed ADAMTS13 in cell lysates samples, %WT ± 
SEM. 
cDNA substitution Normalized protein 
ratio 
% of WT± SEM 
WT 1.0 100 
p.R1060W 1  0.23 23 ±  8.6 
p.R1060W 2  0.06 6 ±  8.6 
p.R7W 1  1.26 126 ±  6.0 
p.R7W 2  1.38 138 ±  6.0 
p.A1033T 2  1.07 106 ±  9.0 
p.A1033T 3  0.88 88 ±  9.0 
p.R1060W + p.R7W 1  0.39 39 ±  5.0 
p.R1060W + p.R7W 2  0.49 49 ±  5.0 
p.R1060W + p.A1033T 1  0.26 26 ± 13.9 
p.R1060W + p.A1033T 2  0.54 54 ±  13.9 
p.R1060W + p.R7W + p.A1033T 1  0.08 8 ± - 2.1 







Figure 4.25 Comparison of normalized protein ratio of ADAMTS13 expressed in cell lysate 











































































































































4.6.8 ImageJ analysis of western blots: conditioned media 
The band intensities on western blots were scanned using ImageJ software 
and the conditioned media samples normalized to the WT positive control on 
the same blot (values ± SEM); (see Table 4.8 and Figure 4.30). 
Table 4.8 Normalized protein ratio of expressed ADAMTS13 in conditioned media samples, 
%WT ± SEM 
cDNA substitution Normalized protein 
ratio 
% of WT ± 
SEM 
WT 1.00 100 
p.R1060W 1  0.06 6 ± 1.6  
p.R1060W 2  0.02 2 ± 1.6 
p.R7W 1  1.28 128 ± 1.0 
p.R7W 2  1.26 126 ± 1.0 
p.A1033T 2  1.52 152 ± 18.4 
p.A1033T 3  1.15 115 ± 18.4 
p.R1060W + R7W 1  0.28 28 ± 5.6 
p.R1060W + R7W 1  0.20 20 ±  5.6 
p.R1060W + A1033T 1  0.32 32 ± 3.5 
p.R1060W + p.A1033T 2  0.25 25 ± 3.5 
p.R1060W + p.R7W + p.A1033T 2  0.26 26 ± 3.0 



















































































































































Figure 4.26 Comparison of normalized protein ratio of expressed ADAMTS13 in 





4.6.9 ImageJ analysis of cell lysates, repeat transient transfections 
The band intensities on western blots for repeat transfections were scanned 
using ImageJ software and the cell lysates normalized to the β-actin 
housekeeping protein and compared with positive control (WT) values ± SEM 
(see Table 4.9 and Figure 4.31). 
 
Table 4.9 Normalized protein ratio of expressed ADAMTS13 in cell lysate samples, repeat 
transfections, % WT ± SEM 
cDNA substitution Normalized 
protein ratio 
% WT ± SEM 
WT 0.41 100 
p.A1033T 1 0.73 100 ±  8.3 
p.A1033T 2 0.61 98 ±  8.3 
p.A1033T 3 0.33 81 ±  8.3 
p.R1060W + p.R7W + p.A1033T 1 1.10 144 ±  16.8 
p.R1060W + p.R7W + p.A1033T 2 1.06 141 ±  16.8 
p.R1060W + p.R7W + p.A1033T 3  0.43 57 ±  16.8 
p.R1060W + p.R7W 1  0.28 29 ±  11.5 
p.R1060W + p.R7W 2  0.52 50 ±  11.5 
p.R1060W 1 0.48 119 ±  5.7 
p.R1060W 2 0.27 61 ±  5.7 
p.R1060W 3  0.47 113 ±  5.7 
p.R1060W + p.A1033T 1 0.58 140 ±  12.1 
p.R1060W + p.A1033T 2 0.09 21 ±  12.1 















4.6.10 ImageJ analysis of concentrated conditioned media, repeat transient 
transfections 
The band intensities on western blots were scanned using ImageJ software 
and the conditioned media samples normalized to the WT positive control 
(values ± SEM); (see Table 4.10 and Figure 4.32). 
 
Table 4.10 Normalized protein ratio of expressed ADAMTS13 in conditioned media samples, 
repeat transfections % WT ± SEM 
Expression vector Normalized protein ratio % WT ± SEM 
WT (mean) 1.0 100 
p.R1060W 1  0.37 37 ± 11.0 
p.R1060W 2  0.59 59 ± 11.0 
p.A1033T 1  0.23 23 ±- 5.7 
p.A1033T 2  0.15 15 ± 5.7 
p.R1060W + A1033T 1  0 0 
p.R1060W + A1033T 2  0 0 
p.R1060W + R7W 1   0.28 28  







































































































































































Figure 4.27 Comparison of normalized protein ratio of ADAMTS13 in cell lysate samples, % WT± 




p.R1060W + R7W + A1033T 1  0.26 26 ± 3.5 
p.R1060W + R7W + A1033T 2  0.20 20 ± 3.5 
p.R7W 1  1.48 128 ± 18.5  














4.6.11 ADAMTS13 ELISA analysis of concentrated conditioned media 
samples 
Cell lysate and conditioned media samples were analysed for ADAMTS13 
antigen with the commercially available IMUBIND® ADAMTS13 ELISA 
(Sekisuidiagnostics UK) according to manufacturer’s instructions (see Chapter 
2). Results can be seen in Table 4.11 and Figure 4.33. The positive control 
(WT ADAMTS13) was taken as 100% expression and all results were 
normalized against this value and expressed as % WT. Each sample was 











































































































































Figure 4.28 Comparison of normalized protein ratio of expressed ADAMTS13 in 
concentrated conditioned media samples, % WT ± SEM, repeat transfections. 
(multi = p.R160W + p.R7W + p.A1033T) 
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Table 4.11 Normalized ADAMTS13 antigen ratio of expressed ADAMTS13 in conditioned 
media samples, repeat transfections %WT ± SEM. 
Expression vector ADAMTS13 concentration 
(ng/ml) 
% WT ± SEM 
WT 242.75 100  
p.R1060W 1 0 0 ± 1.6 
p.R1060W 2 7.84 3.2 ± 1.6 
p.A1033T 2 27.6 11.4 ± 4.2 
p.A1033T 3 48.23 19.9 ±- 4.2 
p.R1060W + p.A1033T 1 20 8.2 ± 0.6 
p.R1060W + p.A1033T 2 16.47 6.8 ± 0.6 
p.R1060W + p.R7W 1 8.24 3.4 ± 1.0 
R1060W + R7W 2 13.33 5.5 ± 1.0 
p.R7W 1 0 0 ± 0.05 
p.R7W 2 2.35 0.1 ± 0.05 
p.R1060W + p.R7W + p.A1033T 1 16.86 6.9 ± 1.0 














































































































































Figure 4.29 ADAMTS13 antigen concentration expressed in conditioned media 
samples as analysed by ELISA, % WT± SEM. 
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4.7 Statistical analysis 
In order to assess the statistical significance of the variation in ADAMTS13 
expression between the mutation R1060W and R1060W in combination with 
SNPs R7W and A1033T singly and in combination with R7W and A1033T, a 
one way analysis of variance (ANOVA) statistical test was performed. The 
values for %WT were utilised for each western blot. Results can be seen in 
Table 4.12  
 
Table 4.12 Results of one way ANOVA analysis for first and repeat transient transfection of 











Cell lysate first 
transfection 
Western blot 0.094 6.59 Accept 
CM first 
transfection 
Western blot 0.387 6.59 Accept 
Cell lysate repeat 
transfection 
Western blot 2.26 3.59 Accept 
CM repeat 
transfection 
Western blot 9.47 18.5 Accept 
CM first and 
repeat 
transfections 
ELISA 0.83 9.23 Accept 
 
In all cases the null hypothesis was accepted in that there is no significant 
difference between the mean ADAMTS13 expression of vectors p.R1060W, 
p.R1060W + p.R7W, p.R1060W + p.A1033T and p.R1060W + p.R7W + 
p.A1033T in cell lysates and conditioned media as analysed by western blot 
and conditioned media as analysed by ELISA.  
4.8 Discussion 
The mechanism of the association between ADAMTS13 mutations and 
disease phenotype is unknown. From previous animal studies (Motto et al. 
2005; Banno et al. 2006), ADAMTS13 deficiency alone and hence genotype, 
may not be sufficient to cause TTP. There also may be additional triggers 
required. This can be evidenced clinically in that siblings with the same 
genotype may present differently with respect to onset and severity of the 
disease and that some patients with severely reduced ADAMTS13 activity 
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present later in life, usually after a triggering event such as pregnancy, severe 
infection or treatment with certain drugs. As explained previously, pregnancy 
is associated with many physiological changes but whether this event serves 
to promote ADAMTS13 deficiency or the event serves to trigger a TTP episode 
is hard to evidence. 
This study investigated the in vitro effect of the individual SNPs p.R7W and 
p.A1033T singly and in combination with the missense mutation p.R1060W on 
ADAMTS13 antigen levels in order to relate genotype to the late-onset 
phenotype observed in patients with USS. 
Usually, to cause severe ADAMTS13 deficiency both alleles of the ADAMTS13 
gene are affected. Heterozygous carriers of a mutation on a single allele are 
usually asymptomatic and do not present with TTP-like symptoms (Crawley & 
Scully, 2013). However, several patients diagnosed with late-onset, 
pregnancy-associated TTP carrying a single p.R1060W mutation, together 
with several SNPs, have been identified (Camilleri et al. 2008). The majority 
of mutations causing severe ADAMTS13 deficiency cause disruption of 
ADAMTS13 protein folding during synthesis, leading to severe intracellular 
retention (Crawley & Scully, 2013). In this study, the homozygous condition 
was studied due to limitations of the experimental procedure.  
 
From the in silico MUSCLE alignment, the p.R7W SNP is located in a variable 
area with respect to conservation between orthologs. The p.R1060W and 
p.A1033T are separated by approximately 80 nucleotides and this region is 
highly conserved in all orthologs except in the mouse and the rat. Conservation 
of amino acids has been postulated to be the second most predictive factor of 
the impact of a mutation (Lee et al. 2009), with a mutation occurring in a highly 
conserved area having more impact. The SNPs p.R7W and p.A1033T are 
predicted to be tolerated by SIFT, which is a sequence homology tool, and 
p.R7W is predicted to have a benign effect by PolyPhen2.0. The latter tool is 
based on phylogenetic and structural information. However, p.A1033T is 
predicted to be possibly damaging by PolyPhen2.0. The p.R1060W mutation 
is predicted to be damaging by both. Predict SNP has predicted the mutation 
pR1060W to be deleterious by all predictive software and the p.A1033T SNP 
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to be deleterious by SIFT and SNAP. However, overall the SNPs have been 
predicted to be likely benign clinically. The I-Mutant tool, which estimates 
changes in Gibbs free energy due to the mutation and hence the effect on the 
stability of the protein, predicted p.R7W and p.R1060W to have no effect but 
estimated p.A1033T to decrease the stability of the protein. Interestingly, the 
occurrence of the p.R7W SNP in the global population is 0.0527, the 
occurrence of p.A1033T 0.0156 and that of p.R1060W, 0.0008 which may 
reflect the evolutionary pressures on these variants. 
 
From the in vitro expression studies, the estimated transfection efficiencies of 
the WT (positive control) and p.R7W SNP were similar at 18%. The variants 
p.R1060W + p.A1033T, p.A1033T and p.R1060W + p.R7W + p.A1033T had 
similar transfection efficiencies of approximately 23%. The variants p.R1060W 
and p.R1060W + p.R7W had the highest at approximately 30%, despite 
ensuring an equal number of cells were plated and the transfection performed 
at 70-80% cell confluency.  When interpreting results these differing values 
should be taken into account. 
 
From the first transfection series, an equal quantity of total protein was loaded 
in each well during SDS-PAGE. However, a housekeeping antibody was not 
used and the values have been normalised against the positive control (WT) 
only. The mean results (expressed as % of WT) for cell lysates are 
summarised in Table 4.13: 
 
Table 4.13 Summary of mean normalized ADAMTS13 expression in cell lysates expressed 
as %WT; first transfection 





p.R7W + p.A1033T 
15 % 132 % 97 % 44 % 40 % 10 % 
 
In consideration of the differing transfection efficiencies, the values could be 
normalized to reflect %ADAMTS13 in cell lysates as WT and p.R7W 
transfection efficiencies were 60% of p.R1060W. The transfection efficiencies 
of p.R1060W + p.R7W were 80% of the other variants. However, the low % 
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ADAMTS13 expression of p.R1060W (which had the highest transfection 
efficiency) may indicate that this mutation is causing aberrant folding of the 
protein and is being targeted and broken down in the cell. However, despite 
these observations, statistical analysis using one way ANOVA found that there 
was no statistical significance in the expression of ADAMTS13 in cell lysates 
between p.R1060W and p.R1060W + SNPs. 
The mean quantity of ADAMTS13 secreted into the conditioned media from 
these variants is summarised in Table 4.14: 
Table 4.14 Summary of mean ADAMTS13 secretion in conditioned media, expressed as 
%WT; first transfection 





p.R7W + p.A1033T 
4 % 127 % 120 % 24 % 29 % 23 % 
 
From these results, the mean secretion of ADAMTS13 in the media from the 
p.R7W SNP has not decreased compared to WT as would be expected and is 
comparable to the cell lysate results. However, expression of ADAMTS13 in 
the conditioned media by this SNP shows an actual increase of 27% that of 
WT. Plaimauer et al. found that the p.R7W SNP ameliorated the effects of the 
detrimental SNPs p.P618A and p.A732V (Plaimauer et al. 2006). An increase 
in secretion by the p.R7W may explain this observation. Interestingly it 
appears that the secretion of ADAMTS13 from the p.A1033T variant is also 
enhanced. This has also been seen by other researchers (Edwards et al. 
2012). The decreased secretion of ADAMTS13 from the p.R1060W variant is 
as expected, particularly when taking into account the lower cell lysate values. 
However, the combination of the SNPs p.A1033T and p.R7W both singly and 
in combination with p.R1060W does appear to ameliorate against possible 
breakdown of ADAMTS13 in the cell and thus leads to an enhanced 
ADAMTS13 secretion. This could partly explain the late-onset phenotype seen 
in patients with the p.R1060W mutation and associated SNPs.  
The mean ELISA antigen results, expressed as average % WT, are 
summarised in Table 4.15. 
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Table 4.15 Summary of mean normalized ADAMTS13 antigen concentrations in conditioned 
media expressed as %WT; first transfection 





R7W + p.A1033T 
3.2 % 0.1 % 16 % 4 % 8 % 6% 
 
These results are unexpected and surprisingly low. The IMUBIND® ELISA 
antigen assay is a commercial assay used in patient diagnostic laboratories 
and details of the ADAMTS13 epitope targeted by the capture antibody are not 
available. It could be assumed that this epitope(s) may be altered by the 
introduction of the mutation or SNP. The quantity of ADAMTS13 secreted from 
HEK293T cells in a 100mm dish is not comparable to that produced in the 
body thus the lower limit of detection of the assay may to too great a 
concentration for this purpose and may give aberrant results. In order to rectify 
this, the conditioned media could be concentrated further and the assay 
repeated. As the IMUBIND assay has been developed and validated for 
diagnostic purposes with plasma or serum used as the matrix, the presence 
of an unknown inhibitor within the in vitro expression experiment cannot be 
discounted. 
These values found on ELISA are below the detection limits for the activity 
assays (FRETS-VWF) and these were not performed as a result. 
The results of the repeat transfections are summarised in Table 4.16: 
Table 4.16 Summary of mean normalized ADAMTS13 in cell lysates expressed as %WT; 
second transfection 





p.R7W + p.A1033T 
35 % 45 % 51 % 41 % 55 % 70 % 
 
The transfection efficiencies were comparable for the repeat transfections at 
approximately 25%. However, the p.R1060W + p.R7W + p.A1033T clone was 
higher at 30%. The quantity of ADAMTS13 secreted in the conditioned media 
for the repeat transfections are summarised in Table 4.17. 
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Table 4.17 Summary of mean ADAMTS13 expression in conditioned media %WT; repeat 
transfection. 





p.R7W + p.A1033T 
48 % 130 % 19 % 0 % 0 % 13 % 
 
Statistical analysis using one way ANOVA found that there was no statistical 
significance in the expression of ADAMTS13 in cell lysates or conditioned 
media between p.R1060W and p.R1060W + SNPs. 
 
There was some variability in the quality of the western blots. In consideration 
of this, there were some changes with respect to the experimental procedure 
for the repeat transfections. The imaging system used in the second series of 
transfections was updated and changed, with a more sensitive camera. This 
greatly enhanced the background noise on the blots which may have skewed 
the ImageJ values. All experimental protocols were followed and controls put 
in place where possible. There was observed variability in the density of signal 
of the positive control and in the housekeeping protein. Both the antibody to 
β-actin antibody and the target anti-myc were reused due to lack of resources. 
However, the secondary antibody was not reused and diluted from frozen 
stock. There was also no protease inhibitor used which could have caused 
breakdown of the target ADAMTS13. This could have explained the variability 
in results. 
 
4.9 Concluding remarks 
These results indicate that the SNPs p.R7W and p.A1003T may have a 
positive modifying effect on the p.R1060W mutation and may, in some part, 
explain the phenotype of late-onset TTP. However, on statistical analysis, no 
significant results have been found on the modifying influence of SNPs. The 
p.R1060W mutation has been shown to decrease ADAMTS13 secretion. 
However, patients may also have a residual level of activity of ADAMTS13 
from the p.R1060W mutation near the endothelial surface where cleavage of 
the newly synthesized ULVWF occurs. Vascular endothelial cells have been 
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found to synthesise and secrete ADAMTS13 in small quantities (Turner et al., 
2006). A sufficient amount of ADAMTS13 could therefore be produced until a 
physiologically demanding event such as pregnancy or infection dramatically 
increases the level of ULVWF produced by activated endothelial cells. 
ADAMTS13 also has no known natural inhibitor therefore plasma levels 
remain fairly constant, with a long half- life. The effect of SNPs on RNA 
processing and stability may also contribute to altered ADAMTS13 expression 
and is discussed in Chapter 6. 
 
Pregnancy is a hypercoagulable state which may be a physiological 
adaptation in order to protect against haemorrhage during parturition and the 
post-partum stage (peri-partum haemorrhage is the leading cause of maternal 
mortality in the developing world; Drury-Stewart et al., 2014; Khan et al., 2008). 
Hypercoagulability can be explained by an increase in VWF synthesis with a 
decrease in the activity of ADAMTS13. The VWF propeptide and activity levels 
in pregnancy have been measured and have been found to increase by 
approximately 500% (Kentouche et al., 2013). During the course of pregnancy, 
VWF levels progressively increase to reach 2.5 - 3 times higher at term 
(however, peak values follow delivery). ADAMTS13 levels decrease by 
approximately 30% at term when compared to baseline levels before 
pregnancy, possibly due to the concomitant increase in VWF levels and 
consumption of VWF substrate (Kentouche et al., 2013). Elevations in pro-
coagulant proteins have also been observed (Brenner, 2004). However, in 
normal, healthy women, ADAMTS13 levels will stay above 10%. The 
physiological significance of an increase in VWF during the second trimester 
may be the trigger for the TTP boot seen in pregnancy-associated TTP as TTP 
occurring in the first trimester is not seen (Veyradier et al., 2012) 
There may also be an effect of pregnancy hormones on ADAMTS13 
metabolism. Powazniak et al. performed a series of studies evaluating the 
effect of 17β-estradiol (E2) on human umbilical vein endothelial cells (HUVEC) 
on the synthesis and secretion of VWF and ADAMTS13 (Powazniak et al., 
2011). Although HUVEC incubated with E2 showed no significant differences 
in secreted ADAMTS13 levels, intracellular levels increased eight-fold and 
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ADAMTS13 mRNA increased nine-fold. There was no increase in VWF 
secretion or intracellular levels. However, VWF mRNA levels increased. 
ADAMTS13 gene inactivation also upregulated the release and intracellular 
VWF levels in HUVEC, indicating that E2 may play a role in the regulation of 
VWF and ADAMTS13 gene expression (Powazniak et al. 2011). 
Another TTP trigger during pregnancy may be complement activation. Atypical 
HUS presents with TTP-like symptoms and results in partial inactivation of 
ADAMTS13. A mutation in factor H has been associated with thrombotic 
microangiopathy associated with ADAMTS13 deficiency (Chapin et al., 2016). 
The use of the anti-complement therapy Eculuzimab has also been reported 
to ameliorate refractory TTP in a patient (Tsai et al., 2013). This indicates that 
complement may have an effect on the VWF-ADAMTS13 axis. 
In summary, the SNPs p.R7W and p.A1033T may positively modify the effect 
of the p.R1060W mutation to explain the late-onset TTP phenotype although 
no statistically significant results have been found. However, due to the 
changes in VWF-ADAMTS13 axis during pregnancy and possible complement 
activation the genotype is only one in a number of factors to consider. The 







The effect of SNPs and mutations on congenital TTP 
phenotype 
5.1 ADAMTS13 polymorphisms 
SNPs have been identified throughout the ADAMTS13 gene (see Table 5.1) 
and various studies have reviewed their contribution to disease phenotype 
(Edwards et al., 2012; Lotta et al., 2010; Plaimauer et al., 2006). Most case 
studies that report screening of the ADAMTS13 gene note that, in addition to 
mutations, patients also carry multiple SNPs. It has been observed that the 
SNPs p.R7W and p.Q448E exist in greater frequencies in TTP patients than 
in the general population (Donadelli et al., 2006). The occurrence of SNPs 
p.R7W and p.A1033T also occur in pregnancy-associated TTP, together with 
the p.R1060W mutation, at a greater frequency than is seen in the general 
population (Scully et al., 2014). This may just be an observation that the SNPs 
have co-evolved with the mutation and it is difficult to make more definitive 
conclusions without more comprehensive reporting of the full ADAMTS13 
genotype. Interestingly, the SNPs in humans p.R7W, p.Q448E and p.A900V 
are in the WT in murine species of the C57BL/6J strain, which could indicate 
these variants have a neutral effect  (Bruno et al., 2005). 
 
The effect of a combination of SNPs in vitro has been investigated by 
Plaimauer et al. The SNPs p.P618A and p.A732V individually led to a 
decrease in ADAMTS13 antigen levels. These SNPs were more detrimental 
in combination (p.P618A + p.A732V in combination showed 4% WT levels); 
this would be sufficient to cause TTP if present on both alleles in a cis-
configuration. The addition of p.R7W or p.Q448E singly increased the 
ADAMTS13 activity to 15% and the addition of all four SNPs increased the 
activity to 40% (Plaimauer et al., 2006). The amino acid substitutions may alter 
the short or long-range interactions of the protein at the active site, the exosites 










Domain dbSNP accession 
number 
Global minor allele 
frequency*(MAF) 
C19T p.R7W Signal peptide rs34024143 0.0527 
C1016G p.T339R Disintegrin - - 
C1342G p.Q448E Cysteine-rich rs2301612 0.2716 
G1368T p.Q456H Cysteine-rich rs36220239 0.0170 
C1370T p.P457L Cysteine-rich rs36220240 0.0063 
C1423T p.P475S Cysteine-rich rs11575933 0.0044 
G1451A p.R484K Cysteine-rich rs28375042 - 
G1810A p.V604I Spacer rs34256013 0.0004 
C1852G p.P618A Spacer rs28647808 0.0323 
G1874A p.R625H Spacer rs36090624 0.0244 
G1900A p.E634K Spacer rs34569244 - 
C2195T p.A732V TSP1-2 rs41314453 0.0056 
G2218A p.E740K TSP1-2 rs36221451 0.0120 
G2494A p.V832M TSP1-4 rs34104386 0.0040 
C2699T p.A900V TSP1-5 rs685523 0.0765 
C2708T p.S903L TSP1-5 - - 
G2944A p.G982R TSP1-6 rs36222275 0.0014 
G3097A p.A1033T TSP1-7 rs28503257 0.0156 
G3287G p.R1096H TSP1-8 rs61751476 0.0146 
C3677T p.T1226I CUB-1 rs36222894 0.0042 
The numbering of nucleotides is relative to the ADAMTS13 cDNA derived from reference 
sequence NM_139025.4, genome build 37.1.  
 
For a given SNP, the less conserved the area in which the variant occurs, the 
greater the variant allele frequency. Thus the rarer SNPs tend to encode more 
conserved residues as this variation may be unfavourable to the function of 
the encoded protein (Tseng & Kimchi-Safarty, 2011). This can be evidenced 
in Chapter 3. It should also be noted that the basal level of ADAMTS13 is 
highly variable, even among healthy controls and between patients of different 
ethnic backgrounds and this should be taken into account when interpreting 
the possible clinical effect of mutations and SNPs (Peyvandi et al., 2004). 
However, TTP diagnosis is made on ADAMTS13 activity levels at <5% normal 
(for a particular population) in the plasma. The normal range for ADAMTS13 
ranges widely from 740-1420ng/ml within normal, healthy individuals (Reiger 
et al., 2006) and this is also dependent on the assay method used. There is 





The aims of this study are to analyse the effect of single nucleotide 
polymorphisms and mutations, either singly or in combination, on congenital 
thrombotic thrombocytopenic purpura phenotype based on patient genotype. 
The mutations and polymorphisms investigated in this study were identified in 
a cohort of TTP patients referred to the TTP Registry at UCLH, London 
(Camilleri et al., 2012); see Tables 5.2-5.4 for genotype information. Those 
mutations for which expression vectors were constructed are marked with * 
The clinical details of these patients can be seen in Table 5.5. 


















Amino acid change Domain SNPs present 
1 C3178T* p.R1060W TSP-7 p.R7W + p.A1033T 














4 G305A* p.R102H MP p.Q448E + p.618A 
+ p.A900V 





MP p.R7W, p.Q448E, 
p.618A, p.A732V, 
p.A900V 











Amino acid change Domain SNPs present 





































Domain SNPs present 
11 C1787T* p.A596V Spacer - 
12 C587T* p.T196I MP p.Q448E 




















Table 5.5 Clinical details and genotype of TTP patients (from Camilleri et al., 2012) 






p.R102H1 18 years* 57ng/ml p.Q448E1, p.616A1, p.A900V1 
p.T196I1 3 years Undetectable p.Q448E1 
p.D217H + 
p.R1060W2 




Birth Undetectable p.Q448E3 




29 years* <10ng/ml p.Q448E3 
p.A596V1 18 months 11ng/ml - 
TSP1-2, 5 and 7 
p.A690T + 
719_724del2  
20 years* 35ng/ml p.R7W + p.Q448E+ p.418A, 
p.A732V, p.A900V 




18 months 17ng/ml p.A1033T3, p.R7W3, p.Q448E3 
*Pregnancy associated 1Homozygous; 2Compound heterozygous; 3Heterozygous, haplotype 
not specified. Minor allele frequency can be seen in Table 5.1. 
 
The positions of these mutations and polymorphisms as they affect the 
ADAMTS13 protein can be seen in Figures 5.1 and 5.2. Mutations near the N-
terminal would be assumed to be more detrimental as this is the functional part 
of the protease and more highly conserved. Hing et al. determined that a 
mutation located within this area was an indicator of the severity of clinical 
phenotype (Hing et al., 2013) although acknowledged that other factors could 




Figure 5.1 Position of mutations within the ADAMTS13 protein 
 
Figure 5.2 Position of SNPs within the ADAMTS13 protein 
Previous investigators have utilised in vitro expression systems to determine 
the effect of mutations and SNPs within the ADAMTS13 gene on ADAMTS 
secretion and activity. A summary can be seen Table 5.6. 
 
Table 5.6 Previous expression studies of the effect of mutations and SNPs on the secretion 
and activity of ADAMTS13 
Mutation Cell line Secretion Activity Reference 
p.R102H (G305A) HEK293T Reduced (28-51%) 12% Camilleri et al., 2012 
p.T196I*(C587T) HEK293T 4% Reduced Camilleri et al., 2012   
p.D217H (G649C) HEK293T 29-112% 24% Camilleri et al., 2012 
p.G241_C242del 
719_724del 
HEK293T Abolished (<3%)  Camilleri et al., 2012 
p.C265S+S266C 
(G794C+A796T) 
HEK293T Reduced (7%)  Camilleri et al., 2012 












Kokame et al., 2002 
Hommais et al., 2007 
Hommais et al., 2007 
Camilleri et al., 2012 
p.R409W (C1125T) HEK293T Abolished (<5%)  Camilleri et al., 2012 
p.R398C (C1192T) HEK293T Abolished (<5%)  Camilleri et al., 2012 
p.Q436H (G1308C) HEK293T Reduced (64-18%)  Camilleri et al., 2012 
p.Q456H (G1368T) HEK293T Increased  
(117-261%) 
Normal* Camilleri et al., 2012 
p.A596V  HeLa 17% No activity Hommais et al., 2007 
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25% Hommais et al., 2007 
Camilleri et al., 2012 
p.A690T (G2068A) HEK293T 7-38%  Camilleri et al., 2012 
p.C754R (T2260C) HEK293T 15-4%  Camilleri et al., 2012 
p.R910X*(C2728T) HEK293T 7%  Camilleri et al., 2012 









Tao et al., 2006 
Camilleri et al.,2008 
SNPs     
p.R7W HEK293 99% 86% Plaimauer et al., 
2006 






Kokame et al., 2002 
Plaimauer et al., 
2006 
p.P475S HeLa Conserved 70% Kokame et al., 2002 
p.P618A HEK293 27% 14% Plaimauer et al., 
2006 
p.A732V HEK293 60% 71% Plaimauer et al., 
2006 
p.A1033T HeLa Conserved 80% Tao et al., 2006 
 
Other researchers have also used in vitro studies using transient expression 
systems to evaluate ADAMTS13 expression both intracellularly (in cell lysates) 
and extracellularly (secreted levels in conditioned media). The results of 
studies with several SNP variants can be seen in Table 5.7 (Edwards et al., 
2012). 
 
Table 5.7 Results of the effect of SNPs within the ADAMTS13 gene on extracellular and 
intracellular expression of ADAMTS13 (Edwards et al., 2012). 
SNP Domain Extracellular expression as % 
of WT ADAMTS13 
Intracellular 
expression as % of WT 
ADAMTS13 
p.Q448E Cysteine rich 100 140 
p.P475S Cysteine rich 105 130 
p.P618A Spacer 31 90 
p.A732V Tsp1-2 80 30 
p.A1033T Tsp1 -7 179 90 
 
Camilleri et al. has also investigated the expected effect of ADAMTS13 





Table 5.8 Expected effect of mutations on secretion of ADAMTS13 
Mutation Effect on ADAMTS13 secretion level 
Q456H (C1368T) Increased 117-261% 
D217H (G649C) 29-112%WT (also reduced activity) 
R102H (G305A) 28-51%WT 
C265C+S266C Reduced 
Q436H (G1308C) Reduced 
A690T (G2068A) Reduced 
C754R (T2260C) Reduced 
C977F (G2930T) Reduced 
R109X Markedly reduced 
T196I (C587T) Markedly reduced 
R268P (G803C) Markedly reduced 
R1060W Severely reduced 
G241_C242del Abolished 
R398C (C1192T) Abolished 
R409W (C1225T) Abolished 
A596V (C1787T) Abolished 
 
5.2 Methods  
5.2.1 In silico analysis 
The following computational tools were used to analyse the putative effects of 
mutations and SNPs found in cTTP patients on the function of ADAMTS13: 
SNPEffect4.0, IMutant, SIFT, PolyPhen2.0 and SNP Effect. Full details of 
methods and results can be seen in Chapter 3. 
 
5.2.2 In vitro expression studies 
Site directed mutagenesis (SDM) was used to create a series of expression 
vectors, as seen in Table 5.9. Each vector contained a mutation, an SNP or 
mutation and/or SNP in various combinations. The multi-SNP vectors p. 
R102H + p.Q448E + p.P618A + p.A900V and p. D217H + p.R7W + p.Q448E 
+ p.A1033T were constructed by multi-site-directed mutagenesis, as 
described in Chapter 2. All other vectors were constructed by single-site-SDM. 
Constructs were validated by Sanger sequencing to ensure that no unwanted 





Table 5.9 Expression vectors constructed by site directed mutagenesis 
Expression vector Mutation and/or SNP 
p. R102H (G305A) Mutation 
p. R102H + p.Q448E Mutation + SNP 
p. R102H + p.P618A Mutation + SNP 
p. R102H + p.A900V Mutation + SNP 
p. R102H + p.Q448E + p.P618A + p.A900V‡ Mutation + 3 SNPs 
p. T196I (C587T) Mutation 
p. T196I + p.Q448E Mutation + SNP 
p.D217H (G649C) Mutation 
p. D217H + p.R7W Mutation + SNP 
p. D217H + p.Q448E Mutation + SNP 
p. D217H + p.A1033T Mutation + SNP 
p. D217H + p.R7W + p.Q448E + p.A1033T‡ Mutation + 3 SNPs 
p. R398C (C1192T) Mutation 
p.R409W (C1225T) Mutation 
p. Q436H (G1308C) Mutation 
p. A596V (C1787T) Mutation 
p. A596V + P475A Mutation + SNP 
p. A690T (G2068A) Mutation 
p. C977F (G2930T) Mutation 
SNPs  
p. R7W (C19T) SNP 
p Q448E (C1342G) SNP 
p. P475S (C1423T) SNP 
p. P618A (C1852G) SNP 
p. A732V (C2195G) SNP 
p. A900V (C2699T) SNP 
p. A1033T (C3097A) SNP 
‡ denotes vectors constructed by multi- site-directed mutagenesis 
The construction of expression vectors in Table 5.10 were attempted but were 
abandoned due to continual corruption of the nucleotide sequencing around 
the nucleotide substitution, as confirmed on Sanger sequencing. 
 










Mutant plasmids were amplified and purified prior to transfection into human 
embryonic kidney cells (HEK293T). Transfection efficiency was measured by 
the co-transfection of the reporter vector carrying the LacZ gene, as described 
previously in Chapter 2. Transfection of WT and mutant vectors were 
performed in 6-well plates as described. After incubation for 72 hours cell 
lysates were collected, the cells lysed in 20mM Triton X and sonicated prior to 
protein quantitation by BCA assay. Conditioned media was harvested and 
concentrated prior to protein quantitation by BCA assay. Western blot analysis 
was performed on cell lysates and conditioned media. An equal quantity of 
protein was loaded per well for SDS-PAGE and during blotting the 
housekeeping antibody anti- β-actin (Abcam, clone 8226) was used as a 
loading control (cell lysates only). Recombinant ADAMTS13 was visualized by 
western blotting using an antibody directed towards the anti-myc tag (Merck-
Millipore, clone A46). HRP-conjugated goat anti-mouse IgG was used as a 
secondary antibody (Sigma-Aldrich, A4416). The western blots were band 
intensities were analysed by densitometry using ImageJ. ADAMTS13 antigen 
quantitation was performed on the concentrated conditioned media using the 
commercially available IMUBIND® ADAMTS13 ELISA. Values (mean of 
replicate transfections) are presented as % of 3 replicate WT values ± SEM 
(WT = 100%). 
5.3 Results 
5.3.1 Sequencing data of expression vectors 
The sequencing data for each expression vector with mutation ± SNP inserted 






ADAMTS13         GGAGGACACAGAGCGCTATGTGCTCACCAACCTCAACATCGGGGCAGAACTGCTTCGGGA 350 
30FD49           GGAGGACACAGAGCACTATGTGCTCACCAACCTCAACATCGGGGCAGAACTGCTTCGGGA 420 
                 **************.********************************************* 
C1342G 
 
ADAMTS13         ACCCAGCTGGAGTTCATGTCGCAACAGTGCGCCAGGACCGACGGCCAGCCGCTGCGCTCC 1380 
30FD43           ACCCAGCTGGAGTTCATGTCGGAACAGTGCGCCAGGACCGACGGCCAGCCGCTGCGCTCC 456 
                 ********************* ************************************** 
C1852G 
 
ADAMTS13         AGGGCGCTATGTCGTGGCTGGGAAGATGAGCATCTCCCCTAACACCACCTACCCCTCCCT 1859 
07AF24           AGGGCGCTATGTCGTGGCTGGGAAGATGAGCATCTCCCCTAACACCACCTACGCCTCCCT 411 
                 **************************************************** ******* 
C2699T 
 
ADAMTS13         CCCTCCCCATGGGGCAGCATCAGGACGGGGGCTCAAGCTGCACACGTGTGGACCCCTGCG 2700 
30FD44           CCCTCCCCATGGGGCAGCATCAGGACGGGGGCTCAAGCTGCACACGTGTGGACCCCTGTG 656 
                 ********************************************************** * 
 
Figure 5.3 Sequencing results of expression vector G305A + C1342G + C1852G + C2699T 





ADAMTS13          ACTAGGTTTGACCTGGAGTTGCCTGATGGTAACCGGCAGGTGCGGGGCGTCACCCAGCTG 594 
07AE85            ACTAGGTTTGACCTGGAGTTGCCTGATGGTAACCGGCAGGTGCGGGGCGTCATCCAGCTG 660 
                  **************************************************** ******* 
C1342G 
 
ADAMTS13           ACCCAGCTGGAGTTCATGTCGCAACAGTGCGCCAGGACCGACGGCCAGCCGCTGCGCTCC 1380 
84CI13            ACCCAGCTGGAGTTCATGTCGGAACAGTGCGCCAGGACCGACGGCCAGCCGCTGCGCTCC 453 
                  ********************* ************************************** 
 
 





ADAMTS13           AGCTGGGCGGTGCCTGCTCCCCAACCTGGAGCTGCCTCATTACCGAGGACACTGGCTTCG 649 
07AF35             AGCTGGGCGGTGCCTGCTCCCCAACCTGGAGCTGCCTCATTACCGAGGACACTGGCTTCC 720 
                   ***********************************************************  
C19T 
 
ADAMTS13           -----------ATGCACCAGCGTCACCCCCGGGCAAGATGCCCTCCCCTCTGTGTGGCCG 49 
07AF35             CGCCGGCCACCATGCACCAGCGTCACCCCTGGGCAAGATGCCCTCCCCTCTGTGTGGCCG 120 
                              ****************** ****************************** 
C1342G 
 
ADAMTS13           ACCCAGCTGGAGTTCATGTCGCAACAGTGCGCCAGGACCGACGGCCAGCCGCTGCGCTC 1379 
07AF48             GACCCAGCTGGAGTTCATGTCGGAACAGTGCGCCAGGACCGACGGCCAGCCGCTGCGCTC 454 
                   ********************** ************************************* 
G3097A 
 
ADAMTS13           CTTGGCCCATGTTCGGCCAGCTGTGGCCTTGGCACTGCTAGACGCTCGGTGGCCTGTGTG 3120 
30FD69            CTTGGCCCATGTTCGGCCAGCTGTGGCCTTGGCACTACTAGACGCTCGGTGGCCTGTGTG 651 
                  ************************************ *********************** 
 
Figure 5.5 Sequencing results of expression vector G649C + C19T + C1342G + G3097A 






ADAMTS13        GCAGCAGTGCATGGGCGCTGGTCTAGCTGGGGTCCCCGAAGTCCTTGCTCCCGCTCCTGC 1200 
45HI66          GCAGCAGTGCATGGGCGCTGGTCTAGCTGGGGTCCCCGAAGTCCTTGCTCCTGCTCCTGC 270 
                *************************************************** ******** 
C1342G 
 
ADAMTS13        ACCCAGCTGGAGTTCATGTCGCAACAGTGCGCCAGGACCGACGGCCAGCCGCTGCGCTCC 1380 
32EG87          ACCCAGCTGGAGTTCATGTCGGAACAGTGCGCCAGGACCGACGGCCAGCCGCTGCGCTCC 452 
                ********************* ************************************** 
 





ADAMTS13        GGAGGAGGTGTGGTCACCAGGAGGCGGCAGTGCAACAACCCCAGACCTGCCTTTGGGGGG 1260 
36AG24          GGAGGAGGTGTGGTCACCAGGAGGTGGCAGTGCAACAACCCCAGACCTGCCTTTGGGGGG 338 
                ************************ *********************************** 
 





ADAMTS13        CGTGCATGTGTTGGTGCTGACCTCCAGGCCGAGATGTGCAACACTCAGGCCTGCGAGAAG 1320 
36AG28          CGTGCATGTGTTGGTGCTGACCTCCAGGCCGAGATGTGCAACACTCACGCCTGCGAGAAG  395 
                *********************************************** ************ 
 





ADAMTS13      ACCAGTGTCTACATTGCCAACCACAGGCCTCTCTTCACACACTTGGCGGTGAGGATCGGA 1800 
30FE18        ACCAGTGTCTACATTGCCAACCACAGGCCTCTCTTCACACACTTGGTGGTGAGGATCGGA 357 




WTADAMTS13              CTACCACTGGGGTGCTGCTGTACCACACAGCCAAGGGGATGCTCTGTGCA  1450 
C1423T6                 CTACCACTGGGGTGCTGCTGTATCACACAGCCAAGGGGATGCTCTGTGCA  521 
                        ********************** *************************** 
 




ADAMTS13                    AGGCCTGGGTGTGGGCCGCTGTGCGTGGGCCCTGCTCGGTGAGCTGTGGG 2100 
G2068A17-Seq03              AGGCCTGGGTGTGGGCCACTGTGCGTGGGCCCTGCTCGGTGAGCTGTGGG 655 
                            *****************.******************************** 
 









ADAMTS13                   GGAGAGGGGTCGTGCGGAGGATCCTGTATTGTGCCCGGGCCCATGGGGAG 2949 
87G2930T_3_+C3484T_2_      GGAGAGGGGTCGTGCGGAGGATCCTGTATTTTGCCCGGGCCCATGGGGAG 901 







ADAMTS13         TCCCCTGGCGGCGCCTCCTTCTACCACTGGGGTGCTGCTGTACCACACAGCCAAGGGGAT 1440 
30FD90           TCCCCTGGCGGCGCCTCCTTCTACCACTGGGGTGCTGCTGTATCACACAGCCAAGGGGAT 516 
                 ****************************************** ***************** 
 





ADAMTS13          GGGCGCTATGTCGTGGCTGGGAAGATGAGCATCTCCCCTAACACCACCTACCCCTCCCTC 1860 
45HI82            GGGCGCTATGTCGTGGCTGGGAAGATGAGCATCTCCCCTAACACCACCTACGCCTCCCTC 936 
                  *************************************************** ******** 
 





WTADAMTS13        ACTGTCCAGTGCCAAGGGAGCCAGCAGCCACCAGCGTGGCCAGAGGCCTGCGTGCTCGAA 2220 
VN004             ACTGTCCAGTGCCAAGGGAGCCAGCAGCCACCAGTGTGGCCAGAGGCCTGCGTGCTCGAA 168 
                  ********************************** ************************* 
 





WTADAMTS13         GCAGGGTCGTGCTCCGTCTCCTGCGGGCGAGGTCTGATGGAGCTGCGTTTCCTGTGCATG 2760 
BS03-05           GCAGGGTCGTGCTCCGTCTCCTGCGGGCGAGGTCTGATGGAGCTCCGTTTCCTGTGCATG 351 
                  ******************************************** *************** 
 
Figure 5.15 Sequencing results of expression vector C2699T SNP 
 
5.3.1.1 Non synonymous mutation introduced by SDM 
It was found that in several vectors, SDM lead to an unwanted amino acid 
change involving the same nucleotide substitution (resulting in a non-
synonymous mutation) at C3484T. 
 
Figure 5.11 Sequencing results of expression vector G2930T mutation 
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The nucleotide change was reverted back to the WT sequence by with a 
further SDM experiment, as described in section 4.7.1.1. Interestingly, the 
unwanted nucleotide change was inserted when the original nucleotide 
change was implemented in the more distal end of the cDNA insert. Those 
nucleotide changes implemented at the more proximal end of the insert did not 
induce this C3484T substitution. 
 
A summary of the vectors which contained the same non synonymous 
mutation as a result of SDM are summarised in Table 5.11. 
 
Table 5.11 Expression vectors carrying C3484T non-synonymous mutation 
C1787T (p.596V) 








The nucleotide change was reverted back to the WT sequence by with a 
further SDM experiment, as described in section 4.7.1.1. Interestingly, the 
unwanted nucleotide change was inserted when the original nucleotide 
change was implemented in the more distal end of the cDNA insert. Those 
nucleotide changes implemented at the more proximal end of the insert did not 
induce this C3484T substitution. 
 
After sequencing and validation as described previously, the expression 
vectors were cleaned and amplified, yielding the DNA concentrations seen in 
Table 5.12. In consideration of the poor DNA yield with QIAGEN Maxiprep, the 






Table 5.12 DNA concentrations of expression vectors following 
Maxiprep/Midiprep*preparation 
Expression vector  Protein concentration (μg/μl) 
G305A * 180 
G305A + C1342G  84 
G305A + C1342G * repeat 1631 
G305A + C2699T  90 
G305A + C1342G + C1852G + C2699T  212 
C587T  148 
C587T+ C1342G  116 
G649C  113 
G649C repeat 130 
G649C + C19T  54 
G649C + C19T repeat 291 
G649C + C19T repeat* 1164 
G649C + C1342G  113 
G649C + C1342G * 1057 
G649C + G3097A 76 
G649C + C19T + C1342G + G3097A 1 66 
C1192T  662 
C1192T + C1342G * 469 
C1225T  503 
C1308C  1212 
C1787T  299 
C1787T + C1423T  441 
G2068A  1435 
G2930T  1380 
C1342G  87 
C1852G  33 
C1852G  180 
C2195T  677 
C2699T  115 
 
As can be seen, DNA yield differs very greatly between expression vectors. It 
can also be noted that the growth rate and colonial morphology also differed 
greatly on the LB-Agar plates. This may possibly reflect the differences at the 
DNA level (possibly reflecting a change in the coiling of the vector) as a result 






5.3.2 Transfection efficiencies of expression vectors 
The transfection efficiency was measured as previously described in section 
2.8; see Table 5.13. 
Table 5.13 Transfection efficiencies of expression vectors 
Expression vector Transfection efficiency (%) 
p.R102H (G305A) 21 
p.R102H + p.A900V( G305A + C2699T) 18 
p.R102H + p.Q448E (G305A + C1342G) 20 
p.R102H + p.R7W + p. Q448E + p.P618A + p.A1033T 
(G305A + C19T + C1342G + C1842G + G3097A) multi 
15 
p.T196I (C587T) 22 
p.T196I + p.Q448E (C587T + C1342G) 21 
p.D217H (G649C) 20 
p.D217H + p.R7W (G649C + R7W) 18 
p.D217H + p.A1033T (G649C + G3097A) 18 
p. D217H + p.Q448E (G649C + C1342G) 21 
p. D217H + p.R7W + p.Q448E + p.A1033T (G649C + 
C19T + C1342G + D3097A) (multi) 
18 
p.R398C (C1192T) 18 
p.R398C + p.Q448E (C1192T + C1342G) 20 
p.R409W (C1225T) 14 
p. Q436H (G1308C) 19 
p.A596V (C1787T) 22 
p.A596V + p.Q448E (C1787T + C1342G) 20 
p.A690T (G2068A) 19 
p.C977F (G2930T) 19 
p.P475S (C1423T) 15 
p.Q448E (C1342G) 13 
p.P618A (C1852G) 12 
p.A732V (C2195T) 16 
p.A900V (C2699T) 14 
 
Following harvesting, lysing (cell lysates) and concentrating (conditioned 
media) the samples were assayed for total protein concentration by BCA 
assay; for results see Appendix 1. 
 
5.3.3 Western blot analyses 
5.3.3.1 Western blots p.R102H series  
The cells were harvested, lysed and sonicated as previously described before 
analysing by western blot (see Figures 5.16 –5.17.).The expected size of 
ADAMTS13 protein (approx. 180kDa) was seen. The housekeeping protein β-
actin of molecular weight 45kDa was used as a loading control. An equal 
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amount of total protein was loaded into each well of the SDS-PAGE gel, as 
determined by BCA assay. 
 
  
Figure 5.16 Western blot analysis cell lysate p.A900V and p.R102H 
 
 





The conditioned media of the expression vectors analysed in Figures 5.16 - 







Figure 5.17 Western blot analysis cell lysates p.R102H + p. A900V; p.R102H + p.Q448E 









The band intensities on western blots were scanned using ImageJ software 
and the cell lysate values normalized to the β-actin housekeeping protein and 
compared with positive control (WT) values % WT ± SEM (see Table 5.14 and 
Figure 5.19). 
Table 5.14 ImageJ analysis of p.R102H series, cell lysates 
Expression vector Normalized protein 
ratio (sample/actin)  
% normalised 
WT ± SEM 
WT 1.0 100 
p.R102H 1 0.64 64 ± 5 
p.R102H 2 0.58 58 ±  5 
p.R102H 3 0.49 49 ±  5 
p.R102H + A900V 1 n/a 45 ± 12  
p.R102H + A900V 2 n/a 68 ± 12 
p.R102H + A900V 3 n/a 63 ± 12  
p. R102H + p.Q448E 1 Rpt 0.19 19 ±  5 
p.R102H + p.Q448E 2 Rpt 0.10 9 ±  5 
p.R102H + p.Q448E 3 Rpt 0.29 15 ±  5 
p.R102H + p.Q448E + p.P618A + A900V (multi) 
1 
1.5 145 ±  33 
p.R102H + p.Q448E + p.P618A + A900V multi 2 1.0 97 ±  33 
*Repeat transfection. The expression vectors p.R102H + p.618A were not transfected.  
 
ADAMTS13 anti-myc 
Figure 5.18 Western blot conditioned media: WT, p.R102H + p.A900V, p.R102H + multi 











The band intensities on western blots were scanned using ImageJ software 
and the conditioned media samples normalized to the WT positive control on 
the same blot (values % WT ± SEM); (see Table 5.15 and Figure 5.20). 
 
Table 5.15 ImageJ analysis of p.R102H series, conditioned media 
Expression vector Normalized protein 
ratio 
% WT ± SEM 
WT 1.0 100 
p.R102H 1 1.07 107 ±  29 
p.R102H 2 1.5 149 ±  29 
p.R102H + p.A900V 1 0.22 22 ±  1.4 
p.R102H + p.A900V 2 0.24 24 ±  1.4 
p.R102H + p.Q448E 1  0.37 37 ± 1.4 
p.R102H + p.Q448 2 0.39 39 ± 1.4 
p.R102H + p.Q448E + p.P618A + A900V (multi) 1 0.67 67 ± 13 










































































































































Figure 5.19 Comparison of %WT ± SEM ADAMTS13 expression in cell lysates, 









Conditioned media samples were analysed for ADAMTS13 antigen with the 
commercially available IMUBIND® ADAMTS13 ELISA kit according to 
manufacturer’s instructions. Results can be seen in Table 5.16 and Figure 
5.21. 
 
Table 5.16 ELISA ADAMTS13 antigen concentration p.R102H series, expressed as %WT 
conditioned media 
Expression vector ADAMTS13  
concentration 
(ng/ml) 
% WT ± SEM 
p.R102H 1 218 90 ± 9.0  
p.R102H 2 174 72 ± 9.0  
p.R102H + A900 1 9 4 ± 1.6 
p.R102H + A900V2 1 1 ± 1.6  
p.R102H + p.Q448E + p.P618A + A900V (multi) 1 73 30 ± 1.0  
p.R102H + p.Q448E + p.P618A + A900V (multi) 2 78 32 ± 1.0  
p.D102H + p.Q448E 1 15 7 ± 1.3  












































































































Figure 5.20 Comparison of %WT ± SEM ADAMTS13 expression in conditioned 











In order to assess the statistical significance of the variation in ADAMTS13 
expression between the mutation p.R102H in combination with SNPs p.Q448E 
and A900V singly and in combination with, a one way analysis of variance 
(ANOVA) statistical test was performed. The values for %WT were utilised for 
each western blot (not all shown) with outlying % WT values excluded. Results 
can be seen in Table 5.17. In the analysis of cell lysates and conditioned media 
by western blot, there was no statistical significance found in ADAMTS13 
expression between the mutation and mutation + SNPs. However, a statistical 
significant difference was found on analysis of ADAMTS13 expression in 
conditioned media as analysed by ELISA. 











Cell lysate  Western blot 0.01 4.35 Accept 
CM  Western blot 0.98 4.35 Accept 













Figure 5.21 ELISA analysis of ADAMTS antigen concentration, %WT ± SEM of 

























































































5.3.3.2 Western blot analyses p.D217H series  
The cells were harvested, lysed and sonicated as previously described before 
analysing by western blot (see Figure 5.21- 5.23). The expected size of 
ADAMTS13 protein (approx. 180kDa) was seen. An antibody directed against 
the housekeeping protein β-actin of molecular weight 45kDa was used as a 
loading control. An equal amount of total protein was loaded into each well of 












The conditioned media of the expression vectors analysed in Figure 5.22-5.23 






Figure 5.22 Western blot analyses of cell lysate: WT, p.D217H + p.Q448E p.D217H 
+ p.R7W; p.D217H. 
Figure 5.23 Western blot analyses of cell lysate: p.D217H + p.A1033T; E: p.D217H + 







The band intensities on western blots were scanned using ImageJ software 
and the cell lysates normalized to the β-actin housekeeping protein and 
compared with positive control (WT) values % WT ± SEM (see Table 5.18 and 
Figure 5.25). 
 
Table 5.18 ImageJ analysis of p.D217H series, cell lysates 
Expression vector Normalized protein ratio % WT ± SEM 
WT 1.0 100 
p. D217H 1 1.5 149 ± 24 
p. D217H 2 1.1 160 ±  24 
p. D217H 3 1.6 114 ±  24 
p. D217H + p.R7W 2 rpt  1.1 112 ±  34 
p. D217H + p.R7W 3 rpt  0.6 64 ±  34 
p. D217H + p.Q448E 1 rpt 0.7 65 ±  18 
p. D217H + p.Q448E 2 rpt 0.9 90 ±  18 
p. D217H + p.A1033T 1 1.1 110 ±  5 
p. D217H + p.A1033T 2 1.2 120 ±  5 
p. D217H + p.A1033T 3 2.6 111 ±  5 
p. D217H + p.R7W + Q448E + A1033T (multi) 1 2.59 40 ±  100 
p. D217H + p.R7W + Q448E + A1033T (multi) 2 0.9 0 ±  100 





Figure 5.24 Western blot analyses conditioned media: p.D217H, p.D217H + R7W, 
p.D217H + multi SNPs. (p.R7W + p.Q448E + p.A1033T), p.D217H + p.A1033T and 









The band intensities on western blots were scanned using ImageJ software 
and the conditioned media samples normalized to the WT positive control on 
the same blot (values % WT ± SEM); (see Table 5.19 and Figure 5.26). 
 
 














Expression vector Normalized protein 
ratio 
% WT ± SEM 
WT 1 100 
p. D217H 1 0.5 50 ±  41 
p. D217H 2 0.3 30 ±  41 
p. D217H 3 1.0 100 ±  41 
p. D217H + p.R7W 1 rpt  0.3 30 ±  28 
p. D217H + p.R7W 2 rpt   0.7 70 ± 28 
p. D217H + p.Q448E 1  0.7 70 ± 56 
p. D217H + p.Q448E 2  1.5 150 ±  56 
p. D217H + p.A1033T 1  0.2 23 ±  2 
p. D217H + p.A1033T 2  0.2 20 ±  2 
p. D217H + p.R7W + Q448E + A1033T 1 0.4 40 ± 14 
















































































































































Figure 5.25 Comparison of %WT ADAMTS13 expression in cell lysates ADAMTS13 












Conditioned media samples were analysed for ADAMTS13 antigen with the 
commercially available IMUBIND® ADAMTS13 ELISA kit according to 
manufacturer’s instructions. Results can be seen in Table 5.20 and Figure 
5.27.  
 
Table 5.20 ELISA ADAMTS13 antigen concentration p.D217H series, expressed as %WT 
conditioned media 




WT 273 100 
p. D217H 1 17.3 7.1 
p. D217H 2 108.0 44.4 
p. D217H + p.R7W Rpt 1 76.0 31.2 
p. D217H + p.R7W Rpt 2 40.0 17 
p. D217H + p.Q448E Rpt 1 0 0 
p. D217H + p.Q448E Rpt 2 0 0 
p. D217H + p.A1033T 1 56.0 23 
p. D217H + p.A1033T 2 55.0 23 
p.D217H + p.R7W + p.Q448E + p.A1033T (multi) 1 161.0 66.4 


















































































































































In order to assess the statistical significance of the variation in ADAMTS13 
expression between the mutation p.D217H in combination with SNPs p.R7W, 
p.Q448E and A1033T singly and in combination, a one way analysis of 
variance (ANOVA) statistical test was performed. The values for %WT were 
utilised for each western blot (not all are shown) Results can be seen in Table 
5.21. 











Cell lysate  Western blot 1.169 3.84 Accept 
Conditioned 
media  
Western blot 2.04 3.84 Accept 
Conditioned 
media  
ELISA 67.2 4.12 Reject 
 
In the analysis of cell lysates and conditioned media by western blot, there 
was no statistical significance found in ADAMTS13 expression between the 
mutation and mutation + SNPs. However, a statistical significant difference 
was found on analysis of ADAMTS13 expression in conditioned media as 


























































































































Figure 5.27 ELISA analysis of ADAMTS antigen concentration, %WT ± SEM of 
conditioned media, p.D217H series. 
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5.3.3.3 Western blots analyses SNP series 
The cells were harvested, lysed and sonicated as previously described before 
analysing by western blot (see Figures 5.28 – 5.29). The expected size of 
ADAMTS13 protein (approx. 180kDa) was seen. An antibody directed against 
the housekeeping protein β-actin of molecular weight 45kDa was used as a 
loading control. An equal amount of total protein was loaded into each well of 
SDS-PAGE, as determined by BCA assay. 
 








The conditioned media of the expression vectors analysed in Figure 5.29 -5.29 
were harvested, concentrated and analysed on western blot (see Figure 5.30). 
The SNP p.A1033T has previously been analysed in sections 4.6.7 and 4.6.8 






Figure 5.28 Western blot analyses SNPs, cell lysates p. R7W, p.A1033T, p.Q448E, 
p.A900V and p.P475S 







No bands were visualised for p.457S, p. A732V and p.P618A after repeat 
transfections.  
 
The band intensities on western blots were scanned using ImageJ software 
and the cell lysates normalized to the β-actin housekeeping protein and 
compared with positive control (WT) values % WT ± SEM (see Table 5.22 and 
Figure 5.31). 
 
Table 5.22 ImageJ analysis of SNP series, cell lysates 
Expression vector Normalized protein ratio % WT 
WT 1.0 100 
p.R9W 1 0.75 75 
p.R7W 2 0.80 80 
p.Q448E 1 0.9053 90 ±  6.5 
p.Q448E 2  0.7769 77 ±   6.5 
p.P475S 1 0.6 60 ±  20.4 
p.P475S 3 0.55 55 ±  20.4 
p.P618A 1  0 0 
p.P618A 2  0 0 
p.A732V 1 0.5774 57 ±  6.0 
p.A732V 3 0.6972 69 ±  6.0 
p.A900V 1 blot 1 0.9396 93 ±  142 
p.A900V 2 blot 1 1.6 166 ±  142 
p.1033T 1 0.73 73 
p.1033T 2 0.75 75 
 
ADAMTS13 anti-myc 









The band intensities on western blots were scanned using ImageJ software 
and the conditioned media samples normalized to the WT positive control on 
the same blot (values % WT ± SEM); (see Table 5.23 and Figure 5.32). 
 
Table 5.23 ImageJ analysis of SNP series, conditioned media 
Expression vector Normalized protein ratio % WT ± SEM 
WT   
p.Q448E 1 blot 1 1.0 103 ±  4.24 
p.Q448E 2 blot 1 1.1 109 ±  4.24 
p.P475S 1 0 0 
p.P475S 3 0 0 
p.P618A 1 blot 2 0 0 
p.P618A 2 blot 2 0 0 
p.A732V 1 0 0 
p.A732V 3 0 0 
p.A900V 1  2.3 233 ±  65 
























































































































Conditioned media samples were analysed for ADAMTS13 antigen with the 
commercially available IMUBIND® ADAMTS13 ELISA kit according to 
manufacturer’s instructions. Results can be seen in Table 5.24 and Figure 
5.33. 
Table 5.24 ELISA ADAMTS13 antigen concentration SNP series, expressed as %WT 
conditioned media 
Expression vector ADAMTS13 concentration 
(ng/ml) 
% WT 
WT 242 100 
p.Q448E 1 100 41 ± 21 
p.Q448E 2 202 83 ± 21 
p.P475S 1 0 0 
p.P475S 2 0 0  
p.P618A 1 137 56.4 ± 28 
p.P618A 2 0 0 ± 28 
p.A732V 1 70 29 ± 3.5 
p.A732V 3 89 36 ± 3.5 
p.A900V 1 10 4.1 ± 6.4 



























































































In order to assess the statistical significance of the variation in ADAMTS13 
expression between the SNPs p.R7W, p.Q448E, p.P475S, p.A732V, p.A900V 
and p.A1033T, a one way analysis of variance (ANOVA) statistical test was 
performed. The values for %WT were utilised for each western blot (not all are 
shown). Results can be seen in Table 5.25. 
 











Cell lysate  Western blot 0.55 4.39 Accept 
CM  Western blot 0.58 6.59 Accept 
CM  ELISA 0.87 3.84 Accept 
 
In the analysis of cell lysates and conditioned media by western blot, there 
was no statistical significance found in ADAMTS13 expression between the 
SNPs on western blot or ELISA. 
 
5.3.3.4 Western blot analysis p.R409W and p.R398C series 
The cells were harvested, lysed and sonicated as previously described before 
analysing by western blot (see Figure 5.34). The expected size of ADAMTS13 
protein (approx. 180kDa) was seen. An antibody directed against the 



















































































Figure 5.33 ELISA analysis of ADAMTS antigen concentration, %WT ± SEM of conditioned 
media, SNP series 
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loading control. An equal amount of total protein was loaded into each well of 
SDS-PAGE, as determined by BCA assay. 
 




The conditioned media of the expression vectors analysed in Figures 5.34 was 






The band intensities on western blots were scanned using ImageJ software 
and the cell lysates normalized to the β-actin housekeeping protein and 










Figure 5.34 Western blot analysis of cell lysate: p.R398C, p.R409W, and p.R398C + 
p.Q448E. 





Table 5.26 ImageJ analysis of p.R409W and p.R398C series, cell lysates 
Clone  Normalized protein ratio % WT ± SEM 
p.R409W 1  0.5 57 ± 2.5 
p.R409W 2  0.5 52 ± 2.5 
p.R398C 1 0.2 24 ± 38.7 
p.R398C 2 1.0 101 ± 38.7 
p.R398C + p.Q448E 1 0.85 85 ± 14.5 









The band intensities on western blots were scanned using ImageJ software 
and the conditioned media samples normalized to the WT positive control on 
the same blot (values % WT ± SEM); (see Table 5.27 and Figure 5.37). 
 
Table 5.27 ImageJ analysis p.R409W and p.R398C series, conditioned media 
Clone  Normalized protein ratio % WT ±  
SEM 
p.R409W 1  0 0 
p.R409W 2  0 0 
p.R398C 1 0.8 87 ± 0.5 
p.R398C 2 0.8 86 ± 0.5 
p.R398C + p.Q448E1  0.1 12 ± 7.0 









































































Figure 5.36 Comparison of %WT ± SEM ADAMTS13 expression cell lysates, p.R409W 










Conditioned media samples were analysed for ADAMTS13 antigen with the 
commercially available IMUBIND® ADAMTS13 ELISA kit according to 
manufacturer’s instructions. Results can be seen in Table 5.28 and Figure 
5.38. 
 
Table 5.28 ELISA ADAMTS13 antigen concentration p.R409W and p.R398C series, 
expressed as %WT conditioned media 
Clone  ADAMTS13 concentration 
(ng/ml) 
% WT ±  
SEM 
WT 243 100 
p.R409W 1  0 0 
p.R409W 2  0 0 
p.R398C 1 0 0 
p.R398C 2 50 21 ±  10.4 
p.R398C + p.Q448E 1  22.1 9 ±  12.4 







































































Figure 5.37 Comparison of %WT ± SEM ADAMTS13 expression conditioned media, p.R409W 








A paired sample student’s t test was performed to analyse of there was any 
significant difference between % ADAMTS13 expression in cell lysates and 
conditioned media between p.R398C and p.R398C + p.Q448E, (p=0.05). The 
calculated result = 0.00123 lysates and 0.0019 in conditioned media. The 
tabulated value with one degree of freedom = 12.71.  
 
The null hypothesis can be accepted that there is no significant difference 
between ADAMTS13 expression with mutation p.R398C and the mutation with 
p.Q448E SNP in cell lysates or conditioned media. However, due to the small 
sample size, any conclusions drawn from this data must be interpreted with 
caution. 
 
5.3.3.5 Western blot analysis p.A596V and p.A690T  
 
The cells were harvested, lysed and sonicated as previously described before 
analysing by western blot (see Figures 5.39). An antibody directed against the 
housekeeping protein β-actin of molecular weight 45kDa was used as a 
loading control. An equal amount of total protein was loaded into each well of 




































































Figure 5.38 ELISA analysis of ADAMTS antigen concentration, %WT ± SEM of 




Figure 5.39 Western blot analyses cell lysates p.A596V, p. A596V + p.P475S and p.A690T 
A690T  
 
The conditioned media of the expression vectors analysed in Figure 5.39 was 







The band intensities on western blots were scanned using ImageJ software 
and the cell lysates normalized to the β-actin housekeeping protein and 
compared with positive control (WT) values % WT ± SEM (see Table 5.29 and 
Figure 5.41). 
Table 5.29 ImageJ analysis of cell lysates p.A596V series and p.A690T 
Clone  Normalized protein ratio % WT ± SEM 
p.A596V 1 0.85 85 ± 43 
p.A596V 2 1.7 171 ± 43 
p.A596V + p.P475S 1 1.6 155 ±  31 
p.A596V + p.P475S 2 2.2 217 ± 31 
p.A690T 1 0.95 95 ±  39  






Figure 5.40 Western blot analysis of conditioned media: p.A596V, p.A596V + p.P475S 
and p. A690T. 
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The band intensities on western blots were scanned using ImageJ software 
and the conditioned media samples normalized to the WT positive control on 
the same blot (values ± %WT SEM); (see Table 5.30 and Figure 5.43). 
 
Table 5.30 ImageJ analysis conditioned media p.596V series and p.A690T  
Clone  Normalized protein ratio % WT ± SEM 
p.A596V 1 0 0 
p.A596V 2 0 0 
p.A596V + p.P475S 1 0 0 
p.A596V + p.P475S 2 0 0 
p.A690T 1 1.06 106 ±  26 
p.A690T 2 0.54 54 ±  26  
 
ELISA antigen concentration of conditioned media of all expression vectors: 
0ng/ml 
A paired sample student’s t test was performed to analyse of there was any 
significant difference between % ADAMTS13 expression in cell lysates and 
between p.A596V and p.A596V + p.P475S, (p=0.05). The calculated result = 
0.0013. The tabulated value with one degree of freedom = 12.71.  
 
The null hypothesis can be accepted that there is no significant difference 
between ADAMTS13 expression with mutation p.A596V and the mutation with 
p.P475V SNP in cell lysates.  
 
5.3.3.6 Western blot analysis cell analysis p.T196I series cell lysate 
 
The cells were harvested, lysed and sonicated as previously described before 
analysing by western blot (see Figures 5.41). An antibody directed against the 
housekeeping protein β-actin of molecular weight 45kDa was used as a 
loading control. An equal amount of total protein was loaded into each well of 







The conditioned media of the expression vectors analysed in Figure 5.41 was 
harvested, concentrated and analysed on western blot (see Figure 5.42). 
 
 
Figure 5.42 Western blot analyses conditioned media p.T196I, p.T196I + p.Q448E 
 
The band intensities on western blots were scanned using ImageJ software 
and the cell lysates normalized to the β-actin housekeeping protein and 
compared with positive control (WT) values % WT ± SEM (see Table 5.31 and 
Figure 5.43). 
 
Table 5.31 ImageJ analysis of p.T196I series, cell lysates 
Clone  Normalized protein ratio % WT ± SEM 
p.T196I 2 1.27 127 ± 17 
p.T196I 3 0.85 85 ±  17 
p.T196I 0.76 76 ±  17 
p.T196I + p.Q448E 0.72 72 ±  25 





Figure 5.41 Western blot analyses cell lysates p.T196I, p.T196I + p.Q448E 
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The band intensities on western blots were scanned using ImageJ software 
and the conditioned media samples normalized to the WT positive control on 
the same blot (values % WT ± SEM); (see Table 5.32 and Figure 5.44). 
 
Table 5.32 ImageJ analysis of p.T196I series, conditioned media 
Clone  Normalized protein ratio % WT 
p.T196I 2 0 0 
p.T196I 3 0 0 
p.T196I + p.Q448E 2 0 0 
p.T196I + p.Q448E 3 0 0 
 











































































































































ELISA antigen concentration of conditioned media: 0ng./ml 
A paired sample student’s t test was performed to analyse of there was any 
significant difference between % ADAMTS13 expression in cell lysates and 
between p.T196I and p.T196I + p.Q448E, (p=0.05). The calculated result = 
0.0008. The tabulated value with one degree of freedom = 12.71.  
 
The null hypothesis can be accepted that there is no significant difference 
between ADAMTS13 expression with mutation p.T196I and the mutation with 
p.Q448E SNP in cell lysates.  
 
5.3.3.7 Western blot cell analysis p.Q436H  
The cells were harvested, lysed and sonicated as previously described before 




































































































Figure 5.44 Comparison of %WT ± SEM ADAMTS13 expression conditioned media 




housekeeping protein β-actin of molecular weight 45kDa was used as a 
loading control. An equal amount of total protein was loaded into each well of 
SDS-PAGE, as determined by BCA assay. 
 




The conditioned media of the expression vector was harvested, concentrated 
and analysed on western blot (see Figures 5.45). 
 
The band intensities on western blots were scanned using ImageJ software 
and the cell lysates normalized to the β-actin housekeeping protein and 
compared with positive control (WT) values % WT ± SEM (see Table 5.33 and 
Figure 5.46). 
 
Table 5.33 ImageJ analysis of p.Q436H, cell lysates 
Clone  Normalized protein ratio % WT ± SEM 
p.Q436H 1 0.7751 77 ±  1.5 
p.Q436H 2 0.7443 74 ±  1.5 
 
The band intensities on western blots were scanned using ImageJ software 
and the conditioned media samples normalized to the WT positive control on 
the same blot (values % WT ± SEM); (see Table 5.34 and Figure 5.46). 
 
Table 5.34 ImageJ analysis of p.Q436H, conditioned media 
Clone  Normalized protein ratio % WT ± SEM 
p.Q436H 1 0.699 70 ±  1.0 









Conditioned media samples were analysed for ADAMTS13 antigen with the 
commercially available IMUBIND® ADAMTS13 ELISA kit according to 
manufacturer’s instructions. Results can be seen in Table 5.35 and Figure 
5.46. 
Table 5.35 ELISA ADAMTS13 antigen concentration p.Q436H expressed as %WT 
conditioned media 
Clone  ADAMTS13 concentration 
(ng/ml) 
% WT± SEM 
WT 242.75 100 
p.Q436H 1 0.36 36 ± 9.5 









5.3.3.8 Western blot analysis p.C977F  
The cells were harvested, lysed and sonicated as previously described before 
analysing by western blot (see Figure 5.47). The expected size of ADAMTS13 
protein (approx. 180kDa) was seen. An antibody directed against the 
housekeeping protein β-actin of molecular weight 45kDa was used as a 
loading control. An equal amount of total protein was loaded into each well of 







































































Figure 5.46 Comparison of %WT ± SEM ADAMTS13 p.Q436H cell lysates (Lys), 







The conditioned media of the expression vector analysed in Figures 5.47 






The band intensities on western blots were scanned using ImageJ software 
and the cell lysates normalized to the β-actin housekeeping protein and 
compared with positive control (WT) values % WT ± SEM (see Table 5.36 and 
Figure 5.49). 
 
Table 5.36 ImageJ analysis p.C977F cell lysate 
Clone  Normalized protein ratio % WT ± SEM 
p.C977F 1 0.9 93 ±  7.5 
p.C977F 2 0.78 78 ± 7.5 
 
The band intensities on western blots were scanned using ImageJ software 
and the conditioned media samples normalized to the WT positive control on 





Figure 5.47 Western blot analyses cell lysates p.C977F 
Figure 5.48 Western blot analyses conditioned media p.C977F 
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Table 5.37 ImageJ analysis p.C977F conditioned media 
Clone  Normalized protein ratio % WT 
p.C977F 2 0 0 









ELISA antigen concentration of conditioned media: 0ng./ml 
 
5.4 Discussion 
When comparing in vitro expression levels of constructs and clinical data, the 
mean levels of ADAMTS13 in citrated plasma from normal donors (n=49) was 
determined as 740 ± 110ng/mL (Peyvandi et al., 2004). 
5.4.1 Challenges in the methodology 
Several setbacks were encountered in this study. The construction of a 
number of  expression vectors was abandoned due to the difficulty in obtaining 
clean nucleotide sequences (i.e. as the wild type sequence) after the mutation 
had been inserted. The method was altered by adding 5% DMSO to the PCR 
mixture, decreasing the Tm to 58°C and increasing the melting temperature to 
98°C in the PCR cycling conditions. These expression vectors were the double 
mutation G794C + A796T, G803C and C1368T. The nucleotide changes were 















































Figure 5.49 Comparison of %WT ± SEM ADAMTS13 expression p.C977F cell 
lysates (Lys) and conditioned media (CM) 
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were difficult to construct. The deletion mutation 719_724del (a deletion of six 
nucleotides) was not successfully inserted, possibly due to the high fidelity and 
proofreading ability of the pfu Ultra polymerase used in the SDM mutagenesis 
kit.  
 
The insertion of the unwanted nucleotide change C3484T, which would lead 
to a non-synonymous variant, was inserted in all constructs after attempting 
nucleotide substitutions after and including nucleotide 1787. In those vectors 
with nucleotide changes before 1787, this was not observed. This was 
puzzling to the manufacturer of the SDM kit (Agilent Technologies, UK) and 
was corrected only by performing another SDM procedure to revert the 
nucleotide change back to the WT sequence. Possibly the attachment of the 
pfu polymerase to the dsDNA created a torsion within the DNA at one 
particular point in the strand, resulting in the nucleotide change. Thymine and 
cytosine are pyrimidine bases with one carbon-ring therefore the substitution 
would be more energetically favourable compared to the substitution of 
pyrimidine bases. The reversion to WT by SDM was invariably successful. 
5.4.2 Mutation p.R102H series 
The transfection efficiencies for expression vectors p.R102H, p.R102H + 
p.Q448E, p.D102H and p.D102H + p.A900V were similar. However, the 
transfection efficiency for p.D102H multi was lower at 15%. Based on the 
densitometry analysis of band intensities on western blots, the average 
synthesis of ADAMTS13 in cell lysates, which have been normalized to the 
housekeeping protein β-actin and expressed as % of WT, were 41% for 
p.R102H, 19% for p.R102H + p.Q448E, 39% for p.D102H + p.A900V and 
121% for p.R102H multi (p.R102H+ p.R7W + p.Q448E + p.A900V). This is 
interesting in consideration of the apparent lower transfection efficiency for 
p.R102H multi. The densitometry analysis of the conditioned media of the 
same vectors were 61% of WT for p.R102H, 69% for p.R102H + p.Q448E, 
64% for p.D102H + p.A900V and 68% for p.R102H multi. In the analysis of cell 
lysates and conditioned media by western blot, there was no statistical 
significance found in ADAMTS13 expression between the mutation and 
mutation + SNPs. However, a statistically significant difference was found on 
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analysis of ADAMTS13 expression in conditioned media as analysed by 
ELISA. The values for ADAMTS13 antigen concentration by IMUBIND ELISA 
was not in agreement with the western blot analysis and thus appeared 
spurious. The ELISA should be repeated in order to make a valid conclusion. 
Based on these low concentrations, the ADAMTS13 activity was not assessed. 
In conclusion, the mutation p.R102H caused a decreased secretion of 
ADAMTS13 (average 61% of WT) by analysis on western blot and the 
presence of SNPs either singly or in combination did not affect ADAMTS13 
secretion.  
 
The disparity between the cell lysate values and the secretion has also been 
documented by other researchers (Edwards et al., 2012).The level of 
ADAMTS13 secretion is in agreement with another expression study, which 
was 51% (Camilleri et al., 2012). This is also in agreement with the clinical 
picture of the patient who developed TTP during her first pregnancy. At 
approximately 60% normal ADAMTS13 secretion, it could be argued that this 
level of ADAMTS13 would be adequate until the changes in the ADAMTS-
VWF axis during pregnancy induced a TTP episode. 
 
5.4.3 Mutation p.D217H series 
The p.D217H mutation was identified in an 18-month-old patient with 
prophylactic PT needed only in severe infections. Based on the densitometry 
analysis of western blots, the average synthesis of ADAMTS13 in cell lysates, 
which have been normalized to the housekeeping protein β-actin and 
expressed as % of WT, were 146% for p.D217H, 88% for  p.D217H + p.R7W, 
76% for p.D217H + p.Q448E, 349% for p.D217H + p.A1033T and 231% for 
p.D217H multi (p.D217H + p.R7W + p.Q448E + p.A1033T). The transfection 
efficiencies were similar, at between 18-20%. There is an apparent increase 
in synthesis of the recombinant ADAMTS13 protein on the addition of the 
SNPs p.A1033T and all four SNPs (which also contains p.A1033T). The 
densitometry analyses of the conditioned media of the same vectors were: 
63% of WT for p.D217H, 70% for p.D217H + p.R7W 179% for p.D217H + 
p.Q448E, 40% for p.D217H + p.A1033T and 90% for p.D217H multi. 
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Comparing the intracellular synthesis to the extracellular synthesis, there is a 
decrease in secretion in the mutation p.D217H, a comparable value for 
p.D217H + p.R7W, an increase in secretion in p.D217H + p.Q448E, a 
decrease in secretion in p.D217H + p.A1033T and a decrease in p.D217H 
multi. This is in agreement with the research performed by Edwards et al. who 
reported on the SNPs p.Q448E and p.A1033T (Edwards et al., 2012). 
However, in the analysis of cell lysates and conditioned media by western blot 
in this study, there was no statistical significance found in ADAMTS13 
expression between the mutation and mutation + SNPs. However, a statistical 
significant difference was found on analysis of ADAMTS13 expression in 
conditioned media as analysed by ELISA.  
 
Previous expression studies performed by Camilleri et al. found the mutation 
p.D217H caused an increased secretion at 112% WT and this study found a 
secretory decrease of 63%, which is not in agreement (Camilleri et al., 2012). 
The mutation in the patient was found as a compound heterozygote with 
p.R1060W, which is associated with late-onset TTP. These mutations acting 
in tandem could precipitate TTP at a younger age when challenged with a 
physiological stress such as severe infection. In conclusion, SNPs in addition 
to the mutation p.D217H does appear to alter the secretion of rADAMTS13. 
However, as haplotype data has not been specified it is difficult to directly 
relate this to the clinical picture. 
 
5.4.4 Mutation p.T196I series 
The p.T196I mutation was identified in a 21-year-old patient who was first 
diagnosed with TTP at aged three. The transfection efficiencies of the mutation 
p.T196I and p.T196I + p.Q448E were similar at 21% and 22% rspctively.  
Based on the densitometry analysis of western blots, the average synthesis of 
ADAMTS13 in cell lysates was 96% for p.T196I and 98% for p.T196I + 
p.Q448E. Densitometry analysis of western blots of the conditioned media 
from the same expression vectors was 0% for p.T196I and p.T196I + p.Q448E. 
In a previous expression study the secretion level was not assessed by 
western blot but was 4% WT on antigen assay (Camilleri et al., 2012). This is 
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in agreement with the clinical picture. In conclusion, the SNP p.Q448E has no 
influence on the effect of the mutation p.T196I, which is found in the 
metalloprotease domain.  
 
5.4.5 Mutation p.R409W  
The mutation p.R409W was found in a patient in homozygous form with no 
SNPs and was diagnosed as a neonate with a requirement for frequent 
prophylactic PT. The transfection efficiency of the expression vector was low 
at 15%. Based on the densitometric analysis of western blots, the average 
synthesis of ADAMTS13 in cell lysates, which has been normalized to the 
housekeeping protein β-actin and expressed as % of WT, was 55%. The 
densitometry analysis of the conditioned media was 0% WT and this was also 
seen on ELISA. As this mutation was seen in a neonate with a requirement for 
frequent PT this expression study is in agreement with the clinical picture. 
 
5.4.6 Mutation p.R398H  
The p.R398H mutation was identified in a patient diagnosed with TTP as a 
neonate, requiring frequent PT. It was in compound heterozygous form with 
the mutation p.Q436H and SNP p.Q448E. The transfection efficiencies for 
expression vectors p.R398H and R398H + p.Q448E were 18% and 20% 
respectively. Based on normalized densitometry analysis of band intensities 
on western blot, the average synthesis of ADAMTS13 in cell lysates were 82% 
p.R398H and 100% R398H + p.Q448E. Densitometry analysis of the 
conditioned media, expressed as %WT, was 86% for the mutation p.R398H 
and 21% for the mutation + SNP p.R398H + p.Q448E. Interestingly the ELISA 
results were 21% for the p.R398H mutation and 21% for the mutation + SNP 
p.R398H + p.Q448E. If this mutation was in homozygous form this genotype 
may present as a different phenotype. However, the mutation was identified 
as a part of a compound heterozygote thus relationship of genotype and 
phenotype is difficult to correlate in this case. These results also do not concur 





5.4.7 Mutation p.Q436H  
This mutation was identified as a heterozygote with the mutation p.R398C as 
described above. It was identified in a neonate who required frequent PT 
prophylactic treatment. Densitometry analysis on the band intensities on 
western blot showed the normalized secretion of ADAMTS13 in cell lysates to 
be 76% of WT and the secretion of 69% WT in conditioned media. Previous in 
vitro expression studies showed the secretion to be 18% WT on western blot 
and 64% on ELISA (Camilleri et al., 2012). The latter figure is more in 
agreement with the findings of western blot analysis in this study. As the 
patient was a compound heterozygote and no other patients have presented 
in homozygous form, the relationship of genotype to clinical phenotype is 
difficult to establish with this mutation. 
 
5.4.8 Mutation p.A596V  
The mutation p.A596V was found in homozygous form in a patient who was 
diagnosed with TTP at aged 18 months. The transfection efficiency for the 
expression vector was 22 % of WT. The densitometry analysis of band 
intensities on western blots revealed the average synthesis of rADAMTS13 in 
cell lysates to be 128% WT and that of the conditioned media and ELISA 0% 
WT. The low levels of secretion would explain childhood onset TTP, although 
the patient would have been more expected to present as a neonate. This 
mutation was also found in another patient as a compound heterozygote with 
p.R1095Q and SNP p.Q448E. The patient was diagnosed with TTP during 
pregnancy. The densitometry analysis of normalized cell lysates on western 
blots was 166% p.A596V + p.Q448E. The western blot analysis of the 
conditioned media was 0% p.A596V + p.Q448E. The ELISA result was 
0ng/mLfor both the mutation and mutation + SNP. Previous expression studies 
found the mutation p.A596V abolished secretion (Camilleri et al., 2012). This 
is in agreement. As p.596V was a compound heterozygote with p.R1095Q, it 
could be argued the latter mutation ‘rescues’ ADAMTS13 levels and TTP does 
not present until the physiological stress of pregnancy. As p.A596V is a severe 




5.4.9 Mutation p.A690T  
The mutation p.A690T was identified in a pregnant patient who had a clinical 
history of one live pregnancy and four losses and an ADAMTS13 antigen level 
of 35ng/mL. Genotype analysis revealed the p.A690T mutation together with 
the deletion mutation G241_C242del and no SNPs. The p.A690T mutation is 
located in TSP1-8 domain. The densitometry analysis of band intensities on 
western blots revealed the average synthesis of rADAMTS13 in cell lysates to 
be 134% WT and that of the conditioned media to be 80% WT expression. The 
deletion mutation G241_C242del has been previously been identified in three 
18-month-old children. The p.A690T mutation as a compound heterozygote 
could be argued to ‘rescue’ the ADAMTS13 levels producing the later onset 
phenotype with the TTP boot being precipitated by pregnancy. 
 
5.4.10 Mutation p.C977F  
The mutation p.C977F was found in homozygous form in a patient who was 
diagnosed with TTP in pregnancy. The densitometry analysis of band intensity 
on western blots revealed the average synthesis of ADAMTS13 in cell lysates 
to be 85% of WT and in conditioned media and ELISA 0%. i.e., the mutation 
in homozygous form would abolish secretion. A previous expression study 
reported secretion was much reduced at <11% ADAMTS13 (Camilleri et al., 
2012). Despite the low ADAMTS13 secretory levels this patient presented a 
late-onset phenotype which highlights the varied clinical nature of TTP and 
suggests there are other factors involved in the pathophysiology that have not 
yet been identified. 
 
5.4.11 Single nucleotide polymorphisms 
On analysis of the secretion of the singular SNPs, the transfection efficiencies 
were low at between 12-16% that of wild type but they were comparable with 
each other. Based on the densitometry analysis of band intensities on western 
blots, the average synthesis of rADAMTS13 in cell lysates, which have been 
normalized to the housekeeping protein β-actin and expressed as % of WT, 
were 84% p.Q448E, 120% p.P475S, 0% p.P618A, 63% p.A732V and 235% 
p.A900V. The expression vector p.P618A was transfected twice but showed 
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no bands on western blot. The densitometry analysis of western blots of the 
conditioned media of the same vectors were 106% p.Q448E, 0% p.P475S, 0% 
p.P618A, 32% p.A732V and 168% p.A900V. Interestingly the ELISA results 
were 62% p.Q448E, 56% p.P618A (in only one vector, which showed no 
visible banding on western blot), 32% p.A732V and 17% p.A900V. The SNP 
p.P618A has been shown to have decreased secretory levels (Kokame et al., 
2002). These results also concur with the different pattern in synthesis an 
secretion for p.Q448E (an increase in cellular synthesis compared with 
secretion) and p.A732V (a decrease in secretion compared to intracellular 
synthesis); (Edwards et al., 2012). This provides further evidence that SNPs 
can have an impact on secretion of rADAMTS and possibly affect phenotype 
in TTP. 
 
5.5 Concluding remarks 
In conclusion, this study has found that, on analysis of western blot SNPs do 
not have a statistically significant modifying effect on the effect of mutations 
within the ADAMTS13 gene. Clinically there may be other environmental 
factors involved that have not been defined; these may be in non-exonic 
regions, such as the promoter region or other parts of the genome, the effects 






Chapter 6  
Discussion and conclusions 
6.1 Aim of this study 
 
The aim of this study was to correlate the effects of mutations and SNPs, either 
singly or in combination, identified in a UK cohort of TTP patients on the 
secretion of rADAMTS13 and to relate genotype to phenotype in congenital 
TTP. 
 
The results of the computational tools used to predict the effect of mutations 
and SNPs in this study can be summarised in Table 6.1 
Table 6.1 Summary of predicted effect of SNPs and mutations on ADAMTS13 expression 
Variant Prediction by computational tools (Predict 
SNP) 
Effect on stability of mutation 
ΔΔG) 
R102H Deleterious by SIFT and SNAP Large decrease 
T196I Deleterious*  Neutral 
D217H Deleterious by PolyPhen and SNAP Neutral 
R398C Deleterious by all tools except MAPP Decrease 
R409W Deleterious*  Neutral/decrease 
Q436H Deleterious by PolyPhen and SNAP Neutral 
A596V Deleterious by all tools except PolyPhen Neutral 
C977F Deleterious*  Neutral 
R1060W Deleterious * Neutral 
 
Variant Prediction by 
computational 
software 
MAF  Effect on stability of 
mutation ΔΔG) 
R7W Neutral 0.09389 Neutral 
Q448E  Neutral  0.5079 Neutral 
P475S Neutral 0.00266 Large decrease 
P618A Neutral 0.09287 Large decrease 
A732V Neutral  0.1553 Neutral 
A900V Neutral 0.0438 Neutral 
A1033T Neutral 0.08744 Decrease 













MAPP PhD-SNP SIFT SNAP 
Expected 
accuracy 
68.1% 69.2% 70.7% 71.5% 70.3% 67.6% 
 
In the analysis of cell lysates and conditioned media by western blot of 
mutations p.R102H, p.D217H, p.R398C, p.A596V and p.R1060W there was 
no statistical significance found in ADAMTS13 expression between the 
mutation and mutation + SNPs either singly or in combination.A statistical 
significant difference was found on analysis of ADAMTS13 expression in 
conditioned media as analysed by ELISA in p.R102H and p.D217H. However, 
the antigen levels as analysed by ELISA were not in agreement with the 
analysis of ADAMTS13 expression levels in conditioned media by western blot 
analysis. These results should thus be interpreted with caution. As discussed 
previously, the ELISA used from a commercial source has been validated for 
use in the clinical diagnostic setting with plasma/serum used as a matrix rather 
than reagents used in an in vitro expression system. The nature of epitope(s) 
of the ADAMTS 13 capture antibody used is also not in the public domain thus 
any conclusions regarding the specificity or the avidity of the antibody which 
may cause low antigen results cannot be made.  
6.2 Discussion of methods used 
A series of expression vectors was created containing nucleotide substitutions 
that were identified in patient genotype and rADAMTS13 was transiently 
expressed in HEK293T cells containing the missense mutation or SNP. 
Several expression vectors with nucleotide changes in a G-C rich area of the 
ADAMTS13 cDNA insert proved difficult to construct, possibly due to the 
enhanced H-bonding in the nucleotide sequence in that region of the DNA 
strand. The nucleotide changes in these vectors were specifically the double 
missense mutation G794C+A796Tand the single mutations G803C and 
G1368T. Vectors containing the individual mutations G794C and A796T could 
be constructed singly but, possibly due to the high fidelity proofreading ability 
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of the proprietary pfu polymerase enzyme, the double nucleotide change 
proved problematic. 
 
Modelling of the cDNA nucleotides 700 – 1400 using the MFold server 
(http:www.unafold.rna.albany.edu) revealed H-bonding between many 
nucleotides within this area. As a result the dsDNA strand may resist 
denaturation needed for the DNA polymerase to bind. In the light of this, the 
PCR conditions were changed to increase the temperature of the denaturation 
step to 98°C and 5% DMSO was added to the PCR mixture to facilitate 
breakage of the H-bonds. The Tm was also decreased to 58°C. It was found 
that the desired nucleotide change was inserted but the nucleotide sequence 
approximately 20 base pairs following the substitution became corrupted. This 
indicated that the primer design was suitable but the polymerase appeared to 
detach from the cDNA strand, possibly due to torsional strains in the strand as 
a result of DNA coiling. 
 
The construction of an expression vector carrying the deletion mutation 
719_724del was also attempted but proved problematic. The design of the 
primer used in the SDM method included the six nucleotide deletion located in 
the central region of the primer. As the pfu polymerase (Agilent Technologies) 
has high-fidelity proofreading ability, this appears to have led to the non-
amplification of the DNA insert. However, by changing the protocol in future 
work, an expression vector containing the desired mutation could be created.  
 
An alternative method published by Pérez-Pinera et al. excludes the 
amplification of the fragment to be deleted through the design of primers to 
include a restriction enzyme target at the 5’ sequence. Briefly, following PCR 
amplification the plasmid is digested with DpnI to digest the template DNA 
strand together with the chosen restriction enzyme and ligated. The method 
has been reported to obtain 100% of transformants containing the desired 
mutation (Pérez-Pinera et al., 2006). The limitation of the method is the 
selection of the restriction enzyme target sequence that must not be present 
in the original plasmid. Restriction enzymes have been identified that do not 
appear in the ADAMTS13 cDNA (see Table 6.2): 
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Table 6.2: Restriction enzymes that can be used in a vector construct that would not 
target ADAMTS13 cDNA 
 
Table 6.2 Restriction enzymes which would not target ADAMTS13 cDNA 
TfiI ApaLI PfIFI DrdI FsPI XmnI 
Tth111I ARSi AscI BcgI BspHI AccI 
PshAI BsaI BsmBI MreI SgrAI BmgBI 
ArrII AseI BssSI AndI kpnI BsaWI 
Acc65I ScaI     
 
It was observed that the DNA yields found in the amplification of the validated 
constructs were very low compared to expected DNA concentrations (see 
Tables 4.9; 5.11). The quality of DNA was checked with each measurement of 
DNA concentration (the absorption ratio at 260nm:280nm ~1.8-2.0) to ensure 
the DNA was of the appropriate quality. The vector used (pcDNA3.1) is 
classified as a high copy plasmid but due to the large ADAMTS13 insert cDNA 
this could impede copy number. Troubleshooting was performed as per the 
protocol and the problem was identified to be the lysis stage. It was ensured 
that the starter culture containing selective media was diluted 1/500-1/1000 
times and incubated in a vessel four- fold greater than the volume of inoculant. 
This was incubated for 12-16 hours and shaken at approx. 230 RPM. The 
optical density at 600nm was measured to ensure growth was in the 
logarithmic phase (OD600 0.8-1.2) and, after centrifugation, the wet pellet 
weight (biomass) was in the region of 3g/L. This reflected a cell density of 
3x104, as per the protocol. The protocol was performed as per high copy 
number plasmid and per low plasmid copy number. A new kit was also 
purchased. However, the DNA yield still remained low and the QIAGEN 
Maxiprep kit was changed for the Invitrogen MidiPrep kit and the problem 
regarding DNA concentration was resolved. 
 
The use of a reporter vector to assess the transfection efficiency does not 
measure the true transfection efficiency of the vector containing the variant. It 
does, however, indicate that the transfection has worked, i.e. can be used as 
a positive control and does provide an indication of transfection efficiency. To 
measure the true transfection efficiency a reporter would ideally be tagged 
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onto the variant vector. However, depending on the size of the reporter itself, 
it could be argued that this may affect the translation of the variant protein. The 
transfection efficiencies found in this study, which used the β-galactosidase 
reporter, were lower than expected. Alternative reporter vectors could be used. 
These include the luciferase reporter vector (Vesuna, 2005) which contains 
the gene from the sea pansy Renilla reniformis, chloramphenicol acetyl 
transferase (CAT) and green fluorescent protein (GFP). The luciferase 
reporter is reported to be used widely (Vesuna, 2005) due to its detection 
sensitivity and ease of quantification when compared to other systems (de Wet 
et al., 1987). However, there have been reports of aberrant activation or 
repression of the control reporter genes by the constructs and the reporter 
promoters used such as simian virus (SV40), cytomegalovirus (CMV) or 
thymidine kinase (TK) (Farr & Roman, 1992; Mulholland et al., 2004). This can 
alter the levels of the control reporter expression which could lead to the 
spurious expression of the control reporter, leading to a bias in the 
normalization of the data. An alternative reporter is enhanced green 
fluorescent protein (eGFP) and this has been reported as robust, with the 
production of consistent results and can also be measured in vivo. The β-
galactosidase reporter used in this study can only be used on fixed cells. 
 
To allow valid comparison for each expression study, a number of control 
measures were put in place during the ADAMTS13 expression studies 
(intracellular and extracellular).  Transfections were performed in triplicate 
together with the transfection of WT to allow comparison among variants 
transfected concurrently. The number of viable HEK293T cells, with viability 
assessed with the use of trypan blue, was counted by haemocytometer and 
an equal number of cells plated for each culture dish. An empty vector was 
used (with no cDNA insert) for the negative control. Transfection efficiencies 
were assessed by the use of co-transfection with a reporter vector containing 
the LacZ gene and on positive transfection the number of blue cells, as a 
percentage of the total number of cells, was quantified (see above). For the 
SDS-PAGE step the appropriate quantity of protein to load was assessed 
initially, as loading too much protein would lead to signal saturation and too 
little would produce too little signal. A WT positive control was used and 
166 
 
differing protein concentrations were loaded. Both target protein antibody 
(anti-myc) and housekeeping protein (β-actin) were used and, after 
densitometry analysis of the western blots, the protein load that gave the 
quantitative reading in the linear dynamic range was chosen. This quantity of 
total protein was used for all blots, as assessed by BCA assay. After blotting, 
the uniform transfer of protein onto the nitrocellulose membrane was assessed 
with the use of Ponceau S staining and those blots with inadequate or non-
uniform transfer were discarded. On completion of western each blot, the 
positive control lanes (WT ADAMTS13) were assessed compared to the 
housekeeping protein and the protein of interest An assessment was made of 
the quality of the primary antibody interaction with ADAMTS13: a low signal 
with both WT and target protein indicated the exhaustion of the ADAMTS13 
anti-myc antibody and the blot was discarded The data was not included in the 
data set. If all lanes showed a low signal on densitometric analysis, poor 
interaction with secondary antibody was indicated and the blot was discarded 
and the data excluded. The protocols used for each expression study did not 
vary. Ideally, the western blots would be repeated three times for densitometry 
analysis and the average taken. However, this was not possible due to time 
and resource constraints. All values of cell lysates were normalized against 
the housekeeping protein β-actin. 
 
6.3 The relationship between patient genotype and clinical phenotype 
It has been argued by Edwards et al. that the effect of a single SNP should not 
be compared to that of SNPs in combination that often appear together as a 
haplotype as the combination may have an alternative significant effect 
(Edwards et al., 2010). Until more data is produced on this rare disorder this 
is difficult to evidence. 
 
Lotta et al. 2010 found that patients with the same ADAMTS13  genotype were 
found to have a similar age of onset (Lotta et al., 2010). A lower residual 
ADAMTS13 was also associated with the age at first TTP episode requiring 
PT. The results from their study also related the amount of residual 
ADAMTS13 activity and the clinical features of the disease. A total of 51% of 
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the mutations described to date in TTP patients are missense and 71% of 
these missense mutations whose data was analysed are localized in the N’ 
terminal end of the protein. The N-terminal domain mutations were associated 
with lower activity and more severe disease in an allele-dosage-dependent 
way. This area contains the catalytic domains and is the area where the 
highest degree of conservation occurs (Lotta et al., 2010). It was also found 
that missense SNPs do not show evidence of skewed distribution. Residual 
plasmatic activity, as measured by SELDITOF mass spectrometry, was 
inversely correlated with the clinical severity of the phenotype. 
 
Some features of this research can also be seen in the results of this 
expression study. Those mutations located nearer to the N-terminal end of 
ADAMTS13 showed less secretory levels which would result in a more severe 
clinical phenotype. The mutations nearer the C-terminal end of the protein 
tended to present a less severe clinical phenotype such as p.R1060W and the 
effect of SNPs could modify the effect of these secretions on ADAMTS13 
expression.  
 
6.4 The effect of mRNA processing on ADAMTS13 expression 
In higher eukaryotes only a small fraction of changes at the proteome level is 
directly reflected by changes at the transcriptome level. There is thus an 
important role played by the translation and post-translational controls of gene 
expression. 
 
Changes in messenger RNA (mRNA) structure/folding may represent one of 
the reasons for altered protein production. In eukaryotes, mRNA is bound to 
messenger ribonucleoprotein complexes (mRNPs). Variants may produce 
changes in the mRNA sequence/structure affecting its association with 
specific proteins and thus alter the fate of the encoded protein. However, most 
effects may be due to altered mRNA conformation and stability rather than 
efficiency of protein translation. The abundance of mRNA may also affect 
extracellular protein expression levels. Significantly lower mRNA expression 
levels compared to WT may account for lower intracellular protein levels and 
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SNPs may affect the levels of mRNA levels. This has been found in the 
multidrug resistant polypeptide MRD1 which is an efflux transporter of drugs. 
An SNP has been associated with decreased mRNA and protein levels via an 
unknown mechanism (Wang et al., 2005). Calculations of mRNA folding using 
software programmes has suggested the decreased level is due to an effect 
on the secondary structure of mRNA. 
 
Changes in protein expression levels could also be explained by alternative 
RNA splicing. This would not affect mRNA levels but could affect the efficiency 
of translation. 
 
6.5 Improvement of the method of protein detection 
The results from analysis of band intensities seen on western blot for cell 
lysate and conditioned media showed a variation in results despite various 
controls put in place in the experimental design (as discussed previously). As 
western blotting involves a sequence of steps, variability can be introduced at 
each stage which may bias the results. However, new techniques for the 
measurements of low concentrations of proteins have now been developed 
and validated and are in use in diagnostic laboratories. Lotta et al., recognised 
that the sensitivity and reproducibility of the commonly used ADAMTS13 
assays were questionable at low concentrations of the protein and used the 
more sensitive surface-enhanced laser desorption/ionization time-of-flight 
mass spectrometry (SELDITOF) (Lotta et al., 2012). A method published in 
2006 measured ADAMTS13 plasmatic activity with high analytical sensitivity 
(limits of detection 0.5%) which was 5-10 fold higher than most commercially 
available assays (Jin et al., 2006; Jin et al., 2008). Not only is this method 
more sensitive but would be more reproducible compared to western blotting. 
The latter  method has a relatively high limit of detection and scarce 







6.6 Synonymous SNPs  
Synonymous variants, whereby the primary structure of the protein (the amino 
acid sequence) does not change, occurs as a consequence of the wobble of 
transfer RNA (tRNA) base pairing during translation and the redundancy in the 
genetic code. However, single base pair changes require different tRNAs to 
decode them even though the tRNA is charged with the same amino acid.  It 
has been previously assumed that synonymous variants or sSNPs are 
inconsequential as the primary structure of the protein is retained. However, a 
number of studies have questioned this, mainly through showing these sSNPs 
are under evolutionary pressure and may have a functional consequence such 
as the alteration in structure, function and expression levels of the protein. 
These synonymous variants exist throughout the entire genome, both within 
exons and in non-coding regions which include promoters and transcription 
factor binding-sites. The mechanism by which these variants can affect the 
structure, function or expression levels of a protein is though messenger RNA 
(mRNA) stability, mRNA structure or alteration of the rate of protein folding, as 
mentioned previously.  
 
The genotype of patients with TTP is now well-documented but has largely 
been focused on the coding regions of the ADAMTS13 gene. As TTP is a 
complex, variable disorder that does not have a direct genotype-phenotype 
correlation, sequencing the whole ADAMTS13 gene and assessing sSNPs 
may provide more data to understand this heterozygous disease. 
 
6.7 Concluding remarks 
 
Phenotypic severity in TTP appears to be a result of multiple environmental 
and genetic factors. Although hundreds of genetic variants certain mutations 
near the N-terminal, functional end of ADAMTS13 seem to have a greater 
impact on phenotype and not be as influenced by physiological factors. Those 
mutations near the C-terminal end of the ADAMTS13 protein appear to have 
a lesser impact on phenotype. SNPs and environmental factors such as 
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hormone levels and the immune system may have greater influence on the 
TTP phenotype in these cases.  
 
Congenital TTP is considered an orphan disease as it is very rare in the 
population. Obtaining more genotype data for the whole ADAMTS13 gene and 
the reporting of synonymous mutations would contribute more data and 
encourage further research in this area. Research into the role of ADAMTS13 
in more widespread conditions such as MI and stroke may give more insight 
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Reagents and media 
 
Triton X cell lysis buffer 
20 mM Tris-HCl (Sigma) (0.6304 g) 
150 mM NaCl (Fisher) (1.75 g) 
0.1 % v/v Triton X-100 (Sigma) (0.2 ml) 
Made up to 200 ml with distilled water 
 
X-gal buffer 
Deoxycholic acid (Sigma Aldrich) 10 mM (0.05 g) 
Potassium ferrocyanate (Sigma Aldrich) 5 mM (1.056 g) 
Potassium ferricyanide III (Sigma Aldrich) 5 mM (0.823 g) 
Magnesium chloride (Sigma Aldrich) 4.3 mM (0.203 g) 
Igepal CA-630 (Sigma Aldrich) 0.02 % v/v (0.1 ml) 
Phosphate buffered saline (Sigma Aldrich) 500ml 
X-gal (Fisher Scientific) was diluted in DMSO (AppliChem) to give a final concentration of 
40mg/ml and stored at -20°C.  
For each 10cm dish, 25μl X-gal was added to 2ml buffer. 
 
Site directed mutagenesis  
 
LB media/l, pH 7.0 NZY+ broth/l, pH 7.5 
25 g LB Broth, Miller (Fisher) 10 g N-Z-Amine® (Sigma-Aldrich) 
Distilled water to 1 l 5 g NaCl (Fisher) 
 5 g yeast extract (Sigma-Aldrich) 
 Distilled water to 1 l 
 After autoclaving, prior to use add: 
 12.5 ml 1 M magnesium chloride* (Sigma-Aldrich) 
 12.5 ml 1 M magnesium sulfate* (Sigma-Aldrich) 
 20 ml 20 % (w/v) glucose (Sigma-Aldrich) 
*filter sterilized through 0.2 μl size filter 
 
LB-ampicillin agar/l 10 mM IPTG/10 ml 
20 g agar (Sigma-Aldrich) 24 mg IPTG (Fisher) 
1 l LB media (Fisher) 10 ml sterile distilled water 
1 ml 1 mg/ml filter sterilized ampicillin sodium 
salt (Calibiochem), added on cooling of LB 
agar to 55 °C 
Spread 100 μl per LB-agar plate 
 
2 % X-gal/ 10 ml 
0.2 g X-gal (Fisher) 
10 ml DMSO (Applichem) 






SDS gel electrophoresis 
Laemmli buffer (x4) 
Reagent Quantity 
1 M Tris (adjusted to pH 6.8 with HCl) (Fisher) 1.25 ml 
Glycerol (VWR) 0.5 ml 
SDS (Sigma-Aldrich) 0.4 g 
Bromophenol blue (Fisher) 0.004 g 
β mercaptoethanol (Sigma-Aldrich) 1 ml 
Deionised water 7.25 ml 
 
Resolving gel buffer 1.5 M Tris HCl (adjusted to pH to 8.8 with HCl) 
Tris base (Fisher) 3.63 g 
 
Stacking gel buffer 0.5 M Tris HCl (adjusted to pH 6.8 with HCl) 
Tris base (Fisher) 1.21 g 
 
10 % acrylamide resolving gel (x2) 
Reagent Volume 
40 % bis-acrylamide solution (Fisher) 2.5 ml 
Deionized water 3.3 ml 
1.5 M Tris buffer (Fisher) 3.8 ml 
10 % sodium dodecyl sulfate (Sigma-Aldrich) 100 μl 
15 % ammonium persulphate (APS) (Sigma-Aldrich) 50 μl 
TEMED (Sigma-Aldrich) 5 μl 
 
4% acrylamide stacking gel (x2) 
Reagent Volume 
40 % bis-acrylamide solution (Fisher) 0.25 ml 
Deionized water 1.5 ml 
0.5 M Tris buffer (Fisher) 0.63 ml 
10 % sodium dodecyl sulfate (Sigma-Aldrich) 25 μl 
15 % ammonium persulphate (APS) (Sigma-Aldrich) 12.5 μl 
TEMED (Sigma-Aldrich) 2.5 μl 
 
Running buffer (1 L) 
Reagent Quantity  
Tris base (Fisher) 14.4 g 
Glycine (Fisher) 3.03 g 




Transfer buffer (x 5), pH 8.3 Transfer buffer (x 1) 
15.5 g Tris base (Fisher) 5 x transfer buffer 
72 g glycine (Fisher) 600 ml deionized water  
1 l deionized water  200 ml methanol (Fisher Chemical) 
 
Tris buffered saline (TBS) x 10, adjusted to pH 7.5 with 5 N NaOH 
TBS Quantity 
NaCl (Fisher) 150 mM  8.76 g 
185 
 
Tris (Fisher) 50 mM 6.05 g 
Deionized water 1 l 
 
Ponceau S stain 
0.1 % w/v Ponceau S (Sigma-Aldrich) 
5 % (v/v) Acetic acid glacial (Fisher Scientific) 
 
 
Blocking buffer (3%) 
3 g Marvel original Dried skimmed milk powder (Premier Foods Group) 
100 ml 1 x TBS  
 
TBST (0.05%) 
50 μl Tween®-20 
100 ml TBS 
 
Antibodies (per blot) 
5 μl Anti-myc tag, clone 4A6 (mouse monoclonal) IgG1, 1 mg/ml (Merck Millipore) 
10ml 3 % blocking buffer in TBS  
 
10μl β actin, clone 8226 (mouse monoclonal) IgG1 (Abcam, clone 8226) 
10ml 3% blocking buffer in TBS  
 
2μl secondary goat anti-mouse IgG monoclonal antibody with HRP (Sigma Aldrich) 





Results of BCA assay, cell lysates 
Clone  Protein concentration (μg/μl) 
G305A 1* 378 
G305A 2* 338 
G305A 3* 350 
G305A+C1342G 1 209 
G305A+C1342G 2 232 
G305A+C1342G 3 179 
G305A + Q448E 1 Rpt 243 
G305A + Q448E 2 Rpt 305 
G305A + Q448E 3 Rpt 284 
G305A multi 1 209 
G305A multi 2 255 
G305A multi 3 289 
C587T 1* 577 
C587T 2* 571 
C587T 3* 529 
C587T+ Q448E 1 255 
C587T+ Q448E 2 308 
C587T+ Q448E 3 317 
G649C 1 214 
G649C 2 241 
G649C 3 242 
G649C + R7W 1 171 
G649C + R7W 2 181 
G649C + R7W 3 182 
G649C+Q448E 1 199 
G649C+Q448E 2 187 
G649C+Q448E 3 200 
G649C + 1033T 1 263 
G649C + 1033T 2 248 
G649C + 1033T 3 271 
G649C multi 1 238 
G649C multi 2 233 
G649C multi 3 266 
G649C + R7W 1 Rpt 250 
G649C + R7W 2 Rpt 275 
G649C + R7W 3 Rpt 286 
G649C + Q448E 1 Rpt 295 
G649C + Q448E 2 Rpt 302 
G649C + Q448E 3 Rpt 292 
C1192T 1 243 
C1192T 2 199 
C1192T 3 247 
C1192T + Q448E 1 197 
C1192T + Q448E 2 193 












































*denotes 10cm cell culture plates. All other cell lysates derived from 6 well plates 
 
Results of BCA assay, cell lysates 
 
Clone Protein concentration (μg/μl) 
WT 1 308 
WT 2 314 
R7W 1 346 
R7W 2 441 
R7W 3 419 
A1033T 2  304 
A1033T 3 251 
R1060W + A1033T 1 361 
C1225T 1 288 
C1225T 2 307 
C1225T 3 340 
C1225T 1 Rpt 466 
C1225T 2 Rpt 508 
C1225T 3 Rpt 479 
C1787T 1 240 
C1787T 2 262 
C1787T 3 215 
C1787T + C1423T 1 279 
C1787T + C1423T 2 268 
C1787T + C1423T 3 247 
C1787T + C1423T 1 Rpt 400 
C1787T + C1423T 2 Rpt 530 
C1787T + C1423T 3 Rpt 517 
G2068A 1 702 
G2068A 2 732 
G2068A 3 553 
G2068A 1 Rpt 516 
G2068A 2 Rpt 476 
G2068A 3 Rpt 518 
R910X 1  C2728T 765 
R910X 2  775 
R910X 3  816 
R910X 1 Rpt 475 
R910X 2 Rpt 397 
G2930T 1 283 
G2930T 2 283 
G2930T 3 253 
Q448E 1* 414 
Q448E 2* 498 
A900V 1* 381 
A900V 2* 380 
C2195T 1 286 
C2195T 2 252 
C2195T 3 265 
188 
 
R1060W + A1033T 2 374 
R1060W 1 346 
R1060W 2 436 
R1060W 3 352 
R1060W + R7W 1 362 
R1060W + R7W 2 445 
R1060W + R7W 3 342 
R1060W + R7W + A1033T 1 796 
R1060W + R7W + A1033T 2 802 
R1060W + R7W + A1033T 3 711 
Negative 372 
 
 Results of BCA assay, conditioned media 
 
Clone Concentration (μg/μl) 
WT 2 (31/7/15) 10 ml 340 
R1060W 1  282 
R1060W 2  298 
R1060W + A1033T 1 301 
R1060W + A1033T 2 288 
A1033T 2  287 
A1033T 3  278 
R7W 1 325 
R7W 2 360 
R1060W+A1033T+R7W 1 294 
R1060W+A1033T+R7W 3 288 
R1060W + R7W 1 340 
R1060W + R7W 2 349 
Neg 250 
 
Results of BCA assay cell lysates from repeat transfections 
 
Clone Concentration (μg/μl) 
R1060W 1 rpt 10ml 384 
R1060W 2 rpt 10ml 671 
R1060W 3 rpt 10ml 530 
A1033T 1 rpt 425 
A1033T 2 rpt 424 
A1033T 3 rpt 411 
R1060W+A1033T Rpt 1 362 
R1060W+A1033T Rpt 2 445 
R1060W+A1033T Rpt 3 342 
R1060W+A1033T+R7W 1 Rpt 796 
R1060W+A1033T+R7W 2 Rpt 802 








Results of BCA assay results repeat transfections: conditioned media 
 
Clone Concentration (μg/μl) 
R1060W 1 rpt 10ml 1,148 
R1060W 2 rpt 10ml 1,041 
R1060W 3 rpt 10ml 1,067 
A1033T 1 rpt 1,137 
A1033T 2 rpt 1,033 
A1033T 3 rpt 1,124 
R1060W+A1033T Rpt 1 1,231 
R1060W+A1033T Rpt 2 1,117 
R1060W+A1033T Rpt 3 1,172 
R1060W+A1033T+R7W 1 Rpt 760 
R1060W+A1033T+R7W 2 Rpt 830 
R1060W+A1033T+R7W 3 Rpt 751 
 
Results of BCA assay conditioned media 
 
Clone conditioned media Protein concentration (μg/μl) 
G305A 1* 159 
G305A 2* 169 
G305A 3* 127 
G305A+C1342G 1 257 
G305A+C1342G 2 287 
G305A+C1342G 3 226 
G305A + Q448E 1 Rpt 869 
G305A + Q448E 2 Rpt 800 
G305A + Q448E 3 Rpt 1020 
G305A + A900V 1 301 
G305A + A900V 2 263 
G305A + A900V 3 239 
G305A multi 1 243 
G305A multi 2 304 
G305A multi 3 229 
C587T 1* 645 
C587T 2* 682 
C587T 3* 842 
C587T+ Q448E 1 1605 
C587T+ Q448E 2 1594 
C587T+ Q448E 3 1541 
G649C 1 253 
G649C 2 303 
G649C 3 389 
G649C + R7W 1 237 
G649C + R7W 2 289 
G649C + R7W 3 275 
G649C+Q448E 1  
G649C+Q448E 2  
G649C+Q448E 3  
G649C + 1033T 1 353 
190 
 
G649C + 1033T 2 327 
G649C + 1033T 3 475 
G649C multi 1 300 
G649C multi 2 332 
G649C multi 3 393 
G649C + R7W 1 Rpt 845 
G649C + R7W 2 Rpt 849 
G649C + R7W 3 Rpt 650 
G649C + Q448E 1 Rpt 923 
G649C + Q448E 2 Rpt 936 
G649C + Q448E 3 Rpt 876 
C1192T 1 1657 
C1192T 2 1640 
C1192T 3 2519 
C1192T + Q448E 1 1393 
C1192T + Q448E 2 1834 
C1192T + Q448E 3 1421 
C1225T 1 977 
C1225T 2 784 
C1225T 3 919 
C1225T 1 Rpt 569 
C1225T 2 Rpt 524 
C1225T 3 Rpt 623 
C1787T 1 2105 
C1787T 2 1561 
C1787T 3 2108 
C1787T + C1423T 1 778 
C1787T + C1423T 2 951 
C1787T + C1423T 3 811 
C1787T + C1423T 1 Rpt 584 
C1787T + C1423T 2 Rpt 589 
C1787T + C1423T 3 Rpt 805 
G2068A 1 2409 
G2068A 2 2189 
G2068A 3 1481 
G2068A 1 Rpt 615 
G2068A 2 Rpt 542 
G2068A 3 Rpt 675 
R910X 1  C2728T 3375 
R910X 2  2442 
R910X 3  1791 
R910X 1 Rpt 545 
R910X 2 Rpt 461 
G2930T 1 2224 
G2930T 2 3523 
G2930T 3 2236 
Q448E 1* 196 
Q448E 2* 180 
A900V 1* 180 
A900V 2* 190 
191 
 
C2195T 1 2280 
C2195T 2 2685 
C2195T 3 2501 
 
 
